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Abstract 
Tuberculosis (TB) is the leading cause of infectious disease mortality in the world by a 
single bacterial pathogen, Mycobacterium tuberculosis. Current TB chemotherapy remains 
useful in treating susceptible M. tuberculosis strains, however, the emergence of MDR-TB 
and XDR-TB demand the development of new drugs. Enzymes involved in mycobactin 
biosynthesis, low molecular weight iron chelators, do not have mammalian homologues; 
therefore they are considered potential targets for the development of new anti-TB drugs. 
The aims of this study were to identify potential inhibitors and to investigate the function 
of the mbtG and AmbtE and AMbtF genes during mycobactin biosynthesis. The full length 
of mbtB and the ArCP domain were successfully cloned and post-translationally modified 
by MtaA, a broad phosphopantetheinyl transferase from Stigmatella aurantiaca, using 
Escherichia coli. Inhibitors identified by virtual screening as well as 13 chemically 
synthesised PAS analogues were initially investigated in whole-cell assay against 
Mycobacterium bovis BCG Pasteur. Seven of these compounds had interesting growth 
inhibition under iron-sufficient conditions. The mbtA gene was cloned and expressed as 
soluble protein using Mycobacterium smegmatis mc2155. Preliminary in vitro MbtA 
assays provided hints of its activity, although, the KM for SAL and ATP have not been 
determined yet. The mbtG and ambtE genes have been cloned and expressed in E. coli to 
further investigate their biochemical function in mycobactin biosynthesis. 
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Chapter 1                                                                                                   Introduction 
1.1 Tuberculosis, an ancient human disease. 
Tuberculosis (TB), one of the oldest recognised human diseases, is still one of the biggest 
killers among infectious diseases, despite the worldwide use of the BCG vaccine and several 
antibiotics to combat it. TB is caused by the successful intracellular pathogen, Mycobacterium 
tuberculosis, a Gram-positive bacterium. Although, M. tuberculosis is the main pathogen 
causing TB in humans, Mycobacterium bovis, Mycobacterium africanum, Mycobacterium 
canettii and Mycobacterium microti may also cause TB (Brosch et al., 2001) and are 
collectively called the M. tuberculosis complex. Also, within the genus there are other 
members of medical, veterinary and environmental importance (Ratledge & Stanford, 1982). 
Interestingly, many mycobacterial species can become human opportunistic pathogens in 
immunodepressed individuals, signifying a high adaptation of the genus to different 
environments (Katoch, 2004). 
 
TB has been recognised in human history, from the dawn of civilisation to the modern 
era, reflecting a constant co-evolution between host and pathogen. Molecular evidence gained 
from analysis of ancient osteological samples, derived from amplification of specific regions 
of M. tuberculosis DNA, supports the existence of TB through ancient human populations 
(Donoghue et al., 2004; Zink et al., 2007). The disease may have also been present in human 
populations dated as far back as 9250-BC as observed in skeleton remains found in Ain 
Ghazal Jordan (Crubézy et al., 2006; El-Najjar et al., 1996). DNA  from members of the M. 
tuberculosis complex has been detected in several ancient Egyptian mummies dated at more 
than 5,000 years ago (Crubézy et al., 1998; Nerlich et al., 1997; Zink et al., 2003a; Zink et al., 
2003b), suggesting that the disease was common among that population (Zink et al., 2001). In 
Europe, there is also evidence that TB was present in the Iron Age (4000-2000 BC) 
(Formicola et al., 1987; Mays & Taylor, 2003; Taylor et al., 2005). In South America, TB has 
been found in pre-Columbian mummies suggesting that the tubercle bacillus was present 
before contact with European populations (Arriaza et al., 1995; Konomi et al., 2002; Salo et 
al., 1994). In Asia, M. tuberculosis DNA has been found in 2000-year-old human skeletons 
(Fusegawa et al., 2003), as well as Mycobacterium leprae DNA dating from 555 BC (Tayles 
& Buckley, 2004).  
     2
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Despite this compelling evidence, the origin and the evolutionary time-frame of M. 
tuberculosis remains controversial. Most of the Mycobacterium members are natural 
inhabitants of soil or water inhabitants and it is logical to assume that the genus had its origin 
in such environments (Falkinham, 2002). How they became pathogenic is still an unsolved 
question, but probably some members adapted to new niches, under certain circumstances, 
leading to the emergence of a new ecotype (Cohan, 2002). 
 
It has been speculated that M. tuberculosis has evolved from M. bovis, by specific 
adaptation of an animal pathogen to the human host (Stead et al., 1995). However, genome 
comparison of members of the M. tuberculosis complex has shown other scenarios; either 
both bovine and human tuberculosis evolved almost at the same time which suggests a 
different common ancestor for both bacilli, the theoretical Mycobacterium prototuberculosis, 
or humans infected cattle resulting in the divergence of M. bovis (Gutierrez et al., 2005; 
Sreevatsan et al., 1997a). Most of the data analysed point to M. tuberculosis as the main 
causative agent of human TB, however, recent data from a study of four archaeological 
samples from a single site in South Siberia indicate that skeletal lesions were attributable to 
infection with M. bovis (Taylor et al., 2007). In addition, genotyping analysis on the oxyR285 
and pncA169 loci, which can be used to distinguish M. tuberculosis from M. bovis, found 
single nucleotide polymorphisms (SNPs) that are typical in M. bovis (Taylor et al., 2007). The 
apparent absence of M. bovis in ancient skeletal and mummified humans (Donoghue et al., 
2004) and the discovery of DNA of tubercle bacillus amplified from a North American 
Pleistocene extinct bison, showed a genetic profile resembling either M. africanum or M. 
tuberculosis more closely than it does M. bovis (Rothschild et al., 2001), supporting the new 
hypothesis.  
 
Analysis of diverse housekeeping genes among modern members of the M. 
tuberculosis complex has suggested a recent evolutionary bottleneck that may have occurred 
20,000 to 35,000 years ago (Brosch et al., 2002; Sreevatsan et al., 1997a). Nevertheless, 
recent findings and characterisation of East African M. tuberculosis strains suggested an age 
of 2.6-2.8 million years (Gutierrez et al., 2005). The same study highlights two interesting 
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scenarios in the co-evolution of the tubercle bacillus and humans. Firstly, the origin of 
tuberculosis could be much older than the plague, typhoid fever, or malaria, and may have 
affected early hominids. Secondly, the fact that the analysed strains came from East Africa, a 
region where early hominids were present 3 million years ago, suggests that tubercle bacillus 
emerged in Africa and then evolved following the expansion of a successful clone to the rest 
of the world, probably parallel to the human migration out of Africa (Gutierrez et al., 2005).  
  
The long lasting association of the tubercle bacillus with the early hominids is likely to 
have directed the intrinsic relation between the host and the pathogen, leading to the outcome 
of a very successful pathogen. Thus, early humans provided selection pressure for different 
phenotypes: strains causing the active disease and the ones which become latent, and probably 
the latter survived as an effective evolutive mechanism. Moreover, M. tuberculosis is still 
evolving and this is demonstrated with the appearance of new strains resistance to drugs 
(Ernst et al., 2007).    
 
1.2 Epidemiology of TB: a persistant human worldwide disease. 
The prevalence of TB has been documented through human history. The molecular analyses 
mentioned earlier suggest that ancient Egyptians suffered TB 5000-BC. Chest pain, coughing 
and blood in the sputum, the common symptoms of pulmonary TB, were described by 
Hippocrates (~ 500 B.C.) from patients who may have been infected with the bacillus. He 
termed the disease phthisis and the frequency of his descriptions of patients with TB-like 
symptoms indicates that the disease was prevalent (Daniel et al., 1994). 
  
During the 16th and 17th centuries Europe had high death rates associated with TB, 
reaching maximum levels in the first half of the 19th century in which was estimated that one-
quarter of all Europeans died of TB. European immigrants brought the disease to the New 
World, but the levels of mortality never reached the levels found in Europe (Daniel et al., 
1994). These high mortality rates were due to the appalling socioeconomic conditions, 
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overcrowding, poor nutrition, and lack of hygiene and sanitation, which prevailed during the 
early years of the industrial revolution (Murray, 1989).  
 
Although, the “Consumption, white plague or King’s Evil disease”, as TB was named, 
was recognised as a very contagious and frequent disease during this time, the etiological 
agent was not identified. In 1882, a breakthrough in medical history was made by Robert 
Koch who discovered and described the agent of TB (Sakula, 1982).  
 
 In the last half of the 19th century, mortality due to TB decreased, in part due to the 
following factors: improved socioeconomic conditions, application of sanitation measures, 
and natural selection of humans resistant to TB may have played a major role (Murray, 1989). 
However, the decline was too rapid to be explained by these changes since the relationship 
between socio-economic factors and TB transmission is complex (Gandy & Zumla, 2002) and 
natural selection, the appearance of gene(s) resistant to TB, may require long period of time 
(Lipsitch & Sousa, 2002).  
  
 TB mortality and morbidity rates dropped during the 20th century aided by the 
development of a vaccine and the discovery of drugs to combat the disease. Albert Calmette 
and Camille Guérin developed an attenuated live vaccine from M. bovis by growing it in serial 
passage on culture medium for over 13 years leading to the creation of the globally-used 
attenuated M. bovis BCG vaccine (Doherty & Andersen, 2005). The discovery of 
streptomycin in 1944, para-Aminosalicylic acid in 1946, and isoniazid and pyrazinamide in 
1952, led to effective chemotherapies that decreased TB globally (Zhang, 2005). This led to a 
decline in funding and interest in many TB research programs. 
 
During the 1980s, TB was neglected as an international health issue since it was 
believed that the disease was under control due to advances in TB chemotherapy and only 
endemic regions, mainly in developing countries, were faced with TB (Raviglione, 2003). 
However, epidemiological studies in the United States of America showed that the new TB 
cases were increasing and diverse factors were attributed to explain this increase (Reichman, 
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1991). The rate of HIV was also increasing and it was associated with TB along with poverty 
in urban areas. Nevertheless, many of the cases of TB reported in USA came from immigrants 
from developing countries. This rise in newly detected cases of TB not only in USA, but also 
in European countries, such as the Netherlands, Switzerland, Sweden, Norway and Denmark. 
These cases of TB were attributed to local and international migration, and it became clear 
that TB was not longer only a problem in developing countries. Thus, TB became recognised 
as an international health emergency (Raviglione, 2003).    
 
The status of the TB epidemic and progress in control of the disease has been assessed 
by the World Health Organization (WHO) since 1997. Much of the data for mortality and 
morbidity was predicted; however, estimations and reliable records begun in 1995 from 
analysis of case notifications due to programs implemented by the WHO. Hence, in 1990 
there were an estimated 7.1 million cases of TB and 2.5 million deaths worldwide, the most 
affected countries were situated in Africa and Asia. An alarming number, 90 million cases and 
30 million deaths were expected in the 1990s (Raviglione et al., 1995). However, the 
mathematical model of Murray and Salomon (1998) estimated 6.7 million new cases and 2.4 
million deaths for 1998 alone. The model also predicted that death and new case rates would 
increase between 1998 and 2030, although the panorama might change with the 
implementation of diverse strategies to combat TB. However, based on a global epidemiologic 
study, in which the incidence of TB and mortality were determined in 212 countries revealed 
another scenario. Thus, in 1997, 7.96 million new cases of TB and 1.87 million deaths were 
reported (Dye et al., 1999). Since the introduction of the Directed Observed Treatment Short-
Course Program (DOTS) by the WHO in the early 1990s, a steady decline in TB cases was 
observed. The new cases detected during this decade were mainly attributed to Multi-Drug 
Resistance-TB (MDR-TB) and the emergence of HIV-AIDS (Espinal et al., 2001; Heym et 
al., 1994; Raviglione, 2003). 
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In 2000 there were an estimated 8 to 9 million new cases of TB, fewer than half of 
which were reported; 3-4 million cases were sputum-smear positive, the most infectious form 
of the disease. Most cases (5-6 million) were in people aged 15-49 years (Frieden et al., 
2003). The global incidence of TB per capita peaked in 2003 and apparently there was a 
decline of new TB cases reported. Nevertheless, the apparent decline of global TB was 
masked by the increase of the global growth population, and for 2005-2006, new TB cases 
incremented to 9.1-9.2 million (an increase of 0.6%). Furthermore, WHO epidemiological 
studies show that one third of the world’s population may be latently infected by M. 
tuberculosis and these people could become ill or infectious at some time during their life 
(Corbett et al., 2003a). Despite various programs to control TB, this scenario has not changed 
and the WHO has reported 9.2 million new cases and 1.7 millions deaths from TB, of which 
0.7 million cases and 0.2 million deaths were in HIV-positive individuals (WHO, 2008). 
Based on current data, the WHO has estimated that 55% of global TB cases (including all 
forms of TB) occur in the high burden countries (HBC) of South-East Asia and Western 
Pacific countries, whereas 31% cases arise in Africa. However, some African countries 
account for a strikingly large number of cases relative to their population. Among the 15 
countries with the highest estimated TB incidence rates, 12 are in Africa. The high incidence 
rates correlate with high incidence of HIV co-infection (WHO, 2008). Figure 1 depicts new 
TB cases by country in 2006.  
 
Diverse factors are involved in the increase of new TB cases worldwide; these include 
high population density, poor nutrition, poor sanitation, synergy between TB and HIV/AIDS 
due to immunosupression and the increase of strains resistant to drugs. This has ultimately 
lead to the emergence of multi-drug resistant strains of TB (MDR-TB) and, more recently, the 
appearance of extensively drug resistant-TB (XDR-TB), linked to the problems caused by 
international migration (Barnes et al., 1991; Gandy & Zumla, 2002). The global distribution 
of TB is skewed towards developing countries, mainly in Asia and Africa, due to HIV co- 
infection. The resurgence of MDR-TB strains in Eastern Europe and XDR-TB in some 
countries, will contribute to new cases and death rates and TB will continue to be a major 
health issue for the international community (Fatkenheuer et al., 1999; WHO, 2008). 
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Figure 1. Estimated new TB cases (all forms) for 2006. Most high burden (coloured orange 
and red) countries are located in Africa and South-East Asia; however, some Western 
European countries have also high incidence of TB cases due to the emergence of MDR-TB 
(WHO, 2008).   
 
  
1.3 Biology of M. tuberculosis: understanding the success of the bacillus. 
Genotype and phenotype plasticity, slow growth, the unique and complex cell envelope, 
dormancy, intracellular pathogenesis, persistence, drug-tolerance (survival despite drug 
treatment), resistance (genetic mutations that result in heritable loss of susceptibility to 
antibiotics) and production of a range of virulence factors, are some of the biological features 
displayed by M. tuberculosis during infection. Understanding the basic biology of M. 
tuberculosis should aid in designing new vaccines and chemotherapy.  
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1.3.1 Taxonomy and classification. 
Lehman and Neumann (1896) proposed the generic name Mycobacterium, from the Middle 
Latin noun meaning fungus rodlet, to include tubercle and leprosy bacilli. Historically, 
classification of mycobacteria represented a problem since only basic features, initially 
morphology then physiology, were considered to categorise related bacteria forming mycelia. 
The original description of the genus Mycobacterium was based mainly on morphological and 
staining properties, features then considered to be sufficiently diagnostic to distinguish 
mycobacteria from corynebacteria and other morphologically similar bacteria. However, the 
introduction of biochemical, chemical, genetical and numerical techniques have led to a re-
grouping of the Class Actinobacteria in which the mycobacteria are grouped (Embley & 
Stackebrandt, 1994; Goodfellow & Wayne, 1982).  
 
 Although, modern techniques, currently used to group the Actinobacteria, such as 
sequence analysis of proteins and nucleic acids, has supported re-classification of this taxon, 
the traditional chemotaxonomic characters have defined specific artificial groups. The 
determination of key chemical structures of components of the cell wall, such as sugar, amino 
acids and lipids enabled the re-classification of bacteria sharing similar features with 
mycobacteria. Simple wall composition provided the first evidence of relationship between 
corynebacteria, mycobacteria and nocardiae, all of which contain large amounts of meso-
diaminopimelic acid (meso-DAP), arabinose and galactose. However, the most predominant 
feature shared by these bacteria are the branched-chain fatty acids, termed mycolic acids, 
which have contributed to the differentiation of actinomycetes to a genus level (Minnikin & 
Goodfellow, 1980). Thus, the genera Corynebacterium (C), Mycobacterium (M), and 
Nocardia (N) were grouped in a monophyletic taxon, the so-called CMN group, within the 
Actinobacteria, based on mycolic acids. The length and composition of these compounds have 
been used as chemotaxonomic markers for differentiating between the genera that produce 
them (Embley & Stackebrandt, 1994).   
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 The current classification of mycobacteria is now based in chemotaxonomy markers, 
morphological and physiological characteristics, as well as molecular analysis, such as 
analyses of DNA-DNA re-association and determination of the 16S rRNA and rDNA 
sequence similarities. All these approaches have contributed to re-define the actinomycetes 
and therefore the genus Mycobacterium (Stackebrandt et al., 1997; Tortoli, 2003; Ventura et 
al., 2007). A phylogenetic tree of Actinobacteria is shown in Figure 2. 
 
Figure 2. Intraclass relatedness of Actinobacteria showing the presence of six orders.  The 
phylogenetic tree is based on >1,200 nucleotides of 16rRNA. The scale bar represents 10 
nucleotide substitutions per 100 nucleotides. [Created in Tree Builder (Cole et al., 2009)].   
 
 
Though, the defined Mycobacterium genus is highly diverse and comprises around 85 
different species; the members share certain characteristics, especially the ability to form 
mycelia. Due to the diversity of the genus it is not easy to propose a simple definition, but in 
general mycobacteria are aerobic, acid-alcohol fast actinomycetes having a genome rich in 
guanidine and cytosine nucleotides. They are aerobic, acid-alcohol fast actinomycetes that 
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usually produce slightly curved or straight rods and coccoid elements, of around 0.2-0.7 X 
1.0-10.0 µm in size (Wayne & Kubica, 1994).   
  
1.3.2 Life style of mycobacteria. 
The diversity of biological life style is immense in mycobacteria. Generally, mycobacteria are 
free-living saprophytes and are well adapted to different habitats, such as soil and aquatic 
environments, whereas other species are obligate intracellular pathogens that infect humans, 
birds and other animals (Goodfellow & Williams, 1983). Although, M. ulcerans has been 
isolated as a soil inhabitant in symbiosis with roots of certain plants present in tropical rain 
forests or similar environments (Hayman, 1991), this species is the third most common in 
mycobacterial disease mediating a chronic disease leading to expanding skin ulcers, the so-
called Buruli ulcer (van der Werf et al., 2005).  
 
In general, mycobacteria are the causative agents of a broad epidemiological, clinical, 
and pathological spectrum of diseases in humans. Mycobacterial diseases are very often 
associated with immunocompromised individuals, especially HIV-AIDS patients. Some 
pathogenic mycobacteria prefer a single host, such as M. tuberculosis and M. leprae being 
human pathogens, whereas others can infect different hosts, for instance M. bovis infecting 
cattle or humans, M. microti being able to infect wood mice, shrews, llamas, cats and very 
occasionally humans (Brosch et al., 2001).    
 
1.3.3 Mycobacterial genomes: insight to the bacilli. 
The clinical course and pattern of TB is highly variable, ranging from life long asymptomatic 
infection to rapidly progressive pulmonary or disseminated disease. This variability was 
assumed to be result of differences in individual responses to the disease. However, modern 
molecular biology techniques are revealing key biological features of M. tuberculosis at the 
genomic level, which are partially explaining the phenotype and genotype plasticity found in 
pathogenic mycobacteria (Brosch et al., 2001).  
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The architecture, size, and function of the genome within mycobacterial species are 
diverse. The genome of the M. tuberculosis H37Rv strain is 4.4 Mb and GC content about 
65.6%, with a 91% coding capacity. More than 20% of the M. tuberculosis genome is devoted 
to genes encoding two different classes of proteins: enzymes involved in fatty acid 
metabolism and acidic, glycine-rich polypeptides of unknown function, the PE and PPE 
proteins (Cole et al., 1998). The remarkable number of genes encoding for fatty acid 
biosynthesis maybe related to the ability of the bacillus to grow in the host’s tissue, where 
fatty acids maybe the major carbon source (Cole et al., 1998). Genome comparisons of the M. 
tuberculosis H37Rv and CDC1551 strains, the latter being a highly virulent strain, revealed 
interesting polymorphisms. The CDC1551 strain contains an extra gene that shares homology 
to the early secreted antigen of 6 kDa (ESAT-6), a major T-cell antigen (Betts et al., 2000). 
 
The M. tuberculosis complex comprises M. tuberculosis together with M. africanum, 
M. bovis, M. canettii, M. pinnipedii and M. microti, which are closely related organism 
sharing >99% identity at the nucleotide level. They share 99.9% similarity at the nucleotide 
level and identical 16S RNA sequences, but differ in terms of their host tropisms, phenotypes 
and pathogenicity (Brosch et al., 2001). It is intriguing that some members are exclusively 
human pathogens, M. tuberculosis, M. africanum, M. canettii, whereas others have a wide 
host spectrum, such as M. bovis. 
 
Although, human and bovine tubercle bacilli can be differentiated by host range, 
virulence and physiological features, the genetic basis for these differences are still unknown. 
The M. bovis AF2122/97 genome has been recently deciphered (Garnier et al., 2003). The 
genome sequence is 4.3 Mb in length, with an average GC content of 65.63%, which 
potentially encodes 3952 proteins (Garnier et al., 2003). The bovine bacillus genome shares 
>99.95% identity at the nucleotide level to that of M. tuberculosis. However, deletion of 
genetic information is the dominant trend in the M. bovis genome, which has many 
pseudogenes. These genes resemble intact genes that are involved in molecular transport, 
structure and biosynthesis of the cell surface, detoxification, intermediary metabolism, fatty 
acid metabolism and cofactor biosynthesis (Garnier et al., 2003). 
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Variation in genes encoding the PE-PGRS and PPE protein families, predicted to be 
involved in adhesion and immune modulation, may contribute to the different host ranges 
displayed by M. bovis and M. tuberculosis. In the M. bovis genome, the sequence sharing 
significant homology with M. tuberculosis wag22 (Rv1759c), which encodes a member of the 
PE-PGRS protein family that binds fibronectin, has been disrupted by the deletion of a single 
nucleotide. This, in turn, suggests that alterations to the PE-PGRS repertoire might influence 
host or tissue tropism (Espitia et al., 1999). Furthermore, six genes belonging to the ESAT-6 
family are either missing or altered in the M. bovis genome and it is possible that these 
changes have an impact upon immune regulation in the host and thus host range (Garnier et 
al., 2003).      
 
Likewise, the obligate intracellular pathogen, M. leprae, has the smallest genome 
sequenced among the mycobacteria. The complete genome of M. leprae TN strain contains 
3.2 Mb, roughly 1.4 Mb smaller than that of M. tuberculosis, and has an average GC content 
of 57.8%. The M. leprae genome only encodes 49.5% of its coding capacity, whereas 27% 
contains pseudogenes, randomly distributed, and the  remaining 23.5% of the genome does 
not appear to be coding (Cole et al., 2001a). The extensive genome downsizing and 
rearrangement must have occurred during evolution of the leprosy bacillus and this might be 
associated with the obligate intracellular habitat of the bacteria. Supporting this hypothesis, 
the prolyl-tRNA synthase, encoded by proS, is more similar to the enzymes of Borrelia 
burdorferi and eukaryotes. The M. leprae proS gene is both displaced and inverted with 
respect to the M. tuberculosis counterpart, consistent with a recent acquisition through 
horizontal gene transfer, from host to pathogen. Other interesting findings are the deletion of 
some polyketide synthases (PKS), involved in lipid biosynthesis, and the mbt operon required 
for the production of mycobactins (Cole et al., 2001a; b). 
 
Since 1989, there has been an increase of cases of Buruli ulcer, a severe human skin 
disease caused by M. ulcerans. The genome of M. ulcerans strain Agy99 has recently been 
deciphered and it comprises two replicons: one corresponding to the chromosome which is 5.6 
Mb and a plasmid (pMUM001) having 17.4 kbp in length (Stinear et al., 2007). Two 
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interesting observations are deduced from the genetic analysis to understand the pathology of 
the Buruli ulcer. Firstly, there is no formation of granulomas, which is typical in other 
mycobacterial infections. Secondly, M. ulcerans is mainly found extracelullarly in mammalian 
tissues. Despite their high abundance and the associated extensive tissue damage, there is no 
acute inflammatory response to the bacteria (van der Werf et al., 2005). This pathology is 
attributed to mycolactone, a macrolide toxin, which seems to have cytotoxic, analgesic and 
immunosuppressive activities. The mycolactone is encoded by the pMUM001 plasmid which 
bears three PKSs genes (mlsA1, mlsA2 and mlsB) (Stinear et al., 2004). On the other hand, the 
reason that M. ulcerans does not form granulomas and occupies predominantly extracelullar 
location in infected tissues might be found in the deletion of the esx1 and espA genes in its 
genome, both M. tuberculosis gene products trigger granuloma formation (Stinear et al., 
2007).  
 
The insight gained from the comparative genomic analyses not only leads the 
development of new hypotheses regarding the biology of mycobacteria and their virulence, 
but has also been useful in the development of new strategies to combat mycobacterial 
infections.  
 
1.3.4 The cell wall. 
M. tuberculosis possesses an unusual cell wall that provides resistance to many antibiotics and 
the components of the killing mechanisms of macrophages. Historically, the inhibition of the 
biosynthesis of this structure has proven useful in TB chemotherapy, with the frontline agents 
ethambutol (arabinan) and isonazid (mycolic acids) and second-line agents like D-cycloserine 
(peptidoglycan) and ethionamide (mycolic acids) inhibiting the production of its various 
components. A more complete understanding of its biosynthesis and structure has been a 
major research focus in order to define potential targets for the development of new drugs 
(Boshoff et al., 2004; Scherman et al., 2003).  
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The cell envelope of M. tuberculosis consists of three main structural components. The 
plasma membrane, cell wall and the capsule (Rastogi et al., 1986). The plasma membrane 
appears to be a typical bacterial membrane and perhaps contributes very little towards the 
pathology of the bacilli. M. tuberculosis and M. leprae possess a complex cell wall and its 
extensive hydrophobic domains contribute to poor permeability which, in turn, leads to an 
inherent resistance against many drugs (Minnikin et al., 2002). The cell wall is composed of 
two layers, upper and lower, both linked through different classes of lipids (Brennan, 2003). A 
proposed model of the mycolyl-arabinogalactan-peptidoglycan (mAGP) cell wall of M. 
tuberculosis and its components is represented in the Figure 3 (Dmitriev et al., 2000; Dover et 
al., 2004).  
 
Figure 3. Structural components in the cell envelope of M. tuberculosis. Mycolic acids are 
sterified to arabinogalactan which in turn is connected to peptidoglycan (PG) to form the 
mycolyl-arabinogalactan-peptidoglycan (mAGP) complex. Other complex free lipids (PGL, 
PDIM, DAT, PAT, SL) interact with mAG [Adapted from Dover et al. (2004) and Dmitriev et 
al. (2000)]. (AG) arabinogalactan, (DAT) diacyl trehalose, (LAM) lipoarabinomannan, (PAT) 
pentaacyl trehalose, (PG) peptidoglycan, (PGL) phenolic glycolipid, (PIM6) 
phosphatidylinositol hexamannoside, (PDIM) phthiocerol dimycocerosate, (SL) sulphated 
tetra-acyl trehalose, (TMM) trehalose monomycolates, (TDM) trehalose dimycolates. 
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Beyond the membrane is peptidoglycan (PG) in covalent attachment to arabinogalactan 
(AG), which in turn is linked to the mycolic acids. All these molecules form the cell wall core, 
the mAGP complex (Brennan, 2003; Minnikin et al., 2002). The mycobacterial PG differs in 
two ways from that commonly found in other bacteria. Some or all of the muramic acid 
residues are N-glycolylated with glycolic acid (MurNGly) and the peptidic crosslinks can 
include bonds between two residues of diaminopimelic acid as well as between 
diaminopimelic acid and D-alanine (Lederer et al., 1975; Wietzerbin-Falszpan et al., 1970) in 
“stationary cultures”.  
 
The AG polysaccharide, unique to mycobacteria and other actinomycetes, is important 
for cell wall integrity and for anchoring the mycolic acids and to the PG layer. It is composed 
of D-arabinofuranose and D-galactofuranose residues. The arabinan chains are linked to the 
galactan chain toward the reducing end and are composed of linear α(1→5)-D-
arabinofuranosyl (Araf) residues with 3,5-branching. The non-reducing terminals of the 
arabinan are capped with a characteristic hexarabinose motif [t-β-D-Araf-(1→2)-α-D-Araf]2-
3,5-α-D-Araf-(1→5)-α-D-Araf. The hexarabinose motifs are esterified at the C-5 positions, in 
clusters of four, with mycolic acids, although only two-thirds of these motifs are mycolated in 
AG (Brennan & Nikaido, 1995); together they produce the inner leaflet of a complex 
asymmetric lipid bilayer.   
   
The mycolic acids are key lipid components in the cell wall of M. tuberculosis. These 
lipids are high molecular weight α-alkyl-β-hydroxy fatty acids, which are predominantly 
linked to AG, but some are found as extractable glycolipids such as trehalose monomycolates 
(TMM) and trehalose 6,6’-dimycolates (TDM). The main part of the branched chain is called 
“meromycolic acid” and the other part the α-branch (Minnikin et al., 2002). Mycolic acids 
from mycobacteria contain about 70-90 carbon atoms and 20-25 carbon atoms in the α-branch, 
while in Corynebacterium diphtheriae, corynomycolates have 30-36 C atoms in total (Dover 
et al., 2004a). The molecular organisation of mycolic acids plays an important role in nutrient 
uptake into the bacterium as well as conferring resistance to a wide range of antibacterial 
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drugs (Takayama et al., 2005). Moreover, the mycolic acids also play a role during cellular 
and innate immune responses during M. tuberculosis infection (Korf et al., 2005). 
 
The outer leaflet of the bilayer and any gaps in the inner leaflet are most likely 
occupied by free lipids, some with longer fatty acids complementing the shorter α-chains of 
mycolic acids, and some with shorter fatty acids complementing the longer chains of mycolic 
acids (Dover et al., 2004). Other components of the cell envelope of M. tuberculosis are the 
lipoarabinomannan (LAM) and related lipomannan (LM); both lipoglycans are based on 
phosphatidylinositol mannoside (PIM) anchors, which may locate into the plasma membrane 
(Minnikin et al., 2002). It is speculated that LAM is linked to the interaction of the pathogen 
with the host, possibly leading to resistance mechanisms associated with macrophage killing 
(Chatterjee, 1997; Karakousis et al., 2004). On the other hand, a family of sulfated acyl 
trehaloses (SL) (Goren, 1970), and phenolic glycolipids (PGL) have been characterised from 
M. tuberculosis and M. canettii, respectively (Daffé et al., 1987; Watanabe et al., 1994). The 
sulfolipids of M. tuberculosis are five structurally related sulfatides, from which the 
sulfolipid-I (SL-I), the most abundant sulfatide, has been identified as a 2,3,6,6’-tetraacyl-a,a’-
D-trehalose 2’-sulfate (Goren, 1970). The PGL consist of a lipid core formed by a long-chain 
β-diol, occurring naturally as diester of the polymethyl branched fatty acids (Malaga et al., 
2008). Since both SLs and PGLs are probably located in the outer leaflet of the envelope, their 
location has prompted speculation that they may be virulence factors involved in host-
pathogen interactions (Reed et al., 2004; Zhang et al., 1991). 
 
1.3.5 Pathology of M. tuberculosis. 
The success of M. tuberculosis is due to the adaptability that the bacterium has developed 
through evolution, i.e. resistance to drugs, multiplication in diverse organs of the host and 
evasion of the host’s immune response. The pathogenesis of tuberculosis is complex and its 
manifestations diverse, which is reflected in a lifetime of dynamic interactions between 
mycobacterial virulence factors and the human immune system (Ellner, 1997; Hingley-Wilson 
et al., 2003; Russell, 2001). Based on Luries’s studies (1964) in rabbits, four stages of 
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pulmonary TB have been distinguished. The first stage is related to inhalation of tubercle 
bacilli. TB is spread by airborne droplet nuclei, which are particles of 1-5 µm in diameter that 
contain one or two M. tuberculosis cells. Since, the particles are small they can remain in the 
air for several minutes after expectoration by people with pulmonary or laryngeal TB during 
coughing, sneezing, singing or talking, and when inhaled these nuclei can pass through to the 
alveoli of the lung (Riley et al., 1995). 
 
 
Once the bacilli have been implanted in the alveoli, the bacteria are disseminated by 
the lymphatic circulation to regional lymph nodes in the lung, forming the primary or Ghon 
complex. The initial infection can initiate a cascade of events that results in either successful 
containment of the infection or progression to active disease (primary progressive TB) 
(Comstock et al., 1974; Sutherland, 1976). The destruction of mycobacteria depends on host 
phagocytes and virulence factors of the ingested mycobacteria. This stage lasts 3-8 weeks 
after M. tuberculosis cells have been inhaled (van Crevel et al., 2002). 
 
 In the second stage, which lasts around three months, tubercle bacilli are able to 
survive by intracellular destruction of macrophages. Mycobacterial multiplication leads to 
disruption of infected macrophages, ultimately attracting blood monocytes and other 
inflammatory cells to the lung. These monocytes differentiate into macrophages which again 
ingest but do not destroy the mycobacteria which are able to grow logarithmically. At this 
stage, dissemination of bacteria to many organs, including other parts of the lung, via the 
circulation might occur; at this time in some individuals, acute and fatal diseases can occur in 
the form of TB meningitis or miliary (disseminated) TB (Schluger & Rom, 1998; van Crevel 
et al., 2002). Also in the second stage, T-cell immunity develops. Antigenic-specific T 
lymphocytes arrive and proliferate within the early lesions or tubercles and then activate 
macrophages to kill the intracellular mycobacteria (Fenton & Vermeulen, 1996). Activated T-
lymphocytes and macrophages form granulomas that limit posteriori replication of M. 
tuberculosis. Generally, the process of granuloma formation serves as a defence for containing 
pathogens and preventing their continued growth and dissemination (Soler & Bernaudin, 
1993). 
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  In the third stage, mycobacterial growth is inhibited by necrosis in primary lesions. As 
a result, infection may become stationary or dormant. Central solid necrosis in primary lesions 
inhibits extracellular growth of mycobacteria. Inflammation of the pleural surfaces can occur 
during the third stage with either hematogenous dissemination or the release of the bacteria 
into pleural space from subpleural concentrations of bacteria in the lung, but this can be 
retarded for two years (van Crevel et al., 2002). Severe chest pains also appear during this 
stage of infection. 
 
 The last stage or resolution of the primary complex, is where the disease is not 
continuous, and may last up to 3 years. At this stage, more slowly developing extrapulmonary 
lesions can appear. However, some individuals infected with TB do not exhibit progression of 
the disease. Nevertheless, 50% of those individuals infected by HIV/AIDS develop the 
reactivation of TB at some time in their lives (Garay, 1996). 
         
Although, the most affected organ is the lung as well as other tissues, M. tuberculosis 
is able to replicate in many parts of human body. Disseminated TB infection is defined as 
involvement of many organs simultaneously and can occur as a result of primary progressive 
disease or reactivation of latent infection. TB can affect any bone or joint, but the spine is the 
most common structure invaded. Genitourinary TB is uncommon, but the most serious clinical 
manifestation of TB is involvement of the central nervous system which may cause meningitis 
(Brodie & Schluger, 2005).  
 
1.4 Combating the bacillus: vaccines and the drug arsenal. 
Historically, TB control started by simply isolating infected individuals in sanatoriums; 
however, this measure did not give effective control of the disease, since the bacillus is readily 
transmitted via the air. TB-associated mortality decreased due to the development and 
introduction of the BCG vaccine into Europe by the early 1920s, as a result of improved host-
defence mechanisms, and especially by reduced transmission. Today, more than 3000 million 
people have received the BCG vaccine (Andersen & Doherty, 2005). In 1944, streptomycin 
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was discovered and subsequently introduced as the first antibiotic for the treatment of TB. 
Then, p-aminosalicylic acid (PAS) was introduced in 1946 and isoniazid in 1952. Further 
research lead to development of other drugs, such as cycloserine (1955), kanamycin (1957), 
ethambutol (1961), capreomycin (1961), rifampicin  (1965), ethionamide (1966), ethambutol 
(1968) and pyrazinamide (1970) (Zhang, 2005). 
 
1.4.1 Vaccines. 
Active immunisation is one of the essential components of TB control, although vaccination is 
currently ineffective. The Bacilli Calmette-Guérin (BCG) live vaccine was successfully used 
to immunise billions of people since the last century. The BCG vaccine is an attenuated strain 
of M. bovis which was isolated by Albert Calmette and Camille Guérin (Andersen & Doherty, 
2005; Fine, 1989). Despite this being the only vaccine, its efficacy has been in doubt because 
of its highly variable protective efficacy in controlled clinical trials (Brewer & Colditz, 1995). 
This variation might be due to the number of mutations and deletions that have occurred since 
its initial isolation in 1905 (Behr et al., 1999). Other reasons that can explain this variation are 
the previous exposure to environmental mycobacteria and genetic variation of the human 
population (Brewer & Colditz, 1995; Osborn, 1983; Springett & Sutherland, 1994). Due to 
this variation in BCG efficacy, a number of alternative living and non-living putative TB 
vaccines are currently being studied (Nor & Musa, 2004). In general, the efforts to make new 
vaccines are based in four strategies: (i) Rationally attenuated strains of M. tuberculosis, such 
as auxotrophic M. tuberculosis mutants (Collins, 2000; Guleria et al., 1996) or less virulent 
mycobacteria, such as M. microti, M. habana, M. vaccae or M. smegmatis that overproduce 
immunogenic antigens of M. tuberculosis (McMurray, 2000); (ii) The use of a recombinant 
BCG (Horwitz et al., 2000; Murray et al., 1996); (iii) Protein subunit vaccines (non-living 
vaccines). These vaccines represent good vaccine candidates because they seem safe and have 
no apparent side effects, which is very important when individuals are infected or exposed to 
HIV (Horwitz et al., 2000); (iv) The use of “Naked DNA vaccines” (plasmids containing 
genes encoding antigens of mycobacteria species) (Johansen et al., 2003).  
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1.4.2 Drug arsenal. 
As outlined before, the 1950s and 60s represented a golden era of TB drug discovery. Despite 
the variety of drugs becoming available at that time, no biochemical characterisation was done 
and the activity of these antibiotics and their biosynthetic targets in M. tuberculosis were 
unknown. Complications soon arose after the introduction of streptomycin; patients improved 
their health, but they subsequently failed to fully recover and the bacteria isolated from these 
patients was resistant to streptomycin. This finding demonstrated that wild-strain populations 
of M. tuberculosis are not uniform in their susceptibility to drugs and to treat the disease it 
was necessary to use it in combination with another drug. Thus, streptomycin and para-
Aminosalicylic acid (PAS) were used for the first time as a combination to combat TB 
(Hopewell, 2006).   
 
 The introduction of isoniazid (INH) in 1952 began a new era of TB chemotherapy, 
because it was highly affective, inexpensive and induced no significant side effects. Again, 
single-drug treatment with INH was not enough and M tuberculosis strains resistant to this 
drug were also observed. The combination of INH and PAS with or without streptomycin 
became the usual therapy for TB. Further investigations lead to the development of the core 
regimen of isoniazid and rifampicin (RIF), supplemented by pyrazinamide (PZA) and 
ethambutol (EMB); this is now recommended as standard treatment for both pulmonary and 
extrapulmonary TB, the so-called First Line anti-TB drugs. Since the introduction of the 
DOTS strategy in the early 1990s by the WHO, considerable progress has been made in 
controlling TB (Saltini, 2006). 
 
However, even with the DOTS program, TB treatment is facing new challenges. 
Toward the end of the 1980s and the early 1990s, cases of patients, who did not respond to 
drug regimens were reported and this was attributed to the appearance of MDR-TB, defined as 
showing resistance to at least the first-line drugs INH and RIF (Crofton et al., 1997). The 
failure of these drugs requires the use of second line drugs which are more toxic, expensive 
and less effective. The scenario has worsened with the emergence of XDR-TB, which are 
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resistant to second line drugs (CDC, 2006). Thus, the emergence of MDR-TB and XDR-TB is 
threatening the public health and TB control worldwide. 
 
 Different molecular mechanisms have been presented to explain the causes of the 
development of resistance against existing drugs, such as impermeability of the highly 
hydrophobic cell envelope to many drugs, a well-developed-efflux system (Nguyen & 
Thompson, 2006), production of certain enzymes to inactivate drugs (β-lactamases, 
aminoglycoside acyltransferase) (Bush & Miller, 1998; Kwon et al., 1995) and, at the 
molecular level, acquisition of resistance due to mutational events in the chromosomes (Heym 
et al., 1994). On the other hand, others factors related to treatment of TB, i.e. patients not 
finishing their chemotherapy, administration of drugs without analysis of strains, have also 
increased the spread of M. tuberculosis strains resistant to front-line and second-line drugs 
(Snider & Castro, 1998).  
 
Generally the targets against TB are based on the biosynthetic pathways which are 
involved in the production of macromolecules: proteins, nucleic acids or cell wall polymers 
(Rattan et al., 1998). The urgent need for new drugs has led researchers to combine genetic 
engineering techniques, genomics and proteomics tools, in a new approach to understand the 
biology of M. tuberculosis and to screen and develop new targets for drugs. Selecting targets 
for anti-TB therapy in this manner, is advantageous because one can avoid metabolic 
pathways occurring in mammalian cells.  
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First Line anti-TB drugs. 
1.4.2.1 Isoniazid (INH). 
 
 
 
 
 N
NHO
NH2
INH acts best in slow-growing mycobacteria, having a minimum inhibitory concentration 
(MIC) of 0.01-0.2 µg/mL for M. tuberculosis, whereas M. smegmatis is 100-fold less sensitive 
(Zhang, 2005). Despite its effectiveness, the molecular mechanism of action was subject to 
debate until recently with several hypotheses suggested to explain its molecular activity. INH 
is a prodrug which requires activation by the M. tuberculosis catalase-peroxidase (KatG) 
(Zhang et al., 1992) to generate a range of reactive oxygen species and reactive organic 
radicals, which then attack multiple targets in the tubercle bacillus, probably DNA synthesis, 
carbohydrates and lipids (Broussy et al., 2003; Rozwarski et al., 1998).  
 
Subsequent biochemical studies demonstrated that KatG activates INH by converting 
the prodrug to a range of activated species, such as an isonicotinic acyl radical that can also 
acylate diverse compounds. Its interaction with NAD+ results in the formation of an INH-
NAD adduct, which inhibits the FASII enoyl ACP reductase (InhA), leading to the 
accumulation of long-chain fatty acids, inhibition of mycolic acid biosynthesis; this results in 
the loss of cellular integrity and ultimately cell death (Vilcheze & Jacobs, 2007). Mutations in 
katG and inhA leads to INH resistance (Rozwarski et al., 1998), but other mechanisms have 
also been postulated (Vilcheze & Jacobs, 2007).  
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1.4.2.2 Rifampicin (RIF). 
 
 
 
 
 
 
 
 
 
 
N
N
N
NH
O
O
O
HOHO
O
H3CO
O CH3
OH
O
OH
RIF was introduced in 1972 as an anti-TB drug. The action of RIF in combination with PZA 
has allowed the shortening to TB treatment from 1 year to 9-6 months. The MIC for RIF is 
0.05-0.5 µg/mL. The drug acts by interfering with the transcription via binding to DNA-
dependent RNA polymerase. RNA polymerase has four different subunits (α, β, β’, σ) 
encoded by rpoA, rpoB, rpoC and rpoD genes, respectively. RIF binds to the β subunit 
hindering transcription and therefore killing both active and slow growing bacilli (Jarvis & 
Lamb, 1998; Telenti et al., 1993; Williams et al., 1998). Mutation and short deletions in the 
rpoB gene confer resistance to M. tuberculosis (Herrera et al., 2003). 
  
1.4.2.3 Pyrazinamide (PZA). 
 
 
 
 
 
N
N
NH2O
Although, PZA was synthesized in 1936, its activity as an anti-TB drug was not discovered 
until 1952 (Tarshis & Weed, 1953). PZA is an interesting and paradoxical drug since it has 
high in vivo but not in vitro activity. Structurally, PZA is an analogue of nicotinamide having 
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a MIC of 20-100 µg/mL (Zhang, 2005). PZA is a pro-drug, which is converted to its active 
form pyrazinoic acid (POA), by pyrazinamidase (PZase) encoded by pncA. The drug acts 
under certain conditions, being most active at acidic pH as well as in old cultures and at low 
oxygen levels or anaerobic conditions. The acidic pH facilitates the formation of uncharged 
protonated POA that permeates through the membrane and causes the accumulation of POA 
and reduces membrane potential in M. tuberculosis. As a consequence, protonated POA brings 
protons into the cell causing acidification and eventually inhibiting vital enzymes, although no 
specific target has been found (Zhang & Mitchison, 2003; Zhang et al., 2003). A derivative of 
PZA (5-chloro-pyrazinamide) inhibits fatty acid biosynthesis by targeting the fatty acid 
synthase I (FAS-I) (Boshoff et al., 2002), but PZA does not act on FAS-I. Work by Scorpio & 
Zhang (1996) and Scorpio et al. (1997) has shown that point mutations in the pncA gene 
confer PZA resistance to M. tuberculosis. The drug is only active against some M. 
tuberculosis complex organisms (M. tuberculosis, M. microti and M. africanum), but not 
against M. bovis due to the presence of point mutations in the pncA gene (Zhang & Mitchison, 
2003). 
 
1.4.2.4 Ethambutol (EMB). 
 
 
 
 
HN
OH
H
N
OH
CH2CH3
H3CH2C
Ethambutol (S,S)-2,2’(ethyl rst identified as an anti-TB 
drug (Thomas et al., 1961). EMB is essential for TB treatment in combination with other 
drugs and its activity is restricted to mycobacterial strains. Early proposals for the mode of 
action of the drug ranged from trehalose, mycolate and glucose metabolism to spermidine 
biosynthesis. However, more recent studies have shown that the primary site of action is 
arabinan biosynthesis both in arabinogalactan (AG) and lipoarabinomannan (LAM) (Deng et 
al., 1995; Mikusova et al., 1995; Telenti et al., 1997). Since, AG and LAM are structurally 
essential for the mycobacterial cell wall, the destruction of these structures renders instability 
enediimino)di-1-butanol (EMB) was fi
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of the mAGP complex and thus may lead to increased permeability of the cell wall. Belanger 
et al. (1996) proposed that the target for EMB is the arabinosyl transferase encoded by emb 
operon both in M. avium and M. tuberculosis. Supporting this hypothesis, various studies have 
identified five mutations in codon 306 in the M. tuberculosis embB gene (Ramaswamy et al., 
2000; Sreevatsan et al., 1997b). Furthermore, two new arabinofuranosyl transferases, AftA 
and AftB, have been recently identified both in M. tuberculosis and C. glutamicum which are 
insensitive to EMB, suggesting that the drug acts only on the emb gene products (Alderwick et 
al., 2006; Seidel et al., 2007). Mutations in the embCAB operon are found in approximately 
65% of clinical isolates of M. tuberculosis resistant to EMB (Sreevatsan et al., 1997b).  
 
1.4.2.5 Streptomycin. 
treptomycin is an alternative first line anti-TB drug. The effect of streptomycin has been 
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demonstrated to take place at the ribosomal level (Carter et al., 2000; Davies et al., 1965). It 
interferes with protein synthesis by inhibiting initiation of mRNA translation, facilitating 
misreading of the genetic code and damage to the cell membrane (Anand & Davis, 1960). The 
drug interferes specifically with the small 30S subunit of the ribosome interacting with the 
16S rRNA and S12 ribosomal protein (rrs and rpsL), inducing ribosomal changes, which 
cause misreading of the mRNA and therefore inhibition of protein biosynthesis (Garvin et al., 
1974). Point mutations in the rrs and rpsL genes are associated with M. tuberculosis resistant 
to streptomycin (Cooksey et al., 1996; Finken et al., 1993).   
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Second Line drugs. 
1.4.2.6 Ethionamide (ETH). 
TH is also a pro-drug which is acti onooxygenase enzyme EthA (also called 
1.4.2.7 para-Aminosalicylic acid (PAS). 
 
 
N
 
 
 
 
 
E
NH2S
vated by the m
EtaA) (Baulard et al., 2000; DeBarber et al., 2000; Vannelli et al., 2002). The drug is a 
structural and mechanistic an analogue of INH and therefore its target is proposed to be InhA 
causing inhibition of mycolic acids biosynthesis which consequently leads to disruption of the 
M. tuberculosis cell wall (Banerjee et al., 1994). The EthA was shown to be important in the 
activation and therefore efficacy of thiocarbamides anti-TB drugs, such as ethionamide 
(ETH), thiacetazone (TAZ) and isoaxyl (ISO) (Baulard et al., 2000; Dover et al., 2007; 
Vannelli et al., 2002). It has been shown that EthA mediates ETH and TAZ activation by 
sulfoxidation (Qian & Ortiz de Montellano, 2006). Mutations in the promoter of the inhA as 
well as in the ethA genes confer resistance to M. tuberculosis to ETH (Morlock et al., 2003; 
Vannelli et al., 2002). The expression of the ethA gene is under the control of the ethR gene 
encoding a repressor which is also implicated in resistance to ETH due to mutations in the 
DNA binding region of the protein (Dover et al., 2004b). 
 
N
OHH2N
OH
O
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The anti-mycobacterial activity of PAS was first reported by Lehmann (1946). It has no effect 
n other bacteria, but it is highly effective against M. tuberculosis. The mode of action of PAS 
 Fluoroquinolones. 
 
 
 
he fluoroquinolones are de xidic acid which inhibit DNA synthesis by 
rgeting bacterial topoisomerases II and IV (Drlica, 1999; Zhao et al., 1997). M. tuberculosis 
cks topoisomerase IV but possesses topoisomerase II or DNA gyrase. The primary target of 
Qs in Staphylococcus aureus is topoisomerase IV, whereas in E. coli and M. tuberculosis it 
o
is still unclear, but it has been suggested to inhibit mycobactin biosynthesis by interfering with 
salicylate-dependent biosynthesis of these iron chelators (Brown & Ratledge, 1975a; 
Ratledge, 2004; Ratledge & Dover, 2000). However, another metabolic pathway has been 
suggested to be the target of PAS. Rengarajan et al. (2004) proposed that PAS also targets the 
thymidylate synthase (thyA), an enzyme involved in the folate biosynthesis pathway.  
 
1.4.2.8
N
O
OH
R
F
O
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H3C
 
 
 
 
 
T rivatives of nali
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F
is DNA gyrase (Ginsburg et al., 2003). The mode of action of the fluoroquinolones is not fully 
elucidated, however, strand-breakage, SOS-mediated autolysis and blockade of replication by 
the gyrase-fluoroquinolone complex have been proposed (Ginsburg et al., 2003). Although 
there is structural diversity in fluoroquinolones, only two are used as second-line drugs in 
MDR-TB treatment, ciprofloxacin (CIP) and ofloxacin (OFL) (Ginsburg et al., 2003). The 
most common mutation in fluoroquinolone-resistant M. tuberculosis isolates involves a 
substitution at codon 94 of the M. tuberculosis gyrA gene (Takiff et al., 1994).     
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1.4.2.9 Aminoglycosides. 
 
 
 
 
 
anamycin (KAN) and am
mmonly used for the treatment of MDR-TB. 
inoglycosides bind to bacterial ribosomes and perturb the elongation of the peptide chain 
ria. Mutations in the  
tance to KAN and AMI (Alangaden et al., 1998; Susuki et al., 1998; Taniguchi et al., 
D-cycloserine is a cyclic analogue of D-alanine which is one of the central molecules in the 
et al., 1969). D-cycloserine is an 
timycobacterial agent but is rarely prescribed and used in TB chemotherapy due to 
s severe secondary effects (Helmy, 1970). D-cycloserine inhibits cell wall synthesis by 
peting with D-alanine for the enzymes D-alanyl-D-alanine synthetase (Ddl) and D-alanine 
O
 
 
 
 
K ikacin (AMI) are aminoglycosides which inhibit protein synthesis 
(Magnet & Blanchard, 2005). Both drugs are co
Am
in bacte rrs gene encoding for the 16S rRNA are associated with
resis
1997). Cross-resistance has been observed between KAN and either AMI, capreomycin or 
viomycin, but a recent study found a little cross-resistance between KAN and AMI  (Krüüner 
et al., 2003).   
 
1.4.2.10 D-cycloserine. 
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racemase (Alr). The D-alanine-racemase gene has been cloned from M. smegmatis and its 
expression from a multicopy DNA vector in M. smegmatis and M. bovis BCG results in 
resistance to DCS (Cáceres et al., 1997), but the genetic basic for D-cycloserine resistance in 
M. tuberculosis has not yet been found.     
 
1.4.2.11 Polypeptides. 
 
 
NH2
 
 
iom bit protein 
nthesis. Both drugs are structurally related, their target has been linked to modification of 
bosomal structures. VIO has been shown to bind both the 30S and the 50S ribosome subunits 
nd to affect the dissociation of the 70S ribosome in M. smegmatis (Yamada, 1976; Yamada et 
l., 1978) and to inhibit ribosomal translocation by arresting peptidyl-tRNA in the ribosomal 
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V ycin (VIO) and capreomycin (CAP) are both basic peptide antibiotics that inhi
sy
ri
a
a
acceptor site (Modolell & Vazquez, 1977). CAP also interferes with ribosomal function yet no 
elucidated. The tlyA gene of M. tuberculosis encodes a putative methyltransferase for rRNA 
methylation which in turn may be required for CAP activity. This suggests that ribosomes 
lacking methylation would be CAP resistant (Maus et al., 2005).    
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1.5 Iron as an element. 
Iron (Fe) is the second most abundant metal, after aluminium (Al), and the fourth most 
bundant element in the earth’s crust. The core of the earth is believed to consist mainly of 
n and nickel (Ni) (Cotton et al., 1995). Approximately one-third of the earth’s mass is 
s concentration is relatively high in most crustal rocks (Theil & 
Raymond, 1994). In the oceans, the concentration of iron is low but increases with depth, 
gen 
romote the reverse reaction (Aisen et al., 2001; Cotton et al., 1995; Kosman, 2003). The 
reduction potential of the ferric/
cates that th
a
iro
estimated to be iron and it
since iron exists as suspended particulate matter rather than as soluble species (Fox, 1984, 
1988). Iron belongs to the transition-metals. The elements of this group share the 
characteristic that their d orbitals are unfilled and, therefore, they may possess several stable 
oxidation states and most of the elements can form complexes (Cotton et al., 1995). Thus, iron 
is able to undergo changes in oxidation states, involving electron transfer, which allow it easy 
access to two oxidation states, Iron II (Fe2+, ferrous iron) and Iron III (Fe3+, ferric iron), 
participating in many reduction-oxidation (redox) processes (Fontecave & Pierre, 1991).  
 
For iron, there are four features in its chemistry and biochemistry that have shaped the 
evolution and selection of iron uptake mechanisms. Firstly, the redox chemistry of iron is 
easily accomplished, due to the one-electron transfer between Fe2+ and Fe3+. Common 
reducing agents will usually convert ferric iron to the ferrous form, while molecular dioxy
will p
ferrous couple, E°' at neutral pH is +0.77 V (Loach, 1968). E° 
means standard reduction potential and measures, in volts (V), the velocity of electron flow 
from the donor to the acceptor (Nelson & Cox, 2004). This value indi is couple is 
reducing in comparison to dioxygen reduction to water (+0.82 V). Thus, under air iron is 
stable as Fe3+, but Fe2+ will quickly auto-oxidize. For many biological iron-complexes 
whether in proteins or simpler molecules, redox chemistry is easy and reversible.  
 
Secondly, ferric iron is insoluble in water at neutral pH. In aqueous solution, Fe3+ 
(H2O)n, hydrolyses, so, it loses protons to form a ferric hydroxide species that polymerises 
into an amorphous gel. Fe3+ is a strong Lewis acid and this relatively positive charge promotes 
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proton loss from the coordinated water molecules in the following hydrolytic deprotonations 
(Wilkin
O+
 
The latter species is extrem  so that the maximum 
concentration of Fe isen et al., 2001; Sylva, 
1972). However, a recent study shows that the major form of iron at pH 7 is not Fe(OH)3 but 
is instead Fe(OH)2, which has a solubility of approximately 1.4 X 10-9 M (Chipperfield & 
Ratledg
 the general 
s, 1991), all reactions take place when the pH is above 2: 
 
[Fe(H2O)6]3+ → [Fe(H2O)5(OH-)]2+ + H3O+
 [Fe(H2O)5(OH-)]2+ → [Fe(H2O)4(OH-)2]+ + H3O+
[Fe(H2O)4(OH-)2]+ → [Fe(H2O)3(OH-)3]+ + H3
 
ely insoluble (KSP 10-38 M),
+3 in aqueous solutions is only about 10-17 M (A
e, 2000). On the other hand, Fe2+ is a weak Lewis acid because the nuclear charge is 
suppressed by an additional electron. The water molecules bound to Fe2+ do not ionise readily 
and therefore the aqua ferrous ion is relatively stable to hydrolysis and soluble at neutral pH. 
Thirdly, Fe3+ binds ligands more tightly, due in part to the charge difference, which makes 
ferric iron complexes exchange inert, that is, any ligand attached to Fe3+ in a complex can be 
replaced but with difficulty. In Fe2+, H2O exchange is ~ 104-fold faster than Fe3+ in otherwise 
similar ligand environments. Even, if the hydrolysis of Fe3+(H2O)n is suppressed, at acidic pH 
values, Fe3+ is still  relatively inaccessible to biological ligands (Wilkins, 1991).  
  
Fourthly, there is high biological competition between different ligands to bind iron 
(Kosman, 2003). Hydroxide complexes of iron readily polymerise by dehydration to form 
polynuclear complexes with iron atoms linked by oxo or hydroxo bridges as in
reaction:  
 
                                                         - nH2O 
nFe+3(OH)3  →   -(FeOOH)n- 
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Iron polyme nge from two iron atoms, as in the proteins 
ith binuclear iron centres (e.g. r ee dimensional arrays of more 
than 40
a variety of transition metals and employ them 
ere they carry out regulatory or catalytic roles 
ic and it its redox capabilities that underlie its toxicity. The one-electron 
reduction of dioxygen by Fe2+, acting as catalyst, results in superoxide formation. This in turn 
leads to •
e cell, in mitochondria during aerobic 
spiration by incomplete reduction of dioxygen, peroxisomes and the endoplasmic reticulum 
of the 
(Hampton et al., 1998). Redox activity of iron not only catalyzes the generation of hydroxyl 
rs in biological systems may ra
w ibonucleotide reductase), to thr
00 iron atoms as in the mineralized core of ferritins (Aisen et al., 2001).       
 
1.5.1 Iron and its biological importance. 
Both prokaryotic and eukaryotic cells acquire 
in structurally constrained binding sites, wh
(Finney & O'Halloran, 2003). Many metals are essential for all living systems, since their 
deficiencies lead to disease, metabolic anomalies, or perturbations in their development 
(Fraústo da Silva & Williams, 2001). An element that is being used by any biological system 
must be abundant in the environment and must be in an easily extractable form, that is, it must 
be “biologically available” from the environment (Fraústo da Silva & Williams, 2001). 
Despite its abundance, iron is not readily available due to its insolubility at physiological pH. 
In the presence of oxygen, Fe2+ is rapidly oxidised to Fe3+, which precipitates as polymeric 
oxyhydroxide. The resulting concentration of free Fe3+ in the environment is less than 10-17 M, 
a concentration too low to allow growth by aerobic microorganisms (Papanikolaou & 
Pantopoulos, 2005).  
 
Free iron is tox
 a Haber-Weiss-Fenton sequence generating hydroxyl radical (OH ) and superoxide 
(O2-•), collectively known as “reactive oxygen intermediates” (ROIs) (Table 1) (Halliwell & 
Gutteridge, 1990; Papanikolaou & Pantopoulos, 2005). 
 
ROIs are produced in diverse compartments of th
re
cytoplasm during enzymatic reactions (Papanikolaou & Pantopoulos, 2005), in the 
membrane-bound NADPH oxidase complex of phagocytic neutrophils and macrophages 
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radicals, but also of organic reactive species, such as peroxyl (ROO-), alkoxyl (RO-), thioyl 
(RS), or thioyl-peroxyl (RSOO-) radicals (Papanikolaou & Pantopoulos, 2005).     
 
Table 1. The toxicity of iron. Iron catalyses the generation of hydroxyl radicals via the 
Fenton reaction and the net Haber-Weiss reaction. 
   Fe2+ + O    → Fe3+ + O -• 2 2
   2O2-• + 2H → H2O2+ + O2
   Fe2+ + H2O  → OH  + OH  + Fe (Fenton reaction) 
t
n) 
• - 3+ 
2
   Ne  reaction:  
                      Fe 
   H2O2 + O2-•  → OH- + OH• + O2 (Haber-Weiss reactio
 
tivated, therefore their biological 
fetime is short. They will react with whatever biological molecule is in their vicinity (Aisen 
et al., 2001). The hydroxyl radical, perhaps the most powerful oxidant encountered in 
biologi
 
These hydroxyl and superoxide radicals are highly ac
li
cal systems, will attack proteins, carbohydrates, nucleic acids and lipids initiating 
chain-propagating lipid peroxidation (Aisen et al., 2001; Valentine et al., 1998), while 
superoxide quickly reacts with [4Fe-4S] cluster-containing proteins (Fridovich, 1998; Liochev 
& Fridovich, 1994). However, aerobic organisms have evolved three enzymes, catalase, 
superoxide dismutase and glutathione peroxidase; the first two enzymes scavenge hydrogen 
peroxide (H2O2), whereas the latter superoxide anion, respectively (Aisen et al., 2001). The 
role of these enzymes, as antioxidants, is to protect biological systems against hydroxyl and 
oxygen radicals, being the first line of defence against ROIs (De Freitas & Meneghini, 2001). 
Despite their presence, free superoxide anion and hydrogen peroxide can still be detected 
during normal metabolism in most biological systems (Aisen et al., 2001). Due to this toxicity 
induced by iron, it must be bound in diverse molecules or ions, which are called ligands to 
avoid ROI production (Housecroft & Constable, 2002). As a consequence, cells and 
organisms have developed several mechanisms to reduce toxicity of iron, which include a 
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highly regulated transmembrane iron transport, intracellular chelators and enzymes that 
destroy ROI (Fridovich, 1998). Thus, the control of iron uptake and storage are primordial 
processes to avoid toxicity of iron (De Freitas & Meneghini, 2001).  
 
At the same time, all organisms have to solve the problem of iron availability since it 
is strongly limited because of its dominant form (ferric iron) and the pervasive competition for 
this lim man, 2003). Most of the organisms share the 
evoluti
erent ligands (Kosman, 2003). Successful organisms elaborate a high 
affinity system, one that binds iron with an association constant that can compete with the 
kinetic 
ited and essential nutrient (Kos
onary strategy of how to scavenge iron. The reduction of Fe3+ for the purpose of 
intracellular incorporation into protein is called assimilatory iron reduction. The reduction of 
the complexed Fe3+ results in a weak Fe2+-chelate complex allowing for dissociation and 
release of Fe2+ for transport or cellular incorporation into haem and non-haem Fe-containing 
proteins (Schröder et al., 2003). In contrast, dissimilatory iron reduction serves the generation 
of energy to fuel cell propagation. The reduction of Fe3+ is coupled to the generation of the 
proton motive force across the cytoplasmic membrane, which is then used to generate ATP by 
a membrane-bound ATP synthase, to fuel active transport of nutrients, or to drive motility 
(Schröder et al., 2003).  
 
Once the organisms have solubilised Fe2+, they must hold it tightly due to extreme 
competition between diff
and equilibrium processes that lead to the precipitation of Fe3+, with the auto-oxidation 
of Fe2+ and with the sequestration of iron by neighbours. Thus, some organisms have 
developed two types of system, (i) which is based on extracellular chelation of ferric iron, and 
(ii) based on ferric iron reduction and subsequent “free” iron permeation (assimilatory 
process) (Kosman, 2003). According to the prevailing iron concentration there are high- and 
low-affinity transport processes carried out by all organisms; both are controlled inversely by 
metal availability. The high affinity system is expressed when the iron concentration is low in 
the environment or media, while the low-affinity is utilised under iron sufficiency (Kosman, 
2003).  
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The requirement for iron is almost universal for prokaryotes and eukaryotes, 
demonstrating its importance in cellular metabolism. All plants, animals, fungi and most 
bacteria use iron. The processes and reactions in which iron participates are crucial to the 
surviva
ortance of iron in organisms. Diverse molecules are produced by 
organisms to fulfil iron requirements as well as to avoid its toxicity. 1Ferritin is among the 
most ancient proteins of iron metabolism. It is conserved from bacteria to plants to 
ligand Ferric=Fe
Ferrous=Fe2+
bound to 
ligand 
l of terrestrial organisms, and include ribonucleotide reduction (DNA synthesis), 
energy production (respiration), energy conversion (photosynthesis), nitrogen reduction, 
oxygen transport (respiration, muscle contraction), and oxygenation (e.g. steroid synthesis 
solubilisation and detoxification of aromatic compounds) (Andrews & Schmidt, 2007; Braun, 
2003). The molecules listed in Table 2 use iron as a cofactor or molecules which serve for iron 
uptake and storage. 
 
 
Table 2. The imp
man.2Three classes of transferrin are recognised: serum transferrin, lactoferrin (Lf) or 
lactoferritin, and ovotransferrin, sometimes named conalbumin. 3Ferric iron reductase is found 
in many prokaryotes and eukaryotes that live in aerobic and neutral environments. 4The 
number of iron atoms being bound varies among organisms (Pierre et al., 2002; Schröder et 
al., 2003). 
 
Ligand Function of Iron form bound 
3+
Iron atoms Ligand producer 
1Ferritin Iron storage Fe3+ 42000-4500 Bacteria, plants, 
mammalian cells 
2Transferrin (Tf) Trans Human cells 
3Ferric reductase Reduction of Fe3+ Prokaryotic and 
Cytochromes Electron transfer         Fe3+, Fe2+ 6 
fer of Fe3+ Fe3+ 2 
2 Fe3+
Eukaryotic cells 
Eukaryotic cells 
Haemoglobin Transport of  
oxygen 
Fe2+ 5 Erythrocytes 
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Iron homeos portant proc in any cell, ei r prok karyotic, 
and must be balanced to supply enough iron for cell metabolism and to avoid excessive toxic 
levels. Thus, the regulation of iron transportation is an important matter of iron homeostasis. 
In all 
lthough, the principal aim of this project is to investigate the potential for inhibiting the 
e  new targets for drugs, it is important to 
understand why iron is used in all organisms. Though many organisms use iron, this section 
ost studies of mammalian iron homeostasis have been conducted in the mouse because it 
odel. Firstly, handlers in laboratories are able to recognise 
physical characteristics when mice are anaemic. Anaemic animals are pale, in comparison 
tasis is an im ess the aryotic or eu
organisms, iron homeostasis is achieved, in part, through the control of its transport 
across various membranes. These transport activities include iron uptake from the 
environment, distribution, and intracellular compartmentalisation, as will be outlined below 
for some groups of mammalian cells and bacteria (Andrews & Schmidt, 2007). Although iron 
has a vital role for almost all living organisms, Lactobacillus and some strains of Bacillus 
avoid the use of iron. Instead, they use manganese as a principal cofactor during their 
metabolism (Archibald, 1983; Archibald & Duong, 1984). 
 
1.5.2 Iron in living organisms. 
A
enzym s that produce mycobacterial siderophores as
will outline how mammals and bacteria have evolved systems to acquire, store and use iron 
for their metabolism. 
 
1.5.3 Iron in mammals. 
M
represents a good genetic m
with healthy ones. Secondly, there are several mutant mouse strains with defects in iron 
metabolism. These strains have provided substantial information about defects in iron 
metabolism which have been useful in characterising iron-deficiency anaemia (Andrews, 
2000). Despite most studies being carried out in mice, some investigators have employed 
human cells lines.   
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In humans, adults typically have a total body iron about 3-5 g which is maintained by a 
balancing adsorption and loss of iron (Conrad & Umbreit, 2002). The amount of iron that 
nters and leaves the body is between 0.5-2 mg per day. Humans conserve iron more 
efficien
 
embranes for the optimal transportation of iron through the cell and into the blood (Morgan 
on 
ansport is mediated by ferroportin 1 (Donovan et al., 2000), named also as Iron-regulated 
anspo
e
tly than other animals. There is no regulated pathway for iron excretion, and normally 
iron leaves the body only through menstruation and sloughing of epithelial cells from the skin 
and from the mucosa of the gastrointestinal, biliary and urinary tracts (Andrews, 1999; 2000). 
 
 Iron absorption is normally carried out by mature enterocytes in the duodenum and 
upper part of the jejunum. In iron absorption, important proteins are expressed in the cell
m
& Oates, 2002). Dietary iron compounds are divided in two types, haem and non haem 
(Bothwell et al., 1979) with most dietary iron present as Fe3+ salts (Riedel et al., 1995). Haem 
probably enters mucosal cells by endocytosis, as the intact iron-protoporphyrin complex 
(Conrad & Umbreit, 2002), and within the cells, iron is released by the action of the 
microsomal enzyme, haem oxygenase (Raffin et al., 1974). Normally non haem ferric iron is 
reduced to the ferrous form by protons from stomach acid (low pH) and by the duodenal ferric 
reductase (Dcytb) that is present on the surface of the intestinal wall (Riedel et al., 1995). 
Then, ferrous iron is transported in across the apical membrane into the absorptive enterocyte 
via the Divalent metal transporter 1 (DMT1). This protein is also known as Natural resistance 
associated macrophage protein 2 (Nramp2) or Divalent cation transporter I (DCT1) (Conrad & 
Umbreit, 2002), and is not specific to iron since it can transport other divalent metals such as 
manganese, cobalt, copper, zinc and cadmium (Fleming et al., 1997; Gunshin et al., 1997). 
 
 Inside the enterocytes, ferrous iron has two possible fates, either it may be stored in 
ferritin or transferred across the basolateral membrane to reach the plasma. Basolateral ir
tr
tr rter (IREG1) (McKie et al., 2000) or Metal transporter protein (MTP1) (Abboud & 
Haile, 2000), which probably works together with the membrane ferroxidase hephaestin, 
facilitating basolateral iron export (Vulpe et al., 1999).  
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Iron in its ferrous form is stored in ferritin, an important storage protein. Ferritin can 
store approximately 4,500 iron atoms. First, it acts enzymatically, converting Fe(II) to Fe(III) 
nalised and sequestered in the ferritin mineral core. Second, its critical role in 
cellula
precursors, forming complexes which localise the clathrin-coated pits 
(Aisen t al., 2001). Clathrin-coated pits (CCPs) are specialised plasma membrane proteins 
respons
as iron is inter
r and organismal iron homeostasis is intimately linked to its primary and best-studied 
function iron sequestration, avoiding the generation of free radicals as discussed above (Torti 
& Torti, 2002). If it is not stored, the ferrous iron absorbed is then transferred into transferrin 
(Tf), an abundant plasma protein, which binds ferric iron with high-affinity, for instance 
human serum transferrin (Kd 10-22 M) (Aisen et al., 1978), Transferrin solubilises and 
attenuates iron reactivity and delivers it to the cells (Aisen, 2004). The transferrins are metal-
binding glycoproteins that function in the transport of iron to cells through a cycle 
denominated the transferrin cycle and act as bacteriostatic agents in a variety of biological 
fluids as ferritin (Aisen et al., 2001). Transferrin is also important since it determines the 
distribution of iron through a cycle denominated the transferrin cycle (Aisen, 2004). There are 
two types of transferrins in mammalian cells. (i) Serum Tf (or serotransferrin) and (ii) 
lactoferrin (Lf) serve to transport iron in blood and mucosal secretions (including milk) (Aisen 
& Leibman, 1972).   
 
During the transferrin cycle, holo-transferrin binds to transferrin receptors on the cell 
surface of erythroid 
e
ible for the selective recruitment of various lipids, proteins and other molecules which 
are transported from the plasma membrane (cell surface) to endosomes (Lodish et al., 2003). 
The CCPs invaginate to initiate endocytosis resulting in the formation of specialised 
endosomes. A proton pump decreases the pH within the endosomes, changing the 
conformation of Tf that results in the release of iron from transferrin. DMT1 removes iron 
across the endosomal membrane, to enter the cytoplasm (Andrews, 2000). Apo-transferrin and 
its receptors are recycled for additional cycles. Iron is distributed into different cell types, such 
as hepatocytes, lung cells, macrophages, neutrophils via this the transferrin cycle (Andrews, 
2000; Turi et al., 2004). 
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In erythroid cells, most iron is transported into mitochondria, where it is incorporated 
into protoporphyrin to make haemoglobin. The majority of body iron (65-75%) is utilised 
within haemoglobin (Andrews, 1999). Each erythrocyte contains a billion atoms of iron. After 
red cel
iron, mediated by their own transferrin cycle, and free 
iron th sferrin-binding sites are fully occupied. Hepatocytes can store 
iron in 
t on regulatory 
feedback between body needs and intestinal iron absorption (Fleming & Bacon, 2005). Three 
general
ls reach their lifespan, they are phagocytosed by reticuloendothelial macrophages, 
where haemoglobin is degraded and iron is released from haem. The enzyme haem oxygenase 
may participate in this process. Thus, iron is transported through the cell. The complete 
mechanism of macrophage iron export is still unknown all but ferroportin 1 and hephaestin are 
probably involved (Andrews, 2000).  
 
Other cells that function in iron storage are the hepatocytes. They have mechanisms 
for acquiring both transferrin-bound 
at circulates when tran
ferritin. When iron is needed for other cells, hepatocytes release it to transferrin, and 
again ferroportin 1 and hephaestin may be involved. Both hepatocytes and reticuloendothelial 
macrophages retain 20-30% of body iron. The remaining body iron is localised in myoglobin 
cytochromes, and iron containing enzymes (Andrews, 1999; Andrews, 2000). 
  
Mammals do not have any physiological pathway for iron excretion and the body iron 
homeostasis is maintained at the level of absorption. It is mainly dependen
 mechanisms have been found to influence the rate of iron homeostasis. Firstly, iron 
homeostasis can be modulated by the amount of iron recently consumed in the diet a 
mechanism known as dietary regulator. Secondly, a regulatory mechanism senses iron levels 
but responds to total body iron. This mechanism has been termed the stores regulator and it is 
capable of changing the amount of iron absorbed to a limited extent. Thirdly, erythropoiesis 
can modulate iron absorption, although a precise mechanism has not been found (Conrad & 
Umbreit, 2002; Fleming & Bacon, 2005). Iron not regulated leads to its deficiency and 
overload, causing anaemia and hereditary haemochromatosis, respectively (Aisen et al., 2001; 
Aisen et al., 1999). 
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1.5.4 Iron in bacteria. 
As in other organisms, bacteria have developed strategies to acquire iron. Escherichia coli has 
een the model to study iron metabolism. However, with the deciphering of genomes of others 
eased understanding of iron metabolism in other bacteria. Iron 
concentrations of 10  to 10–7 M are required by most microorganisms for various metabolic 
echanism involves the direct 
r haem-containing proteins to substrate-specific receptors 
in the ou
rs, i.e. production of 
toxins and adhesion proteins, to establish an infection and their production might depend upon 
be expected to influence bacterial multiplication 
in vivo include temperature, pH, osmolarity, oxygen tension, resistance mechanisms of the 
 of nutrients, such as iron, 
b
species, there is an incr
–6
processes that are crucial for microbial replication, including electron transport, DNA 
synthesis and defence against toxic ROI (Weinberg, 1978). In E. coli, the levels of iron range 
105 to 106 atoms per cell (Andrews et al., 2003).  
 
In general, bacteria have adopted several strategies for the uptake and metabolism of 
iron. In most bacteria, there is a high-affinity iron transport, based on siderophores, which 
enables iron to be acquired from the environment. Another m
binding of transferrin, lactoferrin, o
ter membrane of Gram-negative bacteria. Once ferric iron is acquired from the 
environment, it must be reduced to the ferrous form. However, some bacteria can lower the 
external pH to make ferric iron available. In either strategy to acquire iron, it must be stored in 
specialised proteins and released when external supplies are limited, and also to avoid the 
toxicity of iron by producing resistance systems (Andrews et al., 2003). 
 
1.5.4.1 Siderophores, iron and virulence. 
During the course of infection, a pathogen might yield diverse facto
environmental conditions. Factors that might 
host, and the availability of nutrients (Kuhn et al., 2002).  
 
On the other hand, hosts have developed mechanisms to reduce or avoid invasion by 
pathogens, such as physical barriers, bacterial inactivation, producing antibiotics and 
withdrawal of certain nutrients (Sritharan, 2006). The withdrawal
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has been achieved by producing the glycoprotein transferrins (any of their classes) as transient 
storage
hages, the principal cells that phagocytose invading bacteria, yield proteins that alter 
their own iron status generally by withholding iron (mediated by lactoferritin, ferritin and 
transfer
absorption from the intestine as well as by increasing the synthesis of transferrin (Means & 
Krantz,
 and ferritin as final storage molecule of iron (Aisen et al., 2001; 1978). Thus, these 
molecules hold iron tightly and ensure that no free iron is available for pathogens. A general 
response to infection is to decrease the release of iron from tissues to circulation, with the 
result that iron is not available in extracellular fluid and serum (Wooldridge & Williams, 
1993). 
 
Along with transferrin and ferritin, the hosts have produced another mechanism to 
reduce the amount of iron by altering the status of their internal iron. Specialised cells, the 
macrop
rin), regulating the iron pool via the transferrin receptors or transporting iron from 
endosome by specialised molecules (Agranoff & Krishna, 1998; Buschman et al., 1997; 
Cellier et al., 1996; Wardrop & Richardson, 1999). The importance of withholding iron in 
host cells is a crucial mechanism to reduce infection by pathogens. Three different 
compounds, desferrioxamine (DFO), N,N’-bis(2-hydroxybenzyl)ethylenediamine-N,N’-
diacetic acid (HBED) and a 1-amino-3-(2- bipyridyl)isoquinoline derivative (VUF8514), were 
tested as iron withholding molecules by adding these compounds either in vivo (macrophages 
infected with M. avium) or in vitro (media containing the same pathogen). It was found that 
these chelators inhibited the growth of M. avium as might occur with both transferrin and 
ferritin (Gomes et al., 1999). The molecules involved in iron transport and absorption are the 
natural resistance-associated macrophage proteins (Nramp). There are two, Nramp1 and 
Nramp2, but probably the former is involved during infection (Wardrop & Richardson, 1999). 
 
The phenomenon of limiting iron availability to an invading pathogen has been 
considered as nutritional immunity, although there is no involvement of the immune system 
by the host in this process. The host limits the availability of free iron by decreasing the 
 1992). Haemochromatosis (HH) is a genetic disorder associated with progressive iron 
overload and deposition in multiple organs. Two mutations (C282Y, H63D) in the hfE gene 
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have been found to be associated with HH. Three consequences of the C282Y mutation are 
lack of expression of hfE on the cellular surface, a lowered iron level in macrophages and an 
increased rate of clearance of iron from the instestinal lumen (Moalem et al., 2002). Iron 
deficiency of macrophages in people with hereditary HH mutations is associated with 
increased resistance to infection by intracellular pathogens, such as Yersinia, Coxiella, 
Francisella, Legionella, Mycobacterium and Salmonella, a selection pressure which is called 
Epidemic Pathogenic Selection (EPS). Thus, people with hereditary HH mutations may result 
in increased resistance to these pathogens (Moalem et al., 2004). 
 
Various intracellular bacteria, fungi and protozoa use distinct host-cell compartments 
as niches for survival, where access to nutrients is an important matter (Schaible & Kaufmann, 
2004). M. tuberculosis blocks phagosome maturation to access cellular iron resources 
guyen & Pieters, 2005). Chlamydia trachomatis forms a non-infectious reticulate body 
(RB) w
es for its acquisition. For 
instance, some pathogens produce more than one siderophore in low iron conditions. M. 
tubercu
(N
hich replicates within a specialised vacuole, called inclusion. Its intracellular 
replication might need an intimate association with the host cell which allows it to scavenge 
for nutrients, including ATP (Stephens et al., 1998). Toxoplasma gondii replicates within the 
parasitophorous vacuole membrane (PVM) which forms tight associations with host 
mitochondria and the endoplasmic reticulum (ER) (Sinai et al., 1997). Legionella 
pneumophila creates an ER-derived organelle that supports bacterial growth by a process that 
involves intercepting early secretory vesicles (Kagan & Roy, 2002). 
 
Iron is the only nutrient known to be generally growth-limiting and to play an 
important role in the virulence of bacteria and has lead pathogens to evolve and develop 
different mechanisms to compete with the host iron-bound molecul
losis produces mycobactin and carboxymycobactin (Ratledge & Dover, 2000), P. 
aeruginosa produces pyoverdin and pyochelin (Cox & Adams, 1985; Cox et al., 1981), 
species of enteric bacteria, for instance E. coli, produces enterochelin and aerobactin (Bagg & 
Neilands, 1987).  
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Within the hostile environment of the host, the availability of iron depends on two 
physical conditions, the oxidation-reduction potential (Eh) and the pH, both factors are crucial 
because they control the binding of iron to transferrin (Bullen et al., 2005; 1992). It has been 
ated that iron is insoluble at pH around neutrality and its concentration as Fe3+ is about 10-18 
M that
, by adding a 
ducing agent the bactericidal effect was removed, and after 2 h, the remaining bacteria, 
about 5
 in the biosynthesis of iron chelators, has shown that without these compounds 
pathogens are not able to grow or lose their virulence. On the other hand, in experimental 
studies
ntration of 50 µg ml-1 
ferric ammonium citrate to co-cultures of M. tuberculosis and either murine or human 
macrophages for 4 days tended to enhance growth of the bacteria (Rook et al., 1986). In 
st
 is still low for cells to be able to acquire it and therefore they need specialised 
molecules, such as the siderophores. For instance, in the phagocytic vacuoles of the 
macrophages, where M. tuberculosis grows, the pH is between 6.1 and 6.5  and the maximum 
concentration of Fe3+ is only between 1 and 10 ng/ml (Piddington et al., 2000).  
 
Human plasma has an Eh around +200 mV, pH 7.5 and is strongly bactericidal against 
strains of E. coli and Klebsiella pneumoniae with about 99.9% of approximately 50,000 
bacteria/mL being destroyed in 1h. When the Eh is lowered to -400 mV, pH 7.5
re
0/mL, grew rapidly to reach over 106 bacteria/mL in a further 6 h. At this low Eh, 
about half of the ferric iron attached to the transferrin was reduced to the ferrous form, and 
ferrous form is no longer bound by transferrin and is freely available to bacteria (Bullen et al., 
1992).  
 
Diverse studies have demonstrated the relationship that there is between iron 
availability and pathogenicity of bacteria. The disruption of genes, which encode for enzymes 
involved
 iron enhances the virulence when it is added either in vitro or in vivo (Agranoff & 
Krishna, 1998; Brown & Holden, 2002; Schaible & Kaufmann, 2004). 
 
The importance of iron to enhance infection by mycobacteria and for instance the 
production of its siderophores has been demonstrated in different ways. Addition of iron 
enhances the infection in macrophages by M. tuberculosis. A conce
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another
growth of pathogenic 
mycobacteria in humans, which suggested that mycobactin was important as virulence factor 
for M. 
tuberculosis and M. avium in mice are considerably 
worsened by iron supplementation with the clear implication that addition of iron to the diet of 
human 
iron was sequestered from the host by 
administrating iron chelators (Cowart & Foster, 1985; Sword, 1966). A close association has 
 study, macrophages infected with mycobacteria were exposed to 59Fe-transferrin. The 
study demonstrated that the bacteria could acquire iron delivered through the endocytic route 
(Wagner et al., 2005). Although Fe3+ was released from transferrin to bacteria, the mechanism 
is unknown, and perhaps due to similar association constant and higher affinity for iron, 
mycobactins were able to compete with transferrin for iron. Undoubtedly the interaction of 
many factors could explain that exchange of iron between molecules.  
 
In a recent study, the deletion of the gene that encodes for MbtB in M. tuberculosis 
was shown to interrupt the biosynthesis of the mycobactins under conditions of iron 
limitation. In addition, this mutant was found to be impaired for growth in macrophage-like 
THP-1 cells, macrophages being the preferred cell type for 
tuberculosis (De Voss et al., 2000). However, other studies have shown that the 
importance of mycobactin production and its relation with the growth of M. tuberculosis is 
important at short time intervals, but is not relevant over a longer period of growth (Sassetti et 
al., 2003; Sassetti & Rubin, 2003). 
 
 The relationship between iron availability and growth or virulence of M. tuberculosis 
is also supported further by clinical studies of dietary iron overload in Africa, where a strong 
association between elevated iron and tuberculosis was observed (Moyo et al., 1997). 
Experimental infections with M. 
sufferers, including AIDS patients suffering from M. avium infections, must be 
avoided (Gomes et al., 2001; Lounis et al., 2001). 
 
Iron acquisition via yersiniabactin is also important for the virulence of Yersinia pestis 
during the early stages of infection in mice (Bearden & Perry, 1999). Listeria monocytogenes, 
a causative agent of foodborne illness, has been shown to increase its virulence in mice loaded 
with iron, and the effect was opposite when 
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been o
nd their importance as molecular 
irulence factors for bacteria will be discussed. 
   
any microorganisms, in response to iron deficiency 
Delepelaire, 2004). There are almost 500 
mpounds identified as siderophores. The selectivity of siderophores for Fe(III) is achieved 
through
d. However recent data shows 
that IrtA, IrtB and Rv2895c participate in export and import of M. tuberculosis 
carboxy
bserved between iron acquisition and expression of virulence factors/toxins like the 
diphtheria toxin by Corynebacterium diphtheriae, the shiga toxin by Shigella sp. and exotoxin 
A from Pseudomonas aeruginosa (Payne & Lawlor, 1990).  
 
1.5.4.2 Siderophores in bacteria. 
Although, the fungi also produce siderophores, here this subject will be emphasised in 
bacteria. Chemical and biological features of siderophores a
v
Siderophores are produced by m
under aerobic environments. These molecules have low molecular weight and are considered 
as high-affinity extracellular ferric chelators to solubilise iron prior to transport (Andrews et 
al., 2003; Ratledge, 2004; Wandersman & 
co
 optimal selection of metal binding groups, the number of binding units, and their 
stereochemical arrangements (Boukhalfa & Crumbliss, 2002). 
 
Siderophores must satisfy three criteria. Firstly, they must be iron-regulated 
biosynthesis, secondly, ferric ion binding capability, and thirdly, active transport through the 
cell membrane (Drechsel & Jung, 1998). The uptake of carboxymycobactins (siderophores of 
pathogenic mycobacteria) was thought to be not energy-linke
mycobactins across the membrane and the consequent iron uptake (discussed in 1.7.1) 
(Farhana et al., 2008). Genes related to iron availability and therefore siderophore 
biosynthesis is regulated either positively or negatively. During iron uptake, the siderophore-
Fe+3 complex is transported into the cell by diverse proteins (Andrews et al., 2003; Ratledge 
& Dover, 2000).     
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Not all bacteria can produce siderophores. For instance Clostridium perfringens, a 
Gram-positive bacterium, does not produce siderophores. Instead, they acidify their 
environments in the host tissue so that iron is acquired from molecules, such as transferrin or 
lactofer . These molecules are reduced to Fe (II) and then it is mobilised to the cell 
(Johnso
rotein 
amino acids including both modified and D-amino acids (Boukhalfa & Crumbliss, 2002). 
According to the iron coordination chemistry, various ligands which contain O, N and S atoms 
form complexes, and this is reflected in the chelating 
s 
erived from 2,3-dihydroxybenzoate (DHB). Variants are found, and instead of DHB, some 
siderop
 group is used to chelate iron as N-hydroxy-N-acyl 
erivative of ornithine or lysine. A third type of chelating group, mixed ligands, has been 
suggested by combining the above types (Boukhalfa & Crumbliss, 2002). For convenience 
ritin
n, 2008). On the other hand, Neisseria gonorrhoeae and N. meningiditis do not 
produce their own siderophores, but they can use siderophores produced by other 
microorganisms as an iron source, e.g. aerobactin (Wandersman & Delepelaire, 2004).  
 
1.5.4.3 Structure of siderophores. 
Despite their variety, most siderophores have a peptide backbone with several nonp
donate electrons to iron in order to 
groups of siderophores, having O and N as electron donors (Boukhalfa & Crumbliss, 2002).  
 
There are three main types of iron-coordinating functional groups in siderophores. 
Firstly, there are the N-hydroxy amino acid side chains, with the oxygen atom as one of the 
ligands for Fe3+. Secondly, there are adjacent hydroxyls of catechol rings, almost alway
d
hores have 2-hydroxybenzoate (salicylate) as ferric iron ligands. Thirdly, the nitrogen 
atoms of five thiazoline and oxazoline rings, resulting from enzymatic cyclisation of cysteinyl 
and seryl, or threonyl side chains, respectively, can also coordinate Fe3+ (Boukhalfa & 
Crumbliss, 2002; Crosa & Walsh, 2002). 
 
Other authors have suggested classifiying siderophores considering only two categories 
of chelating groups. The first, the phenolic acid based structures or catechols, second is the 
hydroxamates in which the ω–N(HO)-CO
d
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this cla
ixed ligands. 
Chelating  
group 
Structure Occurrence in  
siderophores 
Producing  
organisms 
References 
ssification is adopted here. Table 3 illustrates these common ligand groups and Figure 
4 shows examples of siderophore structures. 
 
 
Table 3. Common ligand groups found in siderophore iron binding centres. Two types of 
chelating groups are considered, the catecholate rings and hydroxamates. A third type is 
considered when both types are mixed, the m
Catecholate 
 
inia Haag et al. (1993). 
Enterochelin 
Parabactin 
Yersiniabactin 
E. coli 
Paracoccus 
Yers
Raymond et al. ( 2003). 
Bergeron et al. (1985). 
 
id 
Aerobactin 
 
erium 
Aerobacter 
 
 
). 
Gibson & Magrath (1969).  
 
Agrobactin 
Parabactin 
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Independently of structural classification, the chelating groups are arranged in different 
architectures such as linear, tripodial, endocyclic or exocyclic (Boukhalfa & Crumbliss, 2002). 
acterial siderophores are structurally more diverse than fungal siderophores. Catecholate 
 
B
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siderophores, containing 2,3-dihydrobenzoic acid, are exclusively produced by bacteria. 
Bacteria also produce other structural classes of siderophores, hydroxamates and carboxylates 
(Drechsel & Jung, 1998). 
 
 
H
N
O H
N
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O
O
 
Figure 4. Structures of some siderophores that show the chelating groups. Enterochelin 
and parabactin have catecholate groups as iron-chelating. Rhodotorulic acid and exochelin MS 
possess hidroxamates as iron chelators. Vibriobactin and mycobactin T are mixed iron-ligand 
siderophores. 
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Three factors are important in order to bind ferric iron by siderophores. Firstly, 
s available for bonding these can form bonds in hexadentate complexes. Most 
siderop
g to various principles. In early work with siderophores, the colour of some 
derophores played a major role in facilitating detection and study of siderophores. Thus, 
rrichrome, ferrirubin, which only denotes a 
reddish-coloured, iron-containing substance. Since this nomenclature includes iron, the metal-
Enterobacteriaceae. However, this principle has caused confusion, because for enterobactin 
denticity is the number of donor atoms that bind to the metal centre in a complex  (Cotton et 
al., 1995). Thus, if one atom is bonded in the metal centre, the complex is named 
monodentate; two atoms, the complex is considered bidentate, and so on. Because ferric iron 
has six orbital
hores are hexadentate, the optimal denticity to satisfy the six coordination sites of 
Fe(III). Although some siderophores are tetradentate, these need mulltimetallic assembly to 
ensure full ferric iron coordination. In general, hexadentate siderophores, based on 
hydroxamates and/or catecholates, have much higher affinity for ferric iron. These 
discriminate against ferrous form, compared to tetradentate siderophores, which in turn have a 
higher iron affinity compared to bidentate siderophores (Boukhalfa & Crumbliss, 2002). 
Secondly, the ligand structure affects the complex stability to bind iron. Cyclic structures such 
as ferrioxamine E and alcaligin show a higher Fe(III) affinity compared to their linear 
analogues ferrioxamine B and rhodotorulic acid, respectively. Thirdly, denticity also induces a 
concentration effect which favours ligands with high denticity (Boukhalfa & Crumbliss, 
2002). 
 
1.5.4.4 Nomenclature of siderophores. 
Nomenclature of siderophores is problematic because researchers have denominated them 
accordin
si
names were chosen for some siderophores: fe
free ligand has to be designated as desferri-siderophore, for example, desferri-ferrichrome 
(Drechsel & Jung, 1998).  
 
Another characteristic considered to denominate a specific siderophore is naming it 
according to the producer. This was done firstly with enterobactin, isolated from 
     50
Chapter 1                                                                                                   Introduction 
(Pollack & Neilands, 1970) there is another name, enterochelin, which was named by another 
research group (O'Brien & Gibson, 1970). Usually the name of siderophores is formed by two 
parts: the first part is related to the producer and the second part the chemical class of 
siderop
 
1.5.4.5
NRPSs). Ribosomal peptide synthesis is normally 
stricted to a set of 20 amino acids for proteins, but in NRPS several hundred substrates have 
been identified. The presence of additional structures, such as fatty acids, heterocyclic rings, 
d amino acids, is observed in 
hore.   
 
A reasonable siderophore nomenclature would be based upon their chemical 
structures, but there are reasons why this nomenclature has not been adopted. Siderophores are 
already named at the stage of isolation, purification and the optimisation of the fermentation 
procedure, when the chemical structure is still unknown or not fully characterised (Drechsel & 
Jung, 1998).  
Another principle which causes a problem is the spelling of siderophores. Some 
siderophores, isolated and described in France, carried an “e” at the end, for example 
“pyoverdine”. However, this nomenclature is being abandoned in the literature, thus the 
preferred name today is “pyoverdin”. 
 
 Biosynthesis of siderophores: general mechanism. 
Most of the siderophores in bacteria have a peptidic backbone, combined with a prevalence of 
nonproteinogenic amino acid units, which suggests that siderophores are made by 
nonribosomal peptide synthetases (
re
nonproteinogenic amino acids, carboxylic acids, and modifie
siderophores. Thus, structural diversity is a predominant feature of nonribosomally produced 
peptides (Crosa & Walsh, 2002; Finking & Marahiel, 2004; Walsh et al., 1997).  
 
 The NRPSs were originally discovered as enzymes that catalyse the synthesis of 
antibiotics and other substances in Gram-positive bacteria. NRPSs are very large 
multimodular enzymes that produce peptide products of a particular sequence without mRNA 
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as a template. The NRPS enzymatic activity shares similarity with the polyketide synthases 
(PKSs) (Du & Shen, 2001); the latter produce several secondary metabolites, e.g. antibiotics 
nd antitumor agents, from the same substrate used by fatty acid synthases (McDaniel et al., 
in, known also as thiolation domain) 
a
2005). Both NRPSs and PKSs incorporate carrier domains which tether the growing chain via 
their post-translational modification by phosphopantetheine. A thioesterase (TE) domain is 
present in both systems, and this catalyses the release of the peptide or polyketide product. 
(Du & Shen, 2001; Quadri, 2000). Thus, these structural and catalytic similarities between 
NRPSs and PKSs have suggested that both might exist as hybrid enzymatic systems. This new 
enzymatic hybrid results in the production of diverse metabolites by incorporating amino 
acids and short carboxylic acids by NRSPs and PKSs, respectively. Based on the order in 
which either amino acid or carboxylic acid is incorporated, the hybrid NRSP-PKSs can be 
divided in two classes. Those whose biosynthesis do not involve functional interaction 
between NRPSs and PKSs modules and those whose biosynthesis are catalysed by hybrid 
NRPS-PKS systems, involving direct interactions between NRPSs and PKSs modules (Du & 
Shen, 2001). The order of activation and incorporation of the amino acids is specified by the 
order of NRPS domains (Crosa & Walsh, 2002; Finking & Marahiel, 2004; Quadri, 2000). 
NRPSs are structurally organised in modules. A module is defined as a section of the NRPS’s 
polypeptide chain that is responsible for the incorporation of one building block into the 
growing polypeptide chain (Finking & Marahiel, 2004). Thus, NRPSs are used as a template 
(because amino acids to be incorporated are determined by the module) and biosynthetic 
machinery (it is the module that contains all necessary catalytic functions). Fungi use a single 
NRPS to synthesise a complete natural product and these multifunctional enzymes can reach 
remarkable sizes. In bacteria, modules are usually distributed in several NRPSs whose genes 
are organised in an operon (Finking & Marahiel, 2004).   
 
The enzymatic units that reside within a module are called domains which carry out the 
steps of substrate activation, covalent binding, and peptide bond formation (Stachelhaus & 
Marahiel, 1995). The modules can be subdivided into initiation and elongation modules. 
Elongation modules contain at the minimum an adenylation domain (A-domain) for substrate 
recognition, a peptidyl carrier protein domain (PCP-doma
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that holds the activated substrate and a condensation domain (C-domain) for peptide bond 
format
i dentified on the p tein le  Mod es can  subdivided into domains 
that contain the catalytic activities for substrate activation (Adenylation domain, A-domain), 
covalent loading (carrier protein domain, CP-domain) with a phosphopantetheinyl group 
tailored (~SH), and peptide bond formation (condensation domain, C-domain). Modules 
ion. NRPSs initiation modules lack a C-domain. Additionally, a number of tailoring 
enzymes may be present to catalyse the maturation, modification reactions, such as N-
methylation, amino acid epimerisation and heterocyclisation, of the NRPS product. These 
reactions generate the structural diversity of nonribosomal peptides (Figure 5) (Finking & 
Marahiel, 2004; Marahiel et al., 1997; Quadri, 2000). 
 
A PCP C A PCP 
SH SH
A PCP C A PCP 
1 2
gene
Modules
Domains
A A-domain 
PCP CP-domain 
C C-domain 
Figure 5. Genetic and protein organization of nonribosomal peptide synthetases 
(NRPSs). From gene to protein. Modules that are responsible for the incorporation of one 
amino ac d can be i ro vel. ul  be
which lack a C-domain are used to initiate nonribosomal peptide synthesis, while those that 
contain a C-domain are used for product elongation [Adapted from Finking and Marahiel 
(2004)]. 
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1.5.4.5.1 Adenylation domain. 
The adenylation domain (A-domain, ~550 aa), is responsible for the selection of the amino 
acids which will form the product and, therefore, these control its primary sequence. A-
domains activate an amino or carboxy acid substrate as an amino acyl adenylate consuming 
ATP (Finking & Marahiel, 2004). Although, aa-tRNA synthetases and adenylation domain of 
NRPSs carry out similar enzymatic activities, they are structurally unrelated (Weber & 
  
 (ArCPs), are required. 
at they carry during synthesis (Finking & 
arahiel, 2004; Lambalot & Walsh, 1995). 
Acyl carrier proteins (ACPs) of fatty acid and PKSs, carrying acetate, propionate, 
s of proteins do not share sequence similarities 
paring all members of the family. But the sequences around the 
Marahiel, 2001). 
Also during initiation of siderophores biosynthesis, salicylate (2-hydroxybenzoate) and 
2,3-dihydroxybenzoate (DHB) might be incorporated (Walsh et al., 2001; Walsh et al., 1997). 
These aryl acids act as aryl-N-caps and also incorporate iron ligands due to the presence of 
hydroxyl groups in their structure. To add salicyl and DHB groups at the start of siderophore 
synthesis, an A-domain for either salicyl-AMP or DHB-AMP formation and a carrier protein, 
the aryl carrier proteins
 
1.5.4.5.2 Carrier proteins. 
The carrier protein domain (~80-100 aa) is the unit that accepts the activated amino acid, 
which becomes covalently bound to its 4’-phosphopantetheine cofactor as a thioester. These 
proteins belong to the carrier proteins superfamily, which consists a number of different 
members named according to the substrates th
M
 
malonate units or fatty acyl substrates, and aryl carrier protein (ArCP) are involved in 
siderophores synthesis. Peptidyl carrier proteins (PCP) transfer amino acids or peptidyl 
substrates from one catalytic centre to the next (Linne et al., 2001; Linne & Marahiel, 2000). 
Although all carrier proteins carry out different roles within their biosynthetic machinery, they 
are structurally related. However, this clas
when considering and com
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serine 
 
akes the virulence-conferring siderophore yersiniabactin has a five domain PKS module 
followe
All carrier proteins require a post-translational modification in order to become active. Each 
carrier
n of a 
onserved serine residue of the carrier protein domain on the pyrophosphate linkage of 
coenzyme A (Figure 6A), transferring the 4’-phosphopantethenate (P-pant) moiety, producing 
r protein serine side chain and releasing 3’,5’-ADP 
residue (core T-motif), which serves as attachment site for the phosphopantetheinyl 
arm, is similar within ACPs and PCPs but differs among species (Finking & Marahiel, 2004). 
 
Erythromycin, an antibiotic yielded by Saccharopolyspora erythraea, is synthesised by 
a trimer of multidomain proteins, deoxyerythronolide B synthase (DEBS) I, II, III, which act 
sequentially, passing the growing chain from one ACP to the next. This process is a type I 
polyketide synthase (Leadlay et al., 1993). In the biosynthesis of siderophores, such as 
enterobactin, pyochelin, and yersiniabactin, peptidyl and aryl carriers are conjugated to 
produce those iron chelators (Quadri, 2000). A subunit of the synthetase, HMWP1, which
m
d by a four-domain NRPS module (Gehring et al., 1998b). 
 
Although there are some biochemical gaps to be defined in mycobactin biosynthesis, it 
is probably produced by conjugating aryl, peptidyl carriers and polyketide synthases (De Voss 
et al., 1999; Quadri et al., 1998). Mycobactin biosynthesis is discussed in section 1.6.2. 
 
1.5.4.5.3 Phosphopantetheinylation. 
 protein domain, ArCP, ACP, and PCP, must be converted from the apo form to the 
holo form, through a process called phosphopantetheinylation carried out by a 
phosphopantetheinyl transferase (PPTase). PPTases catalyse the attack of the side chai
c
a phosphodiester linkage to the carrie
(Figure 6B). The reaction requires Mg2+ as a cofactor (Lambalot et al., 1996; Walsh et al., 
1997).  
 
Three types of PPTases are recognised according to their size and substrate selectivity 
(Lambalot et al., 1996). The first is the “Acyl Carrier Protein Synthase (ACPS)-type” from E. 
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coli, as the prototype. These PPTases are ~120 amino acids in size, and are very specific for 
CPs of primary metabolism in fatty acid biosynthesis (Chirgadze et al., 2000; Parris et al., 
2000). The second type is the “Sfp-type” PPTases, denominated after Sfp (surfactin 
phosphopantetheinyl transferase), which is required for the production of the lipoheptapeptide 
ntibiotic surfactin in Bacillus subtilis (Lambalot et al., 1996). The size of these enzymes is 
approx
a
imately twice the size of the ACPs-type. Although some Sfp-type PPTases seem to be 
specific enzymes, others are able to modify both ACPs and PCPs (Gehring et al., 1997b; 
Sánchez et al., 2001).    
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Figure 6. Catalytic function of phosphopantetheinyl transferases. A) Structure of coenzyme 
A from which the 4’-phosphopantetheine group is transferred onto a conserved serine residue within 
the carrier protein proteins of modular NRPSs and PKSs. B) Modification of carrier protein domains 
by post-translational phosphopantetheinylation catalysed by phosphopantetheinyl transferase. The 
modification converts inactive form apo-form to active holo-domains. The reaction is dependent on 
Mg2+ and yields 3’,5’-ADP as a second product [Adapted from Lambalot et al. (1996)]. 
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The third type of PPTase is incorporated as a domain at the carboxyl terminus of the α-
subunit of fungal type I FASs, where it catalyses the in cis autophosphopantetheinylation of 
the ACP at the amino terminus of the same polypeptide (Fichtlscherer et al., 2000).  
 
The P-pant introduced contains a terminal sulphydryl group (~SH) allowing 
biosynthetic intermediates to be bound as an energy-rich thioesters that facilitates hydrolysis 
during and after synthesis. Therefore, the P-pa
). During 
fatty acid biosynthesis, the carboxy-activated malonyl-ACP is produced and then it is 
decarboxy
nt groups act as a nucleophile for acylation by a 
substrate, either acyl-CoA or malonyl-CoA for the FASs and PKSs, or aminoacyl-AMPs for 
the peptide synthesis, for instance in siderophores (Figure 7) (Lambalot et al., 1996
lated, yielding a nucleophilic carbanion (negatively-charged carbon) that attacks a 
second acyl thioester to form a new carbon-carbon bond in one of the steps of PKSs. In 
peptides, the aminoacyl-S-PCPs or hydroxyacyl-S-PCPs serve as nucleophiles in amide and 
ester bond-formation (Figure 7) (Lambalot et al., 1996). 
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Figure 7. The terminal thiol of P-pant group acting as a nucleophile. The terminal 
cysteamine thiol of the phosphopantetheine cofactor acts as nucleophile for acyl activation. FASs and 
PKSs transfer acyl groups from acyl-CoA to the phosphopantetheine group attached to ACP. NRPSs 
first activate their aminoacyl or acyl substrates as acyl-adenylates before transfer to the 
phosphopantetheine tether of the carrier protein [Adapted from Lambalot et al. (1996)]. 
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1.5.4.5.4 The condensation domain.  
In NRPSs for siderophores, after activation of the carboxy groups as aminoacyl thioesters 
(aminoacyl-S-PCP), the next process is elongation. The siderophore chain growth is 
directional, from the most upstream, N-terminal PCP domains, to the most downstream, C-
terminal PCP domains. The polypeptide synthetase catalytic domains are named condensation 
 elongation module of the NRPSs assembly line has 
und to the downstream (with respect to the C-domain) module onto acyl 
roup of the amino acid tethered to the upstream module (Stachelhaus et al., 1996). These 
domain
active site to C-domains 
eating et al., 2000a; Keating et al., 2002; Quadri et al., 1998). Like C-domains, these 
extend 
 
domains (C-domains). Basically, a core
the three domains, C-A-PCP, as a functional module (Crosa & Walsh, 2002; Finking & 
Marahiel, 2004). 
 
C-domains (~450 aa) are the central entity of NRPS because they are responsible for 
peptide bond formation between aminoacyl substrates bound to PCPs of adjacent modules. C-
domains catalyse the nucleophilic attack of the amino (or imino, hydroxyl) group of the 
activated acid bo
g
s contain a site for the nucleophile (donor site, number two in Figure 8A) and a 
position for the electrophile (donor site, number one in Figure 8A). 
 
One characteristic of siderophores, such as yersiniabactin, pyochelin and mycobactin, 
is the presence of thiazoline and oxazoline rings. These rings are formed by a C-domain 
variant, the cyclisation domain (Cy-domain). The Cy-domains catalyse the heterocyclisation 
of serine, threonine, or cysteine residues and possess a different 
(K
the growing chain by condensation with the downstream Cysteine-S-PCP, Ser-S-PCP, 
and Thr-S-PCP but before the chain is transferred down, to the next elongation module, Cy-
domains catalyse the ciclysation and dehydration of the side chain providing both metal 
chelating and intercalating groups to the modified peptides (Figure 8B) (Walsh et al., 2001).  
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NH
O
R1
NH2
O
R2
 
) 
 the active site of the next C-domain. B) Cy-domain catalyses the heterocyclisation of 
R2
Figure 8. Domains which are activated during growth elongation of NRPSs products.  A
In condensation (C)-domains two adjacent PCP-domains are loaded with their respective 
amino acid. The electrophile (acceptor) aminoacid enters the acceptor site (number 1) and the 
(donor) nucleophile amino acid is accommodated in the donor site (number 2) of the C-
domain. After the peptide bond has formed, the resulting dipeptide can act as the electrophile 
in
serine, threonine or cysteine residues which lead to the formation of thiazoline or oxazoline 
rings, which act as iron chelating groups [Adapted from Finking and Marahiel (2004)].         
 
1.5.4.5.5 The thioesterase domain.  
A final module is required to release from its phosphopantetheinyl tether. This module 
contains, in most cases, a thioesterase domain (TE-domain, ~ 250 aa), that is important for 
releasing the product (Figure 9) (Schneider & Marahiel, 1998). 
NH2O
A
PCP
A
PCPC
1 2
R1
O
NH2
C
1 2
S S
A
PCP
A
PCPC
1 2
C
1 2
SH
S
PCP
SH
H3N
O
R
H3N
HX+
PCP
SH
PCP
SH
PCP
SH
H3N O
X
N
R
-2H2O
X= O, S
B) Cy-domain 
A) C-domain 
     59
Chapter 1                                                                                                   Introduction 
 
Figure 9. Catalytic activity of TE domain. TE-domain carries out the releasing of NRPS 
product [Adapted from Finking and Marahiel (2004)].         
 
During the process, the release of the product is achieved by a two-step reaction that 
re by an OH or NH2) or water, 
hich forms either a macrocyclic product (surfactin, an antibiotic produced by Bacillus 
subtilis
l TE 
termediate that subsequently suffers a nucleophilic attack by an internal nucleophile 
involves formation of an acyl-O-TE-enzyme intermediate that is subsequently attacked by 
either a peptide-internal nucleophile (intramolecular captu
w
) or a linear peptide like pyochelin (a siderophore produced by Pseudomonas sp.) 
(Crosa & Walsh, 2002; Finking & Marahiel, 2004). The TE-domains are also responsible for 
the structural diversification of NRPSs because these domains carry out some modifications 
such as oligomerisation of peptide units as has been observed in enterobactin synthesis.  
 
 Two types of TE-domains are recognised. Type I is usually found as the last domain of 
NRPS and catalyses cleavage of the assembled peptide product from the PCP domain in the 
last module. In this process the phosphopantetheinyl group is released to give an acy
in
(hydroxyl group). The second type, stand-alone TE, is often encoded within the gene cluster 
and possibly their role is to hydrolytically remove inactivating acetyl groups from the 4-
phosphopantetheinyl thiols of PCP domains to regenerate active thiols (Challis & Naismith, 
2004). 
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1.5.4.5.6 Diversity of siderophore produced by NRPS. 
The great diversity of NRPS products, including siderophores, is due to additional enzymatic 
rocesses, called tailoring domains, which can be involved either during or after other 
 and act in cis (moving along in a 
single protein chain), and the others are distinct enzymes which act in trans (moving from one 
ids for activation and the E-domains epimerise them when 
inoacyl or peptidyl-S-PCP acyl enzyme intermediates (Challis & 
ith, 2004; W
at N-methylation of the amino acid monomer occurs before the 
mation of the peptide bond. In pyochelin and yersiniabactin synthesis, the MT-domains are 
in trans action 
 catalyses the two-electron transfer to 
p
biosyntheses. Some represent an integral part of the NRPS
protein to chain to another) on the way to the mature NRPS product (Challis & Naismith, 
2004; Finking & Marahiel, 2004).  
 
 One interesting feature of NRPS is the presence of D-amino acids. An Epimerisation 
domain (E-domain), is responsible for epimerisation of L-amino acids. In general, the A-
domains of NRPS select L-amino ac
they are installed as am
Naism alsh et al., 2001). In pyochelin and mycobactin synthesis there are E-
domains which act in cis. 
 
 Some siderophores such as mycobactin, pyochelin and yersiniabactin contain N-methyl 
amino acids. These methyl groups are introduced by dedicated methyltransferases (MT), and 
it has been determined th
for
found closest to A-domain, acting in cis (Quadri, 2000), but in yersiniabactin there is an 
additional MT closest to Cy-domain in the HMWP1 unit (Brem et al., 2001). 
 
 As has been seen, Cy-domains catalyse the heterocyclisation of cysteine, serine and 
threonine residues to yield thiazoline or oxazoline rings, but their oxidative state is not always 
the final product. In pyochelin synthesis, a thiazolidine ring is the result of the 
of the NADPH-dependent reductase PchG that
thiazolinyl-S-PchF (Reimmann et al., 2001).   
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1.5.4.5.7 Siderophore biosynthesis independent of NRPSs. 
Several bacterial siderophores are not polypeptides, and are assembled from alternating 
icarboxylic acid and diamine or amino alcohol building blocks (which are nevertheless 
ds. These NRPS-independent 
pathways lead to aerobactin, rhizobactin, achromobactin, vibrioferrin, alcaligin and 
ay Reference 
d
derived from amino acids) linked by amide or ester bon
desferrioxamine E biosynthesis (Table 4) (Challis, 2005). 
 
 
Table 4. Siderophores and their biosynthetic pathways.  
Siderophore Producer Pathw
Aerobactin Escherichia coli 1 de Lorenzo & Neilands (1986). 
Alcaligin Bordetella pertussis 1 Moore et al., (1995). 
Barona-Gómez et al., (2004). 
5). 
 
Desferrioxamine Streptomyces coelicolor 1 
Vibrioferrin Vibrio parahaemolyticus 1 Challis (200
Yersiniabactin Yersinia enterocolitica 2 Brem et al., (2001). 
Mycobactin M. tuberculosis 2 Quadri et al., (1998). 
Vibriobactin Vibrio cholerae 2 Keating et al., (2000b). 
Pyochelin Pseudomonas aeruginosa 2 Quadri et al., (1999). 
1Nonribosomal peptide synthases (NRPSs)-independent pathway. 
2NRPSs pathway. 
 
 
1  
arly attempts at in vitro culture of M. avium subsp. paratuberculosis (previously M. johnei) 
r Johne’s bacillus, that is responsible for the condition of chronic enteritis in cattle, failed 
e a laboratory medium to 
culture the organism, which led to the observation that addition of dried and killed human 
.6 The discovery and structural elucidation of mycobactins. 
E
o
(Twort & Ingram, 1912). Studies were initiated to attempt to defin
tubercle bacilli as supplement promoted growth, presumably a growth factor was necessary 
(Twort & Ingram, 1912). However, the substance was not isolated and identified for almost 40 
years. 
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Francis et al. (1949) isolated a similar growth promoting factor from M. phlei which 
could be crystallised in complex with aluminium, but not in a metal-free form. In 1953, the 
same authors were able to isolate the growth factor, named since then as mycobactin, in a 
metal-free form (Francis et al., 1953). The first structure of mycobactin P, i.e. the mycobactin 
from M
 an amide bond to an acylated ε-N-hydroxylysine residue. This 
lysine was esterified at the α-carboxyl with a β-hydroxy acid that forms an amide link with a 
second 
. phlei, was determined and its constituent fragments identified by chemical 
degradation (Snow, 1954a). However, the structure proposed was tentative, and a further 
analysis determined the correct structure of the active ferric complex of mycobactin P in a 
crystalline form (Snow, 1965b). Mycobactin T was identified from M. tuberculosis by Marks 
(1953), but its structure was solved by Snow (1965a). Both mycobactin P and T were 
identified as very similar chemical entities, differing only in the chain length of a fatty acyl 
substituent. Subsequent structural analysis of other mycobactins from various mycobacteria, 
including M. terrae, M. marinum and M. smegmatis, revealed that all share the same core 
structure (Figure 8), but these are subject to species-specific differences at several sites (Table 
5) (Snow & White, 1969).  
 
The core structure was elucidated as the following. A 2-hydroxyphenyloxazoline 
moiety, arising from either salicylic acid or 6-methylsalicylate according to the specific 
mycobactin was linked via
ε-N-hydroxylysine which was cyclised to give a seven membered lactam. This basic 
structure serves to chelate ferric iron very effectively via the two hydroxamic acids of the ε-N-
hydroxylysines, the N of the oxazoline ring, and the phenolate oxygen atom (Figure 10) 
(Snow, 1970). By X-ray analysis, the ferric iron coordination chemistry of ferrimycobactin P 
was determined. Six atoms, five oxygens and one nitrogen coordinate the Fe3+ atom and form 
an octahedron (Hough & Rogers, 1974). 
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Lysine
Salicylic acid or
6-methylsalicylate
3-hydroxy-butyric acid
Figure 10. General structures of mycobactins and carboxymycobactins. All the known 
mycobactins have the same basic molecular pattern, the core structure which is formed by 
salicylic acid/6-methylsalicylate, serine/threonine, two lysines, and 3-hydroxy-butyric acid. 
Variation in mycobactins is due to changes at five positions in the molecule (R1-R5). The 
carboxymycobactins share the same core structure, but they differ by varying the long-chain 
fatty acid (R5) for a short chain which terminates in either carboxyl or ester functionality. The 
three pairs of ferric iron-chelating groups are boldface [adapted from De Voss et al. (1999) 
and Snow (1970)]. 
 
A nomenclature was proposed to distinguish the mycobactins which have the same 
core structure are grouped in a family (Snow, 1970). Mycobactins have also been 
distinguished by a letter, and each letter represents a family of mycobactins that have the core 
structure. Individual members of a family are distinguished by adding the number of carbon 
atoms in the side chain (Table 5, Figure 10) (Snow, 1970; Snow & White, 1969). Great 
variation in the long-chain fatty acyl component has been observed in M. smegmatis; 17 
different mycobactins have been detected varying only in the R5 substituent (Ratledge & 
Ewing, 1996). A list of diverse mycobactins and their producers is shown in Table 5.  
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Table 5. Diversity of mycobactins (MBs). Within the core structure of mycobactins there are 
five main substitutions which lead to the diversity of these siderophores. The alkyl 
substituents of the hydroxy acid (R3 and R4) and the acyl moiety (R5) are highly variable. 
However, the acyl moiety (R5) is the source of most of the observed structural variation in the 
mycobactins. 
Substituents MB type 
R1 R2 R3 R4 R5
Species 
A CH3 H CH3 H C13 M. aurum 
Av H CH3 CH3CH2 CH3 C11-18 M. avium 
F CH3/H CH3 CH3 H C9-17 M. fortuitum 
H CH3 CH3 CH3 H C17-19 M. thermoresistible 
J H H (CH3)2CH2 H C15 M. avium subsp. paratuberculosis 
P CH3 H CH3CH2 CH3 C15-19 M. phlei 
R H H CH3CH2 CH3 C19 M. terrae 
S H H CH3 H C9-19 M. smegmatis 
T H H CH3 H C17-20 M. tuberculosis 
M H CH3 C15-18 CH3 CH3 M. marinum 
N H CH3 C15-18 CH3 (CH3)2CH2 M. marinum 
Carboxy-MB Av H CH3 CH3CH2 CH3 C2-10 M. avium 
Carboxy-MB T H H/CH3 CH3 H C2-8 M. tuberculosis 
 
 
According to the core structure, two types of mycobactins can be distinguished. 
Mycobactins P, T, A, R, F, H, S and J have the same core structure but differ only in details of 
substitution and absolute stereochemistry. Mycobactins M and N, from M. marinum, differ 
from the others by having a small acyl group at R5, but having a long-chain substituent at R3 
(White & Snow, 1969). The acyl moiety (R5) is the most variable structure in the 
mycobactins. The acyl group is a long-chain fatty acid (C10 to C21) that is often unsaturated 
with an unusual cis double bond conjugated to the carbonyl group, but in mycobactin T in 
which some members of the family probably have saturated alkyl side chains (Snow, 1970). 
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Many mycobacteria are peculiar in their ability to produce both a cell-bound and a 
secreted siderophore, mycobactins and carboxymycobactins, respectively. Mycobactins, 
lipophilic siderophores, are insoluble in water because of the long alkyl chain attached to the 
molecule, but they are extremely soluble in chloroform, fairly soluble in ethanol, and less 
soluble in other alcoholic solvents, such as methanol or propylene glycol (Snow, 1970). It has 
been shown that the long chain is an important feature of the mycobactins not only increasing 
the hydrophobicity of the molecule, but also as a means of preventing siderophore diffusion 
due to its association with the cell membrane. However, mycobactins and other siderophores 
might become amphiphilic in their iron complex (Lin et al., 2001; Martinez et al., 2003). 
 
On the other hand, carboxymycobactins are variations of mycobactins in which the 
long alkyl chain is replaced by a shorter chain terminating in a carboxylic acid, which might 
be further modified as a methyl ester (Figure 11); these modifications are responsible for their 
solubility in aqueous solutions (Lane et al., 1995; Wong et al., 1996). Since, both mycobactins 
and carboxymycobactins have the same core structure, it has been suggested that they are 
synthesised by the same set of enzymes and that only one of the final steps determines if a 
mycobactin or carboxymycobactin is produced (Gobin et al., 1995).  
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H
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Me-CO2-(CH2)1-7
 
 
 
 
 
 
Figure 11. St ycobactin and 
carboxymycobactin T have the same core structure, but they vary in their alkyl substituent 
where in the latter a carboxylic acid group acts as chain termination (Gobin et al., 1995). The 
side chain of carboxymycobactin Av, isolated from M. avium, can be saturated or unsaturated 
ructure of M. tuberculosis carboxymycobactin T. Both m
and terminates with either a carboxylate or methyl ester (Wong et al., 1996).     
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The presence of a second mycobacterial siderophore family has been recognised, the 
exochelins. Exochelins, which have been isolated from non-pathogenic mycobacteria, are 
water s
 
et al. 
(1995a)]. Exochelin structures are based on modified peptides and are highly-water soluble 
The nomenclature of carboxymycobactins has generated confusion since some authors 
have named them exochelins, water-soluble mycobactins or exomycobactins (Gobin et al., 
1995; W
N
oluble. The structures of two exochelins, from M. smegmatis (Macham et al., 1975; 
Sharman et al., 1995b) and M. neoaurum (Sharman et al., 1995b) have been elucidated and 
their structures are as follows. They are linear penta and hexa-peptides in which the 
hydroxamate groups form the major iron binding centres (Figure 12). In exochelin MN from 
M. neoaurum, there is a unique β-hydroxyhistidine residue which forms one of the three iron 
binding pairs of ligands in the molecule (Sharman et al., 1995a).  
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Figure 12. Structure of exochelin MS from M. smegmatis. [adapted from Sharman 
molecules. The exochelins have been only isolated from non-pathogenic mycobacteria.  
 
 
ong et al., 1996; Zhu et al., 1998). Exochelins and carboxymycobactins share some 
physical characteristics in that they are extracellular soluble siderophores, although their 
chemical structure is different. Prior to the structural elucidation of the carboxymycobactin 
structure, all extracellular mycobacterial siderophores were denominated exochelins, 
independent of their solubility differences (Ratledge, 2004; Vergne et al., 2000). To avoid 
confusion the name carboxymycobactins is adopted here to distinguish these from exochelins. 
Although, the carboxymycobactins are produced by pathogenic mycobacteria, such as M. 
avium (Lane et al., 1995) and M. tuberculosis (Gobin et al., 1995), M. smegmatis also 
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produces a carboxymycobactin whose structure was confirmed as identical to the core 
structure of mycobactins (Ratledge & Ewing, 1996).  
 
1.6.1 Organisation of the mycobactin-carboxymycobactin gene clusters. 
 attempt to elucidate mycobactin biosynthesis, early studies were restricted to 
ore structure of 
e data describing the provision of mycobactin 
precurs rs, the genetic determinants of mycobactin assembly remained unknown, until the 
genome
In an
experiments using an isotope-based approach and the identities of the basic c
mycobactins were clarified. The aromatic moiety of the mycobactins has two different 
biosynthetic sources according to the species. The aromatic moiety of mycobactin S, from M. 
smegmatis, arises from salicylate formed via the shikimic acid pathway (Hudson & Bentley, 
1970). Addition of [G-14C]-shikimic acid to the medium led to the radiolabeling of the 
mycobactic acid hydrolysis product of mycobactin and to the extracellular salicylic acid 
excreted by M. smegmatis. However, the aromatic moiety of mycobactin P was not derived 
from this pathway, as shown by the failure to incorporate radiolabel into the siderophore. 
Consistent with mycobactin P bearing a methyl function at R1, it was thought that the 
aromatic moiety was derived from 6-methylsalicylate, which is synthesised  through the 
condensation of four acetate units and is not a shikimate metabolite (Hudson et al., 1970). 
Similarly, the presence of radioactivity from [U-14C]-L-Lysine in the cobactin and mycobactic 
acid hydrolytic products showed that lysine was the precursor of both ε–N-hydroxylysines in 
M. phlei and M. smegmatis (Tateson, 1970). Incubation of M. phlei and M. smegmatis with [2-
14C]-propionate and [1-14C]-acetate, respectively, yielded high radioactivity in the cobactin 
linker fragments of the two mycobactins. 
 
Despite the availability of som
o
 sequence of M. tuberculosis H37Rv was completed (Cole et al., 1998). Initially 
twelve candidate genes for mycobactin biosynthesis were identified; a first cluster of ten genes 
(mbtIJA-H, occupying Rv2386c-Rv2377c) (Figure 13) was designated the mbt (mycobactin 
biosynthesis) locus along with two other genes encoding for phosphopantetheinyl transferases 
(pptT and acpS) (Figure 13).  
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Protein 
name 
Proposed function Domains within each 
module 
Amino  
acids 
Molecular  
weigth (Da) 
Gene 
name 
MbtA Salicylate-AMP ligase (PAE) A 565 59 279.7 mbtA 
MbtB NRPS/PKS hybrid system ArCP, Cy, A1, PCP, T1/TE mbtB 
 
2, PCP2, C2, ACP3   
e  
rolase   
transferase 
1413 151 502.3 
MbtC Polyketide synthase (PKS) KS 444 46 623.4 mbtC 
MbtD Polyketide synthase (PKS) ACP1, AT2, KR, ACP2 1004 105 591.5 mbtC 
MbtE Peptide synthetase (NRPS) C1, A 1682 183 282.0 mbtE 
MbtF Peptide synthetase (NRSP) C3, A3, PCP3, E 1461 156 747.7 mbtF 
MbtG Lysine-N-oxygenase  131 46 943 mbtG 
MbtH Unknown  57 6521.3 mbtH 
MbtI Isochorismate synthas  431 46 976.5 mbtI 
MbtJ Acetyl hyd  306 32 875.9 mbtJ 
PptT Phosphopantetheinyl  227 24 707.5 pptT 
AcpS Phosphopantetheinyl 
transferase 
 130 14 001.8 acps 
Figure 13. Locus involved (mbt-1) for assembly of the core structure of 
my tin/c s. Genes encoding for peptide ar on en PAE on-cobac arboxymycobactin ylati zymes ( S), n
ribosomal peptide synthetases (NRPSs), polyketide synthases (PKSs), and non-ribosomal-peptide-
polyketides (NRPSs/PKSs) hybrid synthetases are shown. Domain abbreviations are as follow: ArCP: 
aryl carrier protein, A:adenylation, C: cyclization, PCP= peptidyl carrier protein, TE, thioesterase, AT: 
acyl transferase, KS: ketoacyl synthase, KR: β-ketoreductase, ACP: acyl carrier protein, C: 
condensation, E: epimerase (Quadri, 2000; Quadri et al., 1998).     
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The gene products of this now renamed mbt-1 cluster encode proteins that resemble 
peptide arylation enzymes (PAEs), nonribosomal peptide synthetases (NRPSs) and polyketide 
synthas
 core structure, then 
both m ay be derived from a common precursor “pre-mycobactin”. 
The de
the genome of M. tuberculosis and the sequenced genomes of other 
mycobacterial species revealed the presence of similar mbt-1 gene clusters for mycobactin-
carboxy
of mbt-1 gene clusters indicated that there are significant 
differences in the organisation of the genes present in the cluster of different species. The 
es (PKSs). Based on analysis of their amino acid sequences, the catalytic function and 
domain organization of the enzymes could be predicted to include: a peptide arylation enzyme 
(MbtA), three nonribosomal peptide synthetases (NRPSs), MbtB, MbtE, MbtF and two 
polyketide synthases (MbtC, MbtD) (Figure 13). Hence, all the machinery necessary to 
produce the complex structure of the mycobactin core from simple building blocks is 
contained in these modular enzymes (Quadri, 2000; Quadri et al., 1998). 
 
Because both mycobactin and carboxymycobactin share the same
ycobacterial siderophores m
letion of the mbtB gene from the mbt-1 cluster of M. tuberculosis resulted in a mutant 
unable to produce either mycobactin or carboxymycobactin, supporting the above hypothesis 
(De Voss et al., 2000). Clearly, the phenotype of the mutant linked the production of 
mycobactin and carboxymycobactin to the same enzymes. In addition to being impaired for 
growth in iron-deficient medium, this mutant did not grow in macrophage-like THP-1 cells, 
which suggested that mycobactins are important virulence factors for M. tuberculosis (De 
Voss et al., 2000).  
 
Comparing 
mycobactin biosynthesis in M. smegmatis mc2155, M. bovis AF2122/97, M. bovis 
BCG Pasteur 1173P2, M. avium subsp. avium strain 104, M. avium subsp. paratuberculosis 
K-10 and M. marinum M (Quadri & Ratledge, 2004). Mycobactin genes are not found in M. 
leprae TN (Cole et al., 2001a), therefore it is a pathogenic Mycobacterium lacking both 
mycobactin and carboxymycobactin siderophores, which is consistent with an early 
observation  (Kato, 1985).  
 
These comparisons 
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clusters
atuberculosis cannot produce mycobactin is 
also explained by analysis of the mbt-1 gene cluster. Comparison of the mbtA-mbtJ cluster of 
M. tub
.6.2 Unified model for mycobactin-carboxymycobactin biosynthesis. 
Several siderophore biosynthetic loci have been recently identified from diverse pathogenic 
bacteria and characterised both genetically and biochemically (Crosa & Walsh, 2002; Miethke 
 of M. tuberculosis and M. bovis appears to be identical, however, in the genomes of 
M. smegmatis, M. avium and M. avium subsp. paratuberculosis mbtJ and mbtI, were not found 
at the 5’ ends or in close proximity to the clusters. Likewise in M. marinum, mbtI is not 
present in the cluster (Quadri & Ratledge, 2004). 
 
The observation that M. avium subsp. par
erculosis, M. avium subsp. avium and M. avium subsp. paratuberculosis show three 
significant differences. Firstly, in M. tuberculosis, mbtI and mbtJ, are adjacent to each other 
and immediately downstream of the mycobactin-carboxymycobactin biosynthesis gene 
cluster. However, in M. avium subsp. paratuberculosis and M. avium, there is a 6.6 and 5.7 kb 
gap, respectively, between the two genes. Moreover, there is 19.3 kb gap in M. avium subsp. 
paratuberculosis and 197.3 kb gap in M. avium between mbtJ and mbtA. The distance 
between these genes does not explain why M. avium subsp. paratuberculosis cannot produce 
mycobactin-carboxymycobactin, since M. avium subsp. avium is still able to make these 
siderophores. Secondly, a frame-shift mutation was identified in both mbtB and mbtE from 
both M. avium subspecies when compared to M. tuberculosis. The presence of these frame-
shifts in M. avium subsp. avium suggests that this difference is not the limiting factor which 
affects mycobactin-carboxymycobactin production in M. avium subsp. paratuberculosis. 
However, the major difference between the mbt-1 gene clusters was found in the mbtA gene. 
The mbtA gene is shorter in M. avium subsp. paratuberculosis, encoding a 400 amino acid 
protein, compared with 565 and 551 amino acid residues in M. avium subsp. avium and M. 
tuberculosis. Hence, the abolition of mycobactin-carboxymycobactin production in M. avium 
subsp. paratuberculosis may be explained by the truncation of MbtA (Li et al., 2005; Semret 
et al., 2004). 
 
1
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& Marahiel, 2007; Quadri, 2000). Analyses of the loci for pyochelin and pyoverdin (both 
uct function predicted, most of the models for the 
iosynthesis of these mycobacterial siderophores are still unknown; only the aryl carrier 
protein
 model for salicylate-containing pre-mycobactin (Figure 14). The first 
committed biochemical reaction is the conversion of salicylic acid from chorismate by MbtI. 
Follow
produced by P. aeruginosa), yersiniabactin (Yersinia pestis), vibriobactin (Vibrio cholera) and 
enterobactin produced by diverse enterobacteria, such as E. coli, Salmonella enterica, 
Klebsiella spp. and Shigella spp., all encode PAESs, NRPSs, PKSs, and NRPSs/PKSs hybrid 
modular enzymes and are useful for comparison with the mycobacterial mbt-1 cluster. There 
are three features that unite the biosynthesis of all these siderophores. Firstly, they all 
incorporate aryl acids, 2,3-dihydroxybenzoate (DHB) or 2-hydroxybenzoate (salicylic acid), 
and are thus designated as aryl-N-capped siderophores. Secondly, they all contain thiazoline 
and oxazoline rings, which provide ligands for binding ferric iron (Crosa & Walsh, 2002; 
Miethke & Marahiel, 2007; Quadri, 2000).  
 
Although, the genes required for the core mycobactin-carboxymycobactin core 
structure have been identified and their prod
b
 of MbtB, MbtA, MbtG, MbtI, and PptT for mbt-1 cluster, have been characterised 
(Harrison et al., 2006; Krithika et al., 2006; Quadri et al., 1998). Recently, a second cluster of 
genes, mbt-2, encoding the acyl chain transfer to the mycobactin core, were also identified 
(Krithika et al., 2006). 
 
Despite the lack of genetic and biochemical characterisation, de Voss et al. (1999) 
proposed a biosynthetic
ing salicylate loading of the aryl carrier protein domain of MbtB, by MbtA via an aryl 
adenylate, the adenylation domain of MbtB activates either serine or threonine, condenses it 
with the salicylate moiety, and cyclises this product to form hydroxyphenyloxazoline. MbtE 
and MbtF have the appropriate activation, condensation, and peptide carrier domains for 
donation of the two lysine-derived moieties of mycobactins.  
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Figure 14. Proposed biosynthetic cascade catalysed by the mycobactin-
carboxymycobactin gene clusters. A) The mbt-1 gene cluster produces the core structure 
(Quadri et al., 1998), whereas B) the mbt-2 produces acyl-S-ACP intermediates, which are 
subsequently transferred to the core structure to produce didehydroxymycobactin. The 
hydroxylation of the lysine residues is carried out by the MbtG to generate the functional 
amphiphilic mycobactin siderophore (Krithika et al., 2006). However, most of the enzymatic 
reactions to produce the core structure are still unknown and the putative function of the 
MbtC, MbtD, MbtE, MbtF, MbtH and MbtJ awaits genetic and biochemical characterisation.     
 
 
MbtF has a terminal domain that was assigned a role either as an epimerisation domain 
or as thioesterase responsible for releasing the mycobactin from the enzyme by lactamisation 
of the terminal hydroxylysine residue. MbtC and MbtD are homologous proteins that might 
function as polyketide synthases and appear to contain the appropriate modules to donate the 
required β-hydroxybutyrate residue. The MbtG protein is a FAD-containing monooxygenase 
required for the production of the ε-N-hydroxylysines. MbtH and MbtJ are proposed to be 
involved in mycobactin biosynthesis, although their biochemical role is not yet clear (De Voss 
et al., 1999).  
 
The biochemical characterization of some enzymes involved in mycobactin-
carboxymycobactin supports the proposed model. The last gene in the mbt-1 cluster, Rv2386c, 
was originally annotated as trpE2; its product resembles the large subunit of anthranilate 
synthase, the enzyme that catalyses the first committed step in tryptophan biosynthesis (the 
conversion of chorismic acid to anthranilic acid). However, the expression of Rv2386c is up 
regulated under iron-low environments, and this indicated that its role could be in siderophore 
biosynthesis (Gold et al., 2001). Hence, the Rv2386c gene was re-annotated as mbtI, 
putatively encoding the enzyme that shares homology to a family of isochorismate synthase, 
anthranilate synthase and salicylate-forming enzymes, consistent with a role in the conversion 
of chorismate to salicylate, the starter unit of pre-mycobactin biosynthesis (Quadri et al., 
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1998). Recently, the crystal structure and biochemical function of the MbtI protein have been 
characterised, both ring isomerisation and pyruvate lyase activities being demonstrated. This 
lead to the conversion of chorimate to salicylate demonstrating the first step in pre-mycobactin 
biosynthesis (Harrison et al., 2006). The same mechanistic conversion of chorismate to 
salicylic acid has also been reported in Y. enterocolitica Irp9 (Kerbarh et al., 2005; Pelludat et 
al., 2003). The second step is carried out by the lone-standing aryl acid adenylation (A) 
domain of MbtA, converting salicylate to an aryl adenylate. The function of MbtA as 
salicylate-AMP ligase was demonstrated using the classical ATP-[32P]-PPi exchange assay. 
Next, the acyl-adenylate is selectively transfered to the N-terminal (holo-ArCP domain) of 
MbtB, which has been followed using [14C] salicylate (Quadri et al., 1998). Clear similarities 
exist in the genes encoding homologous functions in the biosynthesis of other salicylate-
capped siderophores, such as pyochelin produced by P. aerugionsa (Quadri et al., 1999) and 
yersiniabactin produced by Y. pestis (Gehring et al., 1998a). Significant homology is also 
apparent with the adenylation proteins participating in siderophore biosynthesis in E. coli 
(EntE) (Gehring et al., 1997a), DhbE from Bacillus subtilis (May et al., 2002) and VibE from 
V. cholerae (Keating et al., 2000b), which all activate dyhydroxylated aryl acid (DHB) 
instead.   
  
In mycobactins and structurally-related mixed aryl-capped hydroxamate siderophores 
such as vibriobactin (Keating et al., 2000b), acinetobactin (Yamamoto et al., 1994) and 
frankobactin (Boyer et al., 1999), oxazoline rings are found as a result of serine or threonine 
cyclisation. In vibriobactin bioynthesis, the oxazoline ring formation is catalysed by a 
cyclisation domain (Cy) of VibF, a NRPS. Here DHB is first adenylated by VibE and then 
transferred to VibB, an aryl carrier protein, to form the aryl N-cap donor DHB-S-pantetheinyl-
VibB. The VibF protein provides two cyclisation domains, two condensation domains, an 
adenylation domain and a peptidyl carrier protein (PCP), the domains required for 
condensation, heterocyclisation and dehydration, leading to oxazoline ring formation. The A 
domain of VibF activates L-threonine and attaches to the HS-pantetheinylated PCP to yield 
the threonyl-S-PCP substrate for condensation/heterocyclisation by one of the two Cy 
domains with the aryl moiety derived from the DHB-S-VibB donor to form the oxazoline ring 
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in vibriobacin (Keating et al., 2000b). Similar biochemical reactions might occur for the 
formation of the oxazoline ring during pre-mycobactin biosynthesis, in which the interaction 
of the MbtA and MbtB proteins are involved, but this scenario awaits further investigation. 
  
As was outlined before, each of the carrier domains must be converted from the apo 
form to the holo form by adding the phosphopantetheinyl arm by a dedicated 
phosphopantetheinyl transferase (PPTase) (Lambalot et al., 1996). In E. coli there are two 
types of PPTases, one is specific for apo-ACP domains in fatty acid and polyketide synthases, 
CP-specific PPTase (AcpS), and the second specific for modification of apo-PCP and apo-
ArCP domains (EntD domain) in peptide synthetases (Gehring et al., 1997a). Using these 
PPTases as models, homologues were identified in the M. tuberculosis genome. One of these 
homologues (33% similar to E. coli AcpS) was designated as mycobacterial AcpS (Rv2523c) 
(Cole et al., 1998) and the second homologue had similarity to EntD (30%) and was 
designated PptT (Rv2794c) (Quadri et al., 1998). Normally, a PPTase is encoded in a 
siderophore biosynthetic gene cluster (Lambalot et al., 1996). Interestingly, neither the 
mycobacterial acpS nor pptT genes are encoded near the mbt-1 gene cluster.   
 
Recently the function of the MbtG protein was investigated (Krithika et al., 2006). 
This protein is homologous to ornithine and lysine oxygenases, which are responsible for the 
production of ε-hydroxylysines to generate functionally important hydroxamate moietes in 
siderophores. In vitro, the protein was able to carry out the hydroxylation of both lysine and 
an acylated lysine in presence of NADPH and FAD with a clear preference for the latter 
(Krithika et al., 2006). This preference might support a hypothesis in which the oxygenation 
of the two lysines of pre-mycobactin occurs after their incorporation into the siderophore 
precursor and is consistent with the isolation of a proposed mycobactin precursor 
didehydroxymycobactin that has been taken to suggest that hydroxylation might be the last 
step in mycobactin biosynthesis (Moody et al., 2004). However, this model must be 
considered with some caution until a more complex study of MbtG function is completed: the 
two lysinyl residues are diverse structurally, one being N-acylated and the other being 
cyclised, and thus it is implied that MbtG has a very relaxed substrate specificity. 
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Alternatively, the preference exhibited for the acylated lysine could be artefactual in that the 
effective concentration of the substrate might be exaggerated by the recruitment of the enzyme 
to vesicles of this amphiphilic substrate, a property not shared with the unmodified amino 
acid.  
   
In order to reconcile the annotation of MbtJ as acetyl hydrolase, Ratledge (2004) has 
suggested that the “pre-mycobactin” nucleus might be synthesized with an acetyl group 
attached to both N6 atoms of the lysine residues. Both groups will remain until the 
hydroxylation occur in both lysyl-N6 atoms is required to yield the two hydroxamate ligands 
(Ratledge, 2004). The hydroxylation events and the subsequent cyclisation of the terminal 
lysine residue and acylation of the central residue would thus be facilitated by the 
deacetylation activity of MbtJ.  
 
These issues will be clearly resolved by the construction and careful analysis of knock-
out mutants in mbtG and mbtJ, but a comparison of the kinetics of aminoacyl adenylation of 
the A domains of MbtE and MbtF, the NRPSs proposed to incorporate the pre-mycobactin 
lysines, using lysine, N-acetyl and N-hydroxy-lysine, would also provide further mechanistic 
insight.     
 
1.6.3 The mbt-2 gene cluster. 
Because mycobactin and carboxymycobactin share the same core structure, it has been 
suggested that both siderophores are synthesised by the same multienzymatic reactions to 
yield a common precursor “pre-mycobactin”, but the final step must be different due to the 
different alkyl groups in these mycobacterial iron chelators. In both mycobacterial 
siderophores the long chain is usually ligated to the central lysine residue but no candidate 
acyltransferase encoding genes were identified or near the mbt-1 cluster. However, good gene 
candidates for the addition of the long-chain were suggested using transposon mutagenesis 
(LaMarca et al., 2004). Insertion of Tn611 into M. smegmatis LR222 yielded, two potential 
mycobactins mutants, designated LUN8 and LUN9. LUN8 produced a ferric-siderophore 
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whereas LUN9 failed to yield siderophore. The mycobactins produced by the wild type and 
LUN8 strains were compared by an incomplete NMR analysis, the latter produced a modified 
mycobactin, in which the long acyl-chain was abnormal (LaMarca et al., 2004).  
 
Nucleotide sequencing showed that the insertion-flanking region from LUN9 shared 
homology with the mycobactin biosynthesis genes mbtD and mbtE of M. tuberculosis, 
consistent with disruption of pre-mycobactin biosynthesis and the lack of mycobactin-like 
siderophores. The transposon insertion in LUN8 was located in a region that encoded 
orthologues of M. tuberculosis FadD33 (Rv1345, an acyl-CoA synthase), AcpA (Rv1344, an 
acyl carrier protein) and FadE14 (Rv1346, an acyl CoA-dehydrogenase) and specifically 
disrupted the sequence encoding FadD33. Complementation of LUN8 with plasmids encoding 
native FadD33 and FadE14 restored mycobactin biosynthesis, the resulting transformant 
produced the typical mycobactin S. Based on sequence, FadD33 and FadE14 are the enzymes 
required to initiate modification of a pre-existing lipid with subsequent attachment of the lipid 
to an acyl carrier protein with final transfer to the mycobactin core by an acyl-transferase 
(LaMarca et al., 2004).     
 
The Rv1347c gene of M. tuberculosis was predicted to encode for an aminoglycoside 
6’-N-acetyltransferase, however the crystal determination of its product suggested a different 
biochemical function (Card et al., 2005). Rv1347c is a member of the GCN5 related N-
acetyltransferase (GNAT) family of enzymes. Bioinformatics analysis and modelling 
experiments suggested that Rv1347c functions in the acylation of the N-hydroxylysine 
residues of mycobactin. An indication that Rv1347c may have the ability to transfer long acyl 
groups necessary for mycobactin-carboxymycobactin biosynthesis was provided by the 
observation that the enzyme showed thioesterase activity (an essential part-reaction in acyl 
transfer) with a range of acyl CoA substrates with a clear preference for longer acyl chains 
(Card et al., 2005).     
 
Recently, the biochemical function of those putative genes was elucidated and another 
cluster for mycobactin biosynthesis was proposed, mbt-2. The cluster was identified by 
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computational analysis of iron-dependent genes regulated by IdeR repressor with subsequent 
biochemical characterisation of the proteins (Krithika et al., 2006). These studies confirmed 
that this second gene cluster is responsible for the acyl substitution of different aliphatic chain 
lengths and for introducing the unusal cis double bond conjugated to a carbonyl group that 
distinguish mycobactin and carboxymycobactin from other amphiphilic siderophores, such as 
marinobactin, aquachelin and amphibactin (Krithika et al., 2006). This second cluster is 
formed by a fatty acyl-AMP ligase (fadD33= Rv1345), an acyl carrier protein (ACP= 
Rv1344), fadE14 (Rv1346) homologous to acyl-CoA dehydrogenase and the acetyl 
transferase (Rv1347c) which is transcribed in the opposite direction (Krithika et al., 2006).      
 
The enzyme FadD33 (Rv1345) was characterised as a fatty acyl-AMP ligase (FAAL) 
which is responsible for converting fatty acids into acyl adenylates. This mode of activation 
and transfer of fatty acids is contrary to the previously described universal mechanism, 
involving the formation of acyl-coenzyme A thioesters (Trivedi et al., 2004). The enzyme is 
able to use a variety of medium and long chain fatty acids to form acyl adenylates. Then, the 
activated acyl adenylates are transferred onto the phosphopantetheinyl group of AcpA 
(Rv1344) (Krithika et al., 2006). 
 
The fatty acid chain of mycobactin contains an unusual double bond. The formation of 
double bonds is normally catalysed by an acyl-CoA dehydrogenase during β oxidation of 
saturated fatty acids where FAD is the electron acceptor (Nelson & Cox, 2004). The fadE14 
gene, a proposed acyl-ACP dehydrogenase, could catalyse this reaction. The next step in the 
assembly of the amphiphilic mycobactin would involve N-acylation of these ACP tethered 
long-chain fatty acids directly onto the ε-amino group of lysine. This reaction is catalysed by 
the novel proposed acetyl-transferase (Rv1347c) using a wide range of medium to long chain 
fatty acids (C6-C16) (Krithika et al., 2006). Whether this single enzyme participates in the 
acylation of pre-mycobactin toward the synthesis of both mycobactin and carboxymycobactin 
is yet to be established. 
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Hence, the genes described above carry out the incorporation of an unsaturated fatty 
acid chain in to the core structure of the cell-bound mycobactins. Following the nomenclature 
for the existing mycobactin cluster for the biosynthesis of the core structure, the four genes are 
annotated as mbtK, mbtL, mbtM, and mbtN for Rv1347c, Rv1344, fadD33 (Rv1345), and 
fadE14 (Rv1346), respectively (Table 6) (Krithika et al., 2006).  
 
Probably, after the synthesis of the core structure, “pre-mycobactin” is transferred 
from the cytoplasm, where its biosynthesis may occur, and it is finally positioned in the cell 
envelope (Ratledge, 2004). Carboxylic and methyl ester groups, positioned in 
carboxymycobactins, suggest that the final biosynthetic steps must be different. A 
dicarboxylic acid has been proposed as precursor for the carboxylic acid end, but nothing is 
known about this step and the genome does not indicate how it might be accomplished 
(Ratledge, 2004). 
 
 
Table 6. Characteristics and designation of proteins proposed for mbt-2 in M. 
tuberculosis (Krithika et al., 2006). 
Protein name Proposed function Amino  
acids 
Molecular  
weight (Da) 
Gene name 
MbtK  Acetyl transferase 210 23 798.94 mbtK 
MbtL Acyl carrier protein 106 11 399.93 mbtL 
MbtM Fatty acyl-AMP ligase 521 53 957.26 mbtM 
MbtN Acyl-ACP dehydrogenase 386 41 180 mbtN 
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1.7 Transport of ferri-siderophore across the membrane.  
Differences in the complexity of ferri-siderophore uptake between Gram-negative and Gram-
positive bacteria are necessitated by the former’s possession of an outer membrane (OM), 
essentially transport requires additional proteins (receptors and accessory proteins). It is the 
challenge of crossing this outer membrane that shall be considered first; the elements of the 
subsequent steps in Gram-negative bacteria are very similar to the processes employed by 
Gram-positive bacteria. The uptake of ferri-siderophore requires their efficient capture at the 
cell surface. Gram-negative bacteria synthesise a range of specific high-affinity receptor 
proteins that effectively concentrate these ligands at the cell surface (Ratledge & Dover, 
2000). 
 
Porins are membrane transporters that allow energy-independent passage of solutes of 
molecular weight ≤ 600 Da across the membrane. These proteins are found in the outer 
membrane of Gram-negative bacteria, acid fast Gram-positive bacteria, plastids, chloroplasts 
and mitochondria (Saier, 2000). Siderophores and haem are too big to cross the outer 
membrane through porins and are also present at low concentrations in the extracellular 
medium, making necessary the production of high affinity protein receptors (Wandersman & 
Delepelaire, 2004). For this reason, the first step in the internalisation process, for Gram-
negative bacteria, requires that outer membrane receptor proteins bind ferri-siderophores with 
high specificity (Andrews et al., 2003; Ratledge & Dover, 2000; Wandersman & Delepelaire, 
2004).  
 
 Currently, the structures of four metal-chelate receptors are known. FepA (Buchanan et 
al., 1999), FhuA (Endriss et al., 2003; Locher et al., 1998) and FecA (Ferguson et al., 2002; 
Yue et al., 2003) are the receptors for enterobactin, ferrichrome, and ferric dicitrate, 
respectively, and BtuB is the receptor for vitamin B12. The latter though, is not a siderophore, 
but is also transported through a TonB-dependent receptor (Chimento et al., 2003). These 
structures show remarkable similarities. All of them consist of 22 anti parallel β strand barrels 
formed by ~600 C-terminal amino residues and a plug formed by ~150 N-terminal residues. 
The β strands are connected on the extracellular side by loops of variable length while in the 
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periplasmic side they are connected by shorter loops. The plug or cork domain consists of 
multiple β short strands connected via loops and α helices. Mutagenesis studies of the FepA 
and FhuA plug domains suggest that conformational rearrangements of this domain are 
responsible for substrate passage rather than complete displacement of the plug (Chakraborty 
et al., 2007). A representative of this type of receptor is shown in Figure 15. 
 
 
 
 
 
 
 
 
 
Figure 1  in 
blue. The molecule is presented as found in the outer membrane with extracellular loops 
extending into the solvent (top) and periplasmic turns oriented toward the periplasm (bottom). 
The plug domain is shown in green, with helices in purple and loops in yellow. B) Dinuclear 
ferric citrate is represented as a bond model with oxygen atoms in red and carbon atoms in 
green; both ferric ions are shown as orange spheres [Adapted from Ferguson et al., (2002)]. 
 
5. Crystallographic structure of FecA. A) The 22-stranded β barrel is shown
nce these receptors bind ferri-siderophore complexes, they change their conformation 
in the 
rhodotorulic acid). 
 
O
external loop and periplasmic pocket; this is believed to prepare the complex and 
receptor for the next stage in the transport process. The outer membrane siderophore receptors 
are induced by low concentrations of iron and are not present under iron-sufficient conditions 
(Andrews et al., 2003). In E. coli K-12, there are at least six OM receptors which acquire iron 
via eight different iron-chelate complexes, either produced by itself (enterobactin) or using 
other siderophores produced by other organisms (coprogen, ferrichrome, ferrioxamine and 
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   Although binding of ferri-siderophores to OM receptors is independent of other factors, 
transport of ferri-siderophores through OM receptors requires energy. This energy is provided 
ent, the Ton box, at 
e N terminus of TonB-dependent OM receptors and has been found to be required for TonB-
 
by the electrochemical charge gradient of the cytoplasmic membrane (CM) and is delivered by 
the energy-transducing Ton protein complex (Higgs et al., 1998; Larsen et al., 1994). The Ton 
system consists of three proteins, TonB, ExbB and ExbD that interact at the cytoplasmic 
membrane (CM) (Bradbeer, 1993; Braun, 2003; Cadieux et al., 2002; Faraldo-Gómez & 
Sansom, 2003). ExbB and ExbD are integral CM proteins, while TonB is periplasmic and 
anchored to the CM by its hydrophobic N-terminal domain (Letain & Postle, 1997). The 
energy transduction requires direct contact between TonB and receptors. 
 
 In E. coli, there is a conserved hydrophobic seven-amino acid segm
th
mediated uptake of ferri-siderophores (Postle, 1993). A mutation study showed that 
substitution in this region inactivated the transport capability of the receptors, but 
complementary TonB substitutions reversed the effect, suggesting that the TonB box region 
interacts physically with the TonB protein (Bell et al., 1990; Moeck et al., 1997; Schöffler & 
Braun, 1989; Tuckman & Osburne, 1992). The interaction of TonB with the TonB box of OM 
receptors, including FhuA, may be only an initial event in the transport of siderophores, and 
further interaction between TonB and the various siderophores receptors may be necessary to 
effect siderophore uptake (Braun, 1997). It is believed that ExbB and ExbD use the membrane 
electro-chemical charge gradient to produce an “energised” form of TonB that mediates a 
conformational change in the liganded OM receptor (Reynolds et al., 1980; Wooldridge & 
Williams, 1993). In some bacteria, there is more than one TonB-ExbB-ExbD system. Vibrio 
cholerae contains two TonB proteins, TonB1 and TonB2, which appear to have specificities 
for different OM receptors (Mey & Payne, 2001). TonB1 is associated with ExbB1, ExbD1 
and haem-specific permease, HutBCD, on chromosome II, and TonB2 is associated with 
ExbB2, ExbD2 on chromosome I. V. cholerae produces haemoglobin receptors: HutA, HutR, 
and HasR, and several other receptors for siderophores, including ferrichrome, vibriobactin 
(ViuA), and enterobactin (IrgA, VctA) (Occhino et al., 1998).   
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1.7.1 Transport across the periplasm and cytoplasmic membrane. 
Transport of ferri-siderophore complexes across the periplasmic space and cytoplasmic 
embrane is mediated by periplasmic binding protein-dependent transport (PBT) systems and 
 
acteria are similar in structure and 
ic binding-dependent systems of Gram-negative bacteria 
(Nikaido & Saier, 1992). 
teins only pick up the ferri-siderophore from the periplasm 
bclass of the ATP Binding Cassette (ABC) 
superfam
t are delivered to them by specific binding proteins (Nikaido & Hall, 
1998). The binding proteins act as a shuttle, collecting the ferri-siderophore released from the 
m
associated CM transporters (Nikaido & Saier, 1992).  
Although Gram-positive bacteria lack an OM, binding protein-uptake systems occur, 
and these proteins must be anchored to the cell to concentrate nutrients at the cell surface. 
Such binding proteins found in Gram-positive b
organization to the periplasm
 
Each binding protein accepts one ferri-siderophore complex at a time. It is unclear if 
the binding proteins of Gram-negative systems collect the ferri-siderophore directly from the 
OM receptors, or if the binding pro
(Köster, 2001). The PBT belongs to the su
ily of transport proteins which are energised by ATP (van der Does & Tampe, 2004). 
The ABC transporters are a class of proteins that use energy from ATP hydrolysis to pump a 
diverse set of compounds across biological membranes. They require a minimum of four 
domains. Two transmembrane domains (TMDs) form the ligand binding sites and provide 
specificity. The TMDs span the membrane multiple times via putative α-helices, usually six 
predicted per domain. The other two domains are the nucleotide binding domains (NBDs) that 
bind and hydrolyze ATP to drive the tranlocation of the bound ligand. The NBDs are 
hydrophilic and periferically associated with the cytoplasmic face of the membrane (Davidson 
& Maloney, 2007).   
 
Although, most eukaryotic ABC transporters export hydrophobic molecules from the 
cytoplasm (Dean & Allikmets, 2001), bacterial ABC transporters predominantly import 
essential nutrients tha
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OM re
he FecB protein of the Fe(III)-dicitrate transport system (Staudenmaier et al., 1989), 
e FepB protein of the ferric-enterochelin transport system (Elkins & Earhart, 1989), and the 
FhuD p
to the cell to concentrate 
nutrients at the cell surface (Nikaido & Hall, 1998). 
 al., 2003; Taboy et al., 2001). In 
Staphylococcus aureus, a Gram-positive bacterium, two FhuD homologues, FhuD1 and 
FhuD2
ceptor and delivering it to a specific permease in the inner membrane (Andrews et al., 
2003). 
 
Although, E. coli K-12 possesses six iron-transporting OM receptors, it only contains 
three associated binding-protein dependent ABC systems implicated in iron transport (Köster, 
2001). T
th
rotein which binds ferric-hydroxamates, such as ferrichrome, coprogen, rhodotorulic 
acid, ferrioxamine A, B, and E, and aerobactin (Clarke et al., 2002; Clarke et al., 2000; Köster 
& Braun, 1990). While Fe-siderophores that bind to OM receptors are completely buried in 
their external cavities prior transport, there are fewer residues involved in the recognition of 
ligand interaction; this is consistent and therefore there is a need for several OM receptors. On 
the other hand, the ABC transporters show higher ligand promiscuity for substrate binding 
compared to that of OM receptors (Davidson & Maloney, 2007).   
 
Although, Gram-positive bacteria lack an OM, the existence of permeases and their 
associated ATP-binding, they share similarities with Gram-negative bacteria systems. In 
Gram-positive bacteria, the binding proteins must be attached 
 
Similarly, a periplasmic Fe(III) binding protein (FbpA) has been identified for both 
Haemophilus and Neisseria, and are associated with receptors for iron binding proteins, such 
as TbpAB (Adhikari et al., 1995; Dhungana et
 have been found. The protein FhuD2 is involved in the transport of iron(III) in 
complex with ferrichrome, ferrioxamine B, aerobactin, and coprogen, whereas FhuD1 shows a 
more limited substrate range, capable of only iron(III)-ferrichrome and iron(III)-ferrioxamine 
B transport in S. aureus (Sebulsky & Heinrichs, 2001). 
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Iron uptake in mycobacteria is more complex since, the production of siderophores 
depends whether the strain is pathogenic or saprophytic. M. tuberculosis produces two types 
f mycobactins, the cell-bound mycobactin (intracellular) and the extracellular 
carbox
erophore 
transpo t both in M. tuberculosis and M. smegmatis (Farhana et al., 2008; Rodriguez & Smith, 
2006).
 
o
ymycobactin, whereas M. smegmatis can produce both mycobactins as well as the 
extracellular exochelins (Ratledge, 2004). The uptake of ferric exochelins into saprophytic 
mycobacteria, involves the transfer of the ferric-exochelin complex which requires the input 
of metabolic energy (Ratledge, 2004). There are various proteins involved in the uptake 
process. Ferric-exochelin is probably recognised by its receptor, a 29 kDa protein (Dover & 
Ratledge, 1996) and then the complex is taken across the cell envelope, possibly in association 
with the FxuD protein. The participation of the ferric-exochelin uptake proteins, FxuA, FxuB 
and FxuC, which share amino-acid sequence similar to the ABC transporters, might be 
required for translocation of the complex across the membrane (Fiss et al., 1994). To release 
the iron from the exochelins to the cytoplasm, a reductase is involved in which the ferric iron 
is reduced in the presence of NAD(P)H to ferrous iron (Brown & Ratledge, 1975b). After 
releasing iron, the exochelin is transferred back into the extracellular environment of the cells 
mediated by the Exit protein, in conjunction with other proteins (Zhu et al., 1998).     
 
On the other hand, two genes encoding for ABC transporters, irtA and irtB, as well as 
the function of Rv2895c, have been identified and characterised to mediate sid
r
 IrtA and IrtB have motifs typical of integral membrane ABC transporters, and they 
closely resemble the Y. pestis iron transporter YbtPQ (Rodriguez & Smith, 2006). Rv2895c is 
also predicted to be extracytoplasmic (Farhana et al., 2008). Inactivation of irtA and irtB has 
no effect on growth of M. tuberculosis in high-iron conditions, but it does affect the ability of 
the bacilli to multiply under iron-low conditions. The IrtAB system is important for 
replication not only under iron-deficient conditions in vitro, but also in human macrophages 
and mouse lungs. Based on amino-acid sequence, the N-terminal of IrtA was suggested to act 
as substrate-binding protein (SBP), as well as a translocation system, features which are 
required for recognition and transport of the substrate into the cell (Rodriguez & Smith, 2006).   
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The current model for iron transport in M. tuberculosis suggests a transfer of iron from 
Fe-carboxymycobactin to mycobactin in the cell surface, the latter functioning as an iron 
storage molecule in the cell envelope (Ratledge, 2004). However, results shown in the study 
conduc
cteria cell. 
nce internalised, the ferri-siderophore complex must be dissociated to liberate the 
complexed iron for use in cellular metabolism (Andrews et al., 2003). There are two processes 
 through the OM and CM.  
 by free 
intracellular electron donors or by more specific siderophore reductases (Pierre et al., 2002; 
Schröd
ted by Rodriguez and Smith (2006) and Farhana et al. (2008) suggest a different 
pathway. In the proposed model, the carboxymycobactin is transported outside the cytoplasm 
in an energy dependent manner by means of the IrtA exporter protein. Then, the 
carboxymycobactin extracts iron from host molecules, such as transferrin and ferritin. The 
Fe3+-carboxymycobactin complex is subsequently internalised and assimilated into the 
mycobacterial cytoplasm in which the interplay of the IrtB-Rv2895c importer system is 
involved (Farhana et al., 2008). Since only carboxymycobactin was tested during these 
experiments, there is still controversy how both mycobactins contribute exactly during iron 
uptake and storage in M. tuberculosis.  
 
1.7.2 Intracellular release of iron into ba
O
suggested for iron release from siderophores after passing
 
In the first hypothesis, siderophores have a much lower affinity for ferrous iron than 
for ferric iron, and iron release may therefore be spontaneous after iron reduction
er et al., 2003). After iron is released, the siderophore may be recycled for another 
cycle ferric iron uptake. This hypothesis has been controversial because specific ferri-
siderophore reductases have not been isolated, efflux of unloaded siderophores has not been 
studied in detail, and siderophores have such a low redox potential that iron reduction by 
intracellular electrons donors is only likely if coupled with efficient Fe(II) trapping (Müller et 
al., 1998). In addition, purified bacterial ferri-siderophore reductases are neither substrate 
specific nor subjected to iron-dependent regulation (Halle & Meyer, 1992).   
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Only two classes of ferric reductases are known. The soluble prokaryotic flavin 
reductases and the membrane cytochrome β-like reductases, found in eukaryotes (Pierre et al., 
2002). All soluble ferric reductases seem to be biochemically similar and the majority use 
NADH
and thus, Fe(II) is now available to be removed from siderophore and enter cytoplasm, and 
therefore it is
 
losis, M. smegmatis, 
eisseria gonorrhoeae, Pseudomonas aeruginosa, and Vibrio vulnificus (Schröder et al., 
2003). 
 iron-dependent regulation mediated by the Fur repressor 
nd substrate specificity to a set of Fe-hydroxamate siderophores including ferrioxamine B, 
Fe-cop
 or NADPH as the electron donor for ferric iron reduction (Schröder et al., 2003). The 
next general reaction occurs in all cases: 
 
Fe(III)-siderophore + NAD (P) H → Fe(II)-siderophore + NAD (P)+
 
 able to be incorporated into porphyrins or into apoproteins. 
Many bacterial ferric iron reductases have been described from a variety of different 
bacteria including E. coli, Bacillus subtilis, Mycobacterium paratubercu
N
The localisation of ferric reductases, in the cytoplasm, periplasm and cytoplasmic 
membrane, depends on the bacterial species and the strategy for iron uptake (Schröder et al., 
2003). The majority of the ferric reductases are either localised in the bacterial cytoplasm or in 
the periplasm of Gram-negative bacteria. P. aeruginosa has been described to contain a 
periplasmic ferri-pyochelin reductase (Cox, 1980). Other pathogens like Listeria monocyto-
genes, a Gram- positive, produce a surface-bound ferric reductase that may also be secreted 
into the culture medium (Barchini & Cowart, 1996). Membrane-bound reductases have been 
found in Spirillum itersonii (Dailey & Lascelles, 1977), E. coli (Fischer et al., 1990) and S. 
aureus  (Lascelles & Burke, 1978). 
 
A new type of ferrisiderophore reductase was discovered with the E. coli FhuF protein 
that shows for the first time both an
a
rogen and ferrichrome (Matzanke et al., 2004). However, the iron of some ferri-
siderophores can not be reduced because their redox potentials are too negative and 
thermodynamically unfavourable (Pierre et al., 2002). For instance, the redox potential of 
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ferri-enterochelin/ferro-enterochelin is -750 mV at pH 7 and is the lowest of all siderophores. 
It has been considered that neither NAD nor NADP could ever act as reductants for ferric-
enterochelin, because the redox potential for those reductants is -324 mV, and another 
mechanism would be required to release iron from the siderophore (Ratledge & Dover, 2000). 
    
The second mechanism involves the intracellular breakdown of the siderophore and 
thus implies that some siderophores are used once without recycling them. In E. coli an 
esterase encoded by fes (located within a cluster of genes (ent-fec) involved in enterobactin 
biosynt
n from the reduced siderophore and 
effectively removed from participating in the back reaction, since the reactions are never in 
equilib
ter in E. coli 
and Salmonella enterica (Lin et al., 2005). The product encoded by these genes showed 
differen
hesis) hydrolyses the ester bonds of internalised ferri-enterobactin producing 
dihydroxybenzoyl serine (Earhart, 1996). However, the function of the enzyme is unclear 
because in vitro the esterase can hydrolyze enterobactin as well as ferric-enterobactin. Its 
activity was four-fold higher in catalysing the hydrolysis of free enterobactin than ferric-
enterobactin, indicating that the protein possesses a distinct esterase activity that is 
independent of any potential reductive mechanism of iron removal from the ferric 
enterobactin complex (Brickman & McIntosh, 1992).  
 
Although the equilibrium of reaction is in favour of Fe(III)-enterochelin its reduction 
might proceed as long as the Fe(II) can be withdraw
rium (Ratledge & Dover, 2000). The function of the esterase may simply be to 
inactivate the potent chelator in the bacterial cytoplasm in order to minimise any adverse 
effects it might generate in bacterial iron homeostasis (Ratledge & Dover, 2000). 
 
Recently, two other hydrolases have been found in pathogenic enteric bacteria, which 
are encoded by the iroD and iroE genes of the virulence-associated iroA gene clus
t substrate preference as well as cellular localization. IroE was predicted to be 
membrane-tethered and only hydrolyses cyclic salmochelins only once in the periplasm, 
leading to the release of linear salmochelin trimer. IroD, located in the cytosol, mediated iron 
release from the enterobactin and salmochelin complexes (Lin et al., 2005). However, another 
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study has shown different substrate specificities for these esterases: IroD preferred free iron 
enterobactin and salmochelin substrates over the ferri-siderophores, while IroE hydrolased 
both free iron-siderophores and iron-charged diglucosylated enterobactin (Zhu et al., 2005).  
  
 Another hydrolase has been characterised in B. subtilis, the Fe-bacillabactin esterase 
BesA (YuiL). The esterase was found to hydrolyse Fe-bacillabactin into monomers without 
generating detectable amounts of hydrolysis intermediates; iron-free bacillabactin used as 
fter uptake, iron can be stored for eventual use when external iron supplies are restricted. 
Three types of iron storage proteins are recognised in bacteria. The archetypal ferritins which 
haem-containing bacterioferritins found only in eubacteria 
owski et al., 2008). Unexpectedly, the metal 
inding centre of bacterioferritin from M. smegmatis contains zinc instead of the typically 
observ
substrate led to intermediate accumulation. Furthermore, the catalytic efficiency of BesA was 
25-fold higher for ferri-bacillabactin than for iron-free siderophore (Miethke et al., 2006b). 
 
1.7.3 Iron storage in bacteria.  
A
are also found in eukaryotes, the 
and the smaller Dps proteins present only in prokaryotes. All types can exist in the same 
bacterium and multiple ferritin or bacterioferritin genes are common (Andrews et al., 2003; 
Wandersman & Delepelaire, 2004). Dps proteins, ~ 250 kDa, have a lower storage capacity 
around 500 iron atoms (Zhao et al., 2002), while ferritins and bacterioferritins, ~ 500 kDa, can 
bind between 2000-5000 iron atoms (Carrondo, 2003). Ferritins and bacterioferritins use 
oxygen and peroxide, respectively, to bind soluble Fe+2. Both ferritin and bacterioferritin are 
composed of 24 identical subunits, but Dps contains only 12 monomers. Specific sites, called 
ferroxidase centres, are found in the central region of individual subunits and catalyses the 
redox process in ferritin and bacterioferritins.  
 
The X-ray structures of bacterioferritins from M. smegmatis and M. tuberculosis have 
recently been solved (Gupta et al., 2008; Jan
b
ed iron ions in other bacterioferritins (Janowski et al., 2008).  
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1.7.4 Gene regulation by iron in bacteria. 
The importance of iron as a cofactor in many proteins and as a virulence factor has been 
tal process in bacteria. Many enzymes and other 
proteins change their activities according to iron concentration within the cell. Such changes 
highlighted, and its regulation is a transcenden
might result in an increase of a particular protein when the cell is deprived of iron, but at the 
same time there are decreases in the production of other proteins. Thus, the response for iron 
concentration suggests control at the gene level (McHugh et al., 2003; Rodriguez, 2006).  
  
The Fur protein (ferric-uptake regulator), which is widely distributed among the Gram-
negative bacteria, controls iron-dependent expression of more than 90 genes in E. coli 
antke, 2001). These genes are involved in diverse functions including iron and haem 
acquisition, virulence factor produc  
ber of specific operator sequences which block the transcription of 
functional genes (Saito & Williams, 1991; Saito et al., 1991). Also, the complex is mediated 
by other divalent m +
ion of an an all RNA (sRNA) (Masse 
 the post-transcriptional level to repress translation of 
rget 
(H
tion and acid resistance (McHugh et al., 2003). Some
genes are positively regulated by Fur. An iron-containing superoxide dismutase, SodB, 
increases its activity in presence of iron and Fur (Dubrac & Touati, 2000). Also genes which 
encode for ferritin, bacterioferritin, and aconitase A, are positively regulated. On the other 
hand, the Fur gene can also be autoregulated in a negative way. During oxidative stress the 
Fur gene is turned on by peroxide via OxyR regulation, allowing a decrease of iron uptake 
(Zheng et al., 1999).  
 
Fur protein forms a complex with Fe+2 when iron is available, and that complex, Fur-
Fe+2, binds to a num
etals such as Co+2 and Mn 2. 
 
 Fur acts positively on the expression of a number of proteins. It acts often indirect 
mediated by Fur-dependent repress tisense regulatory sm
& Arguin, 2005). This RNA acts at
ta genes. For instance, the E. coli RyhB, a 90 nt sRNA is repressed by Fur in an iron-
dependent manner. In an iron-defficient environment, or in a fur mutant, expression of RyhB 
is derepressed thereby causing a decrease in the level of target mRNAs. Several target genes 
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are regulated this way such as acnA (aconitase A), fumA (fumarase A), sdhCDAB (succinate 
dehydrogenase), bfr (bacterioferritin) and ftnA (ferritin) and sodB (Masse & Arguin, 2005). 
 
 Another iron regulation protein is found in Corynebacterium diphtheriae. The 
diphtheria toxin repressor protein, DtxR, regulates genes related to iron uptake and virulence 
ellaboina et al., 2004), in particular the prophage-encoded diphtheria toxin gene (Tao et al., 
rR (designated after 
aphylococcal iron regulator repressor) (Rodriguez, 2006). IdeR is closely related to DtxR. 
the 
xpression of katG gene, thereby modulating the response against oxidative stress (Pym et al., 
2001; 
(Y
1992). DtxR also requires Fe+2 as a co-repressor. 
  
 M. tuberculosis contains two Fur-like proteins (FurA and FurB) and two members of 
the DtxR family, the iron-dependent regulator protein (IdeR) and Si
st
As for Fur and DtxR, IdeR needs Fe+2 to form a complex and subsequently binds to DNA and 
that complex interacts with “iron-box” operator sequences (Dussurget et al., 1996; Dussurget 
& Smith, 1998; Schmitt et al., 1995). IdeR regulates about 40 M. tuberculosis genes involved 
in iron uptake and metabolism by binding to operator regions of these genes and usually 
repressing transcription, although the transcription of some genes are enhanced (Gold et al., 
2001). Many of these genes are involved in the synthesis of the mycobacterial siderophores, 
the mycobactins and exochelins (Dussurget & Smith, 1998; Manabe et al., 1999). On the other 
hand, the metal binding site of M. tuberculosis SirR might be an orthologue of S. epidermidis  
SirR which has both iron and manganese-dependent regulatory activity (Hill et al., 1998). 
 
M. tuberculosis contains two genes, furA and furB, which encode proteins more similar 
to E. coli Fur than to IdeR/DtxR (De Voss et al., 1999). FurA negatively regulates 
e
Zahrt et al., 2001), whereas FurB might be involved in sensing and controlling Zn-
sensitive genes (Canneva et al., 2005).    
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1.8 Aims of the project. 
l for the growth and survival of mycobacteria, as well as being 
involved in host macrophage defence by catalysing the production of toxic hydroxyl radicals 
ycobacterial siderophores as virulence factors during infection of 
acrophages has been demonstrated by a M. tuberculosis H37Rv mutant lacking the mbtB 
gene, which
B drugs must act on a target that is essential for bacterial survival, be 
ecific, and without affecting the mammalian cells. Snow (1970) proposed that most of the 
enzyme
 
Iron homeostasis is essentia
via the Haber-Weiss-Fenton reaction. M. tuberculosis resides within the macrophage 
phagosome and prevents phagosome-lysosome fusion by an unclear mechanism. During 
infection, a competition for iron occurs between the host macrophage and the pathogen. The 
macrophage attempts to suppress pathogen proliferation by complex iron-withholding 
mechanisms. However, M. tuberculosis perceives the phagosome as iron-low environment, 
and in response the bacterium needs to compete for iron by producing the high affinity iron-
chelators, the siderophores.  
 
The importance of m
m
 encodes a NRPS for the initial step in mycobactin biosynthesis (De Voss et al., 
2000). Furthermore, a structure related to mycobactins, the didehydroxymycobactin (DDM), 
functions as an antigen by activating CD1 proteins which ultimately stimulates T cells, 
highlighting the importance of the molecule during host-M. tuberculosis interaction (Moody et 
al., 2004).  
 
New anti-T
sp
s involved in the synthesis of mycobactin may not have an equivalent in animals, 
which do not synthesise siderophores, and therefore would be safe targets for any drug as 
adverse inhibitory effects would be avoided. Thus, salicylic acid synthesis, the formation of 
N-hydroxylysine and the final acyltransferase involved in assembling the long chain acyl 
group are considered to be attractive targets for new drugs (Ratledge, 2004; Ratledge & 
Dover, 2000).  
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PAS has been demonstrated to inhibit the biosynthesis of mycobactin (Brown & 
Ratledge, 1975a; Ratledge & Brown, 1972). The authors suggested that PAS could inhibit the 
conver
n of the aryl-capped siderophore biosynthesis in pathogenic bacteria such 
.  tuberculosis and P. aeruginosa has been recently demonstrated (Ferreras et 
al., 20
e elucidation of the chemical structures of mycobacterial siderophores was an 
portant step forward, however, the mechanism of their biosynthesis is still not fully 
resolve
 
sion of salicylic acid to mycobactin, and therefore carboxymycobactin, probably in the 
first reaction that involves its interaction with ATP or its subsequent condensation with 
serine/threonine. PAS is an analogous of salicylic acid and therefore blocks the biosynthesis 
of mycobactin, probing its activity as an anti-TB drug by preventing the bacteria to acquire 
iron from the host.  
  
The inhibitio
as Y.  pestis, M
05; Miethke et al., 2006a; Somu et al., 2006a). The first step during aryl-capped 
siderophore biosynthesis is the activation of either salicylic acid or 2,3-dihydroxybenzoate 
(DHB), depending on the enzymatic equipment of the microorganism, by an adenylation 
domain. In this reaction the α-phosphate of ATP is charged by the substrate to generate a 
tightly bound acyl adenylate, salicyl-AMP for instance, with subsequent release of 
pyrophosphate. This biosynthetic step resembles a similar mechanistic reaction in all members 
of the adenylate-forming enzyme superfamily and the functionally related aminoacyl tRNA 
synthetases (Schimmel et al., 1998). Analogues of the acyl adenylate have been developed 
and tested in vitro for the depletion of siderophore biosynthesis. Those analogues were 
designed to act as intermediate mimics that could inhibit the adenylate-forming and thus stop 
the initial siderophore biosynthesis (Ferreras et al., 2005; Miethke et al., 2006a; Somu et al., 
2006a).  
 
Th
im
d. Since, siderophores biosynthesis, as well as secretion and uptake or transport after 
iron chelation represents outstanding candidates as targets for the development of new 
antibiotics for the treatment of tuberculosis and other mycobacterial diseases, the aims of this 
study are to investigate: 
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1. The expression, post-translational activation and biochemical characterisation of M. 
tuberculosis MbtB protein.  
 
AS analogues in vitro and in vivo.  
ation of lysine residues.  
 
 
 
 
2. Potential inhibitors of enzymes during siderophore biosynthesis, specifically MbtA, by 
testing a series of SAL and P
 
3. The expression and biochemical characterisation of M. tuberculosis MbtG and the 
adenylation protein domains of MbtE and MbtF during hydroxyl
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2.1 Post-translational modification of MbtB. 
Numerous microorganisms utilise a nonribosomal process for the biosynthesis of small 
peptides that are mainly products of secondary metabolic pathways, such as the siderophores. 
Domains within each NRPS module provide sites for the recognition and activation of a 
substrate amino acid (adenylation, or, A domain); transfer of this activated intermediate to a 
phosphopantetheinyl residue (bound by a thiolation domain, or T, domain); and a peptide 
bond formation (catalysed by a condensation domain, or C domain), so that the activated 
residue is incorporated into the growing peptide chain. A final thioesterase (T) domain might 
be present in this multienzyme complex that cleaves the growing molecule from the terminal 
NRPS. This domain may also serve a further catalytic process such as the internal cyclisation 
of the residue (Challis & Naismith, 2004).  
 
In the original M. tuberculosis genome annotation, only mbtB, mbtE, mbtF, which 
participate in pre-mycobactin biosynthesis (Quadri et al., 1998), along with Rv0101, to which 
no function has yet been assigned, were annotated to encode potential NRPSs (Cole et al., 
1998). However, in recent studies other M. tuberculosis genes were ascribed with putative 
features of NRPSs. By mimicking the acidic phagosomal environment, in which M. 
tuberculosis resides during infection, and using Microarray and Real Time-Reverse 
Transcription-PCR (RT-R T- PCR) techniques, genes involved in fatty acid metabolism, as 
well as the Rv3083-Rv3089 operon were positively regulated by the acidic environment 
(Fisher et al., 2002). Additional, in silico analysis of that operon showed that the genes 
displayed NRPSs features: Rv3089 contains an AMP-binding domain, as occurs in the A 
domains of NRPSs; Rv3087 and Rv3088 possess a partial condensation domain, which 
includes the HHXXXDG catalytic site to the C domains; Rv3084 contains a partial 
thioesterase domain. The Rv3083 and Rv3086 genes resemble genes encoding the 
organisation of a NRPS/PKS hybrid system for rapamycin biosynthesis in Streptomyces 
hygroscopicus (Fisher et al., 2002). In another study, microarray analysis of the over-
expression M. tuberculosis sigma factor (SigM) positively regulated two gene operons 
(Raman et al., 2006). The first operon carries a gene of unknown function, PPE19, whereas 
the second operon, Rv0096-Rv0101, contains the PPE1 and NRPSs genes along with other 
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three genes of unknown function and a putative fatty acid biosynthetic gene. The Rv0096-
Rv0101 operon is found highly conserved in M. bovis and M. leprae, but not in M. smegmatis. 
Further analysis of this operon found that the Rv0099 and Rv0100 have NRPSs domains, the 
adenylation and peptidyl carrier protein, respectively. The authors of this study suggested that 
the Rv0099, Rv0100, and Rv0101 might function as three separate NRPS entities to produce a 
bioactive molecule to modulate host-pathogen interactions (Raman et al., 2006). The analysis 
of a M. bovis mutant in which the Mb100, the homologue of Rv0097, was disrupted by 
transposon mutagenesis, supports this hypothesis (Hotter et al., 2005). Disruption of the 
Mab100 gene had polar effects in the Mb101-Mb104 genes, generating phenotypes unable to 
produce phthiocerol and phthiodiolone dimycocerosate esters (PDIMs) and glycosylphenol-
PDIMs, suggesting a role involved in the biosynthesis of these molecules (Hotter et al., 2005). 
However, this finding waits further genetic and biochemical analysis of these genes, 
specifically the role of Rv0101.  
 
On the other hand, the recently sequenced M. marinum genome shows the presence of 
23 NRPS-encoding genes, 18 of which cannot be ascribed a precise function since there are no 
orthologues of genes in other mycobacteria (Stinear et al., 2008). This finding suggests the 
existence of complex and diverse novel secondary metabolites produced by M. marinum 
compared to that of M. tuberculosis. 
 
The MbtB, MbtE, and MbtF proteins are conserved among mycobacterial species that 
produce the mycobactins, but not in M. leprae. However, there are differences in the domain 
organisation of these modular enzymes. The MbtB in M. tuberculosis and M. bovis share high 
similarity internal domain organisation, however the T domain (originally annotated as an 
acyl-transferase), predicted at the C-terminus of the protein is replaced by a non-integrated 
stand-alone predicted T, MbtT, encoded downstream of MbtB in the clusters of M. avium 
subsp. avium, M. avium subsp. paratuberculosis, and M. smegmatis or upstream of MbtE in 
M. marinum (Quadri & Ratledge, 2004).   
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The M. tuberculosis MbtB protein possesses the following predicted domains: ArCP, 
Cy, A1, PCP and T/AT1. Those integrated domains lead to the formation of the 
oxazoline/thiazoline rings like those also found in vibriobactin and pyoverdin biosynthesis. 
The remarkable catalytic activity of the Cy domains represents an attractive target for new 
anti-TB drugs. Thus, dissecting the activity MbtB domains not only would aid in fully 
understanding mycobactin-carboxymycobactin biosynthesis, but also in rational design of new 
drugs.  
 
In order to be active, the carrier protein domains of the MbtB must be post-
translationally modified by the dedicated phosphopantetheinyl transferase. Two candidates for 
phosphopanthethienylation of MbtB were apparent on analysis of the M. tuberculosis genome 
(Quadri et al., 1998). The mycobacterial acpS encodes a 14 kDa protein and pptT a 25 kDa 
protein. In vitro biochemical studies showed that PptT carried out post-translational 
modification of both carrier proteins, the ArCP domain in the peptide synthetase, MbtB, and 
the PCP domain of MbtE, respectively (Quadri et al., 1998). In the genome of M. tuberculosis 
there are more than 18 type-I PKSs and two fatty acid synthase (FAS) systems (Cole et al., 
1998). The function of those enzymes depends of a post-translational modification of the acyl 
carrier proteins of FAS and PKSs by phosphopantetheinyl transferase. Recently, it has been 
demonstrated that both of the PPTases of M. tuberculosis are essential for mycobacterial 
viability. The protein AcpS was shown to be responsible for the post-translational 
modification of Fatty acid synthase-I and AcpM subunit of Fatty acid synthase-II, whereas the 
protein PptT activates the condensing enzyme Pks13 and various type-I Pks required for the 
formation of lipid (Chalut et al., 2006). Bioinformatic analyses led to the finding of 
orthologues of acpS and pptT genes in both mycobacterial and corynebacterial species. The 
amino acid sequences of the encoded proteins were > 80% similar for the mycobacterial 
proteins, with ~ 40% similarity between corynebacterial proteins and their M. tuberculosis 
counterparts (Chalut et al., 2006).     
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Previously other researchers had not achieved the molecular cloning of full length 
MbtB. Here, the isolated ArCP and the full mbtB genes have been cloned, expressed and 
successfully post-translationally modified in E. coli by a heterologous “broad substrate 
phosphopantetheinyl transferase”. Subsequent purification of the protein has allowed the 
confirmation of these goals by molecular analyses and thus facilitates further biochemical 
characterisation of the protein toward mechanistic studies and the testing of novel compounds 
that might target the initial step in mycobactin-carboxymycobactin biosynthesis (Chapter 3).   
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2.2 Material and methods. 
A range of approaches was tested to achieve the post-translational modification of the carrier 
proteins of MbtB. In this study, the first approach was to clone both the full-length mbtB 
(Rv2383c) and the intrinsic phosphopantetheinyl transferase (pptT, Rv2794c) of M. 
tuberculosis to carry out either in vivo or in vitro post-translational modification of the carrier 
proteins. Nevertheless, non of these approaches were successful and other ways were 
attempted to achieve this aim. Secondly, the ArCP domain of MbtB was cloned and 
successfully expressed but, as for the MbtB, no evidence of modification was found. Thirdly, 
the use of a “broad substrate phosphopantetheinyl transferase” rather than the intrinsic PPTase 
of M. tuberculosis, afforded the phosphopantetheinylation in the carrier proteins for both the 
ArCP domain as well as the full-length of MbtB. Material and methods will be described in 
the next pages in the order outlined above.   
 
2.2.1 In vivo post-translational modification of the MbtB protein. 
A method to achieve post-translational modification of carrier proteins is to co-express both 
the mbtB and the intrinsic phosphopantetheinyl transferase pptT, involved in mycobactin-
carboxymycobactin biosynthesis, in suitable heterologous expression host and using 
compatible vectors. To achieve this, two expression vectors must be used, each of them being 
controlled under different replicons and resistance genetic markers. Therefore, pET23b and 
pCDFDuet1 (Novagen) expression vectors were used and features of each expression vector 
are summarised in Table 7. 
 
Table 7.  Genetic features of the vectors used in expression of the mbtB and pptT genes.  
Vector Origin of replication Resistance marker Promoter 
pET23B ColE1 Ampicillin T7 
pCDFDuet-1 CloDF13 Streptomycin/Spectinomycin T7 
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2.2.2 Molecular cloning and expression of the mbtB and pptT genes of M. tuberculosis. 
The recipe and the typical conditions for PCR reactions to clone the genes of interest were 
derived from the following generic conditions: 
 
A) Recipe  
2 µL 
2 µL 
1 µL 
2 µL 
10 µL 
8 µL 
2 µL 
1 µL 
72 µL 
5’ Cloning primer (100 pmole) 
3’ Cloning primer (100 pmole) 
Genomic DNA (H37Rv) (1 µg/µL) 
dNTP’s  
Thermostable buffer (10X) 
DMSO (optional) 
MgSO4 (optional) (100 mM) 
DNA polymerase1 
ddH20 (for molecular biology) 
1Deep VentTM DNA polymerase was used for cloning both mbtB and pptT genes.  
 
 
B) Thermal cycling conditions 
 
95ºC 
95ºC 
3 minutes 
1 second 
 
60-70ºC 
68ºC 
30 seconds 
0.5 minutes per kb 
35 cycles 
68ºC 
4ºC 
10 minutes 
∞ 
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For each gene, the conditions were adjusted to yield the desired PCR product. The 
PCR products were electrophorosed on agarose gel, DNA was visualised using Ethidium 
bromide (EtBr). The appropriate DNA fragment was excised from the gel and extracted using 
the Qiagen Gel extraction Kit. The purified PCR products were digested with appropriate 
restriction enzymes according to the plasmid in which they were inserted. The cut PCR 
product and similarly digested plasmid DNA were assessed by DNA electrophoresis and EtBr 
staining. The cut PCR product was ligated with the cut vector by T4 DNA Ligase (New 
England Biolabs) at 16ºC for 16 hours. The ligation mix was used to transform the 
corresponding E. coli heterologous cloning host for selecting the right genetic construct. 
Screening was done by double digestion followed by electrophoresis analysis on agarose gel 
and staining with EtBr. All genetic constructs generated were verified by sequencing by 
means of ABI PRISM Byg DyeTM Terminator v3.0 kit (Applied Biosystems) and an ABI 
PRISM 3700 sequencer (Applied Biosystems). 
 
Amplifcation of the mbtB and pptT genes was achieved using Deep VentTM DNA 
Polymerase (New England Biolabs) and M. tuberculosis H37Rv chromosomal DNA. Primers 
for each gene are listed in Table 8. After digestion with NdeI and NotI (New England 
Biolabs), the mbtB amplicon was then directly ligated into pET23b vector (Novagen), which 
was cut in the same manner as the PCR product, to give the mbtB-pET23b construct. The 
design of the primers is such that recombinant MbtB product was modified with a C-terminal 
hexahistide tag, derived from pET23b, to facilitate its purification by metal chelate affinity 
chromatography; the stop codon of the gene was therefore excluded from the mbtB down 
primer design. The ligation mix was used to transform E. coli TOP 10 (Invitrogen) cells for 
screening under Ampicillin (Amp, purchased from Sigma Aldrich) resistance marker. 
Similarly, after amplification, the pptT PCR product was digested with NcoI and NotI (New 
England Biolabs), which was then ligated into the NcoI/NotI sites of the pCDFDuet1 plasmid 
(Novagen), thus giving rise to pptT-pCDFDuet-1. The ligation mixture was used to transform 
E. coli XL1 Blue (Strategene) cells for screening under Streptomycin (Str, purchased from 
Sigma Aldrich) resistance marker. Both genetic constructs were subjected to nucleotide 
sequencing to verify their integrity. The pptT-pCDFDuet1 was then subsequently used to 
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make E. coli C41 (DE3) (OverExpress) chemical competent cells to carry out in vivo post-
translational modification of the MbtB. 
 
Table 8. Primers used for cloning the mbtB and pptT genes into pET23b and pCDFDuet-
1, respectively. Restriction sites are underlined. 
mbtB up 5’-GATCGATCCATATGGTGCATGCTACGGCGTGC-3’ 
mbtB down 5’-GATCGATCGCGGCCGCTCGGACATCGGCACTCACC-3’ 
pptT up 5’-GATCGATCCATGG ACGGTAGGCACGCTGGTG-3’ 
pptT dwn 5’-GATCGATCGCGGCCGCTTATAGCACGATCGCGGTCAGCAC-3’ 
 
 
2.2.3 Determination of expression levels of the mbtB-pET23b in E. coli C41 (DE3). 
Expression levels of the mbtB-pET23b were determined by testing different temperatures, 
incubation time and isopropyl β-D-1-thiogalactopyranoside (IPTG) concentrations using E. 
coli C41 (DE3) (OverExpress) as a heterologous host. A stock of 50 µL E. coli C41 (DE3) 
(OverExpress) chemical competent cells was transformed with 1 µL mbtB-pET23b by heat 
shock at 42ºC for two minutes. Cells were incubated with 150 µL of Luria Bertoni (LB) broth 
medium at 37ºC for 1 hour, followed by selection in LB agar plates supplemented with Amp 
(100 µg/mL). Cells forming single colonies were used to inoculate 5 mL of LB broth 
supplemented with Amp (100 µg/mL) and were cultured overnight at 37 ºC with shaking (160 
rpm). From this starting culture, 1 mL was transferred to fresh LB broth medium (100 mL) 
supplemented with Amp (100 µg/mL) and this was incubated until the optical density (OD) at 
600 nm reached 0.5-0.6 when, where appropriate a subsequently shifted to 30ºC or 16ºC was 
affected. Cells incubated at 37ºC and 30ºC were allowed to grow for an additional 4 hours, 
whereas cells growing at 16ºC were incubated for an additional 16 hours. At each temperature, 
various concentrations of IPTG (1 mM, 0.5 mM, 0.1 mM) were tested to induce gene 
expression. A negative control (no addition of IPTG) was performed along with the 
experimental conditions for comparison. 
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2.2.4 Preparation of E. coli C41 (DE3) chemical competent cells harbouring pptT-
pCDFDuet1. 
A stock of 50 µL E. coli C41 (DE3) (OverExpress) chemical competent cells was transformed 
with 1 µL pptT-pCDFDuet by heat shock at 42ºC for two minutes. Cells were incubated with 
150 µL of LB broth at 37ºC for 1 hour, which were then selected on LB agar supplemented 
with Str (50 µg/mL). Cells from a single colony on a LB agar plate were then used to 
inoculate 50 mL of LB Broth supplemented with Str (50 µg/mL) and cultured overnight at 
37ºC with shaking (180 rpm). From this starting culture, 5 mL was transferred to fresh LB 
broth medium (100 mL) supplemented with Str (50 µg/mL) and this was incubated until the 
OD600 reached 0.5-0.6. Cells were centrifuged (3000 rpm) for 5 minutes at 4ºC. Cell pellets 
were resuspended with 20 mL of ice cold buffer TFB1 (40%) and incubated on ice for 30 
minutes, followed by centrifugation (3, 000 rpm) for 5 minutes at 4ºC. Then, cells were 
resuspended with 2 mL of ice-cold buffer TFB2 (40%). E. coli C41(DE3)-pptT-pCDFDuet1 
chemical competent cells were flash frozen in 50 µL aliquots using liquid nitrogen and stored 
at -80ºC until required. 
 
 
2.2.5 Co-overexpression of mbtB-pET23b and pptT-pCDFDuet1 in E. coli C41(DE3). 
A stock of 50 µL E. coli C41(DE3)-pptT-pCDFDuet-1 was transformed with 1 µl of mbtB-
pET23b by heat shock at 42°C for two minutes. Cells then were incubated with 150 µL of LB 
broth at 37ºC for 1 hour followed by selection on LB agar supplemented with Str (50 µg/mL) 
and Amp (100 µg/mL). Cells from a single colony were used to inoculate 50 mL of LB Broth 
supplemented with the above antibiotics and cultured overnight at 37ºC with shaking (180 
rpm). From this starting culture, 5 mL was transferred to 1 L of Terrific Broth (TB) media 
(solution 1) supplemented with salts (solution 2) and both antibiotics. The large-scale culture 
was initially incubated at 37ºC until the OD600 reached 0.5-0.6 and recombinant gene 
expression induced with 1 mM IPTG and culture incubated for 16 hours at 16ºC followed by 
centrifugation at 8000 rpm for 5 minutes at 4ºC. 
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The cell pellet was resuspended in buffer (50 mM Tris-HCl, pH 7.9, 500 mM NaCl) 
and broken by passing through a French Pressure cell twice (3000 psi) in the presence of a 
cocktail of serine protease inhibitors (PMSF, benzamidine, and DNAase at 1 mM final 
concentration). The extract was clarified by centrifugation at 15 000 rpm for 30 minutes at 
4ºC. The supernatant was collected and loaded onto a Ni2+pre-charged and equilibrated His-
Trap column (5 mL) following the manufacturer’s instructions (Amersham). The clarified 
extract was applied to the column (50 mL maximum volume for 5 mL column capacity) and 
non-binding material collected for analysis. The column was then washed with 50 mL of 
binding buffer A (50 mM Tris-HCl pH 7.9 and 500 mM NaCl) and the protein eluted with a 
step gradient (10-500 mM) of increasing imidazole concentrations in buffer A. The purity of 
the protein was monitored by sodium dodecyl sulphate polyacrylamide gel electrophoresis 
(SDS-PAGE) on 12% gels and Coomasie blue staining. Purified protein fractions were pooled 
and dialysed against buffer B (10 mM HEPES, 100 mM NaCl, 1 mM EDTA, 1 mM DTT, and 
10 % glycerol, pH 8.6) and concentrated using a Centricon YM-50 filter unit (Millipore) and 
stored at -80C ºC until use. Protein concentration was estimated by the Bicinchoninic acid 
protein (BCA) assay (Pierce) and by absorbance at 280 nm with the predicted molar extinction 
coefficient (ε= 151 601.9 M-1 cm-1).  
 
2.2.5.1 Screening for in vivo post-translational modification of the carrier proteins by 
MALDI-Mass Spectrometry.  
To verify in vivo modification, proteins were separated by gel electrophoresis, followed by in-
gel trypsin digestion and peptide mass fingerprint analysis by positive ion mode matrix-
assisted laser desorption ionization-mass spectrometry (MALDI-MS). The recombinant 
protein was separated by 12% SDS-PAGE and bands of the expected size of MbtB (151 kDa) 
were excised from the gel, eliminating as much polyacrylamide as possible. These bands were 
transferred to microtubes and treated with 200 µL of 100 mM NH4HCO3 (pH 7.8)/50% 
acetonitrile (ACN) and incubated at 37ºC for 30 minutes. The supernatant was removed and 
100 µL 100% ACN was added to the gel slices for 5 minutes. At this stage, the slices became 
whitish and much smaller due to dehydration; the gel slices were dried for further analysis.  
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Since trypsin is a serine protease that specifically cleaves at the carboxylic acid side of 
lysine and arginine residues, it was possible to generate peptides in order to analyse them by 
mass spectrometry, and determine potential modification of MbtB. Trypsin Gold Mass 
Spectrometry Grade (Promega) was used for this purpose. Trypsin Gold was resuspended at 1 
µg/µL in 50 mM acetic acid, 5 mM β-mercaptoethanol, 0.1% SDS as was indicated by the 
manufacturer. Gel slices were initially incubated with 50 µL of trypsin (100 µg/mL in 40 mM 
NH4HCO3/10% ACN) at room temperature for 1 hour. Then, another 25 µL of tryspin was 
added (same concentration as above) to the gel slices and incubated at 37ºC overnight. Digests 
were stopped by adding 5µl of 0.1 % trifluoroacetic Acid (TFA).  
 
Since MS analyses do not tolerate salts, two desalting methods were tested to 
determine which one could allow the analysis of peptides by using Zip Tip C18 (Millipore). In 
the first method, the preparation of tips was as follows: tips were hydrated and washed with 10 
µL of 100% ACN, twice, and then equilibrated with 10 µL of 0.1 % TFA (three times). After 
preparation of tips, 10 µL of the sample (peptides generated from in-gel digestion) was taken 
and aspirated 10 times by pipetting fully into and out of tips and the liquid was expelled. Tips 
were washed in 5% methanol/0.1% TFA. To elute the peptides from tips, 10 µL of 1% formic 
acid/50% methanol solution was used. Samples were then ready for mass spectrometry 
analysis. The second method was as follows: tips were hydrated and washed with 10 µL of 
50% ACN three times, and then equilibrated with 1% acetic acid for three times. After 
preparation of tips, 10 µL of the sample were aspirated by pippeting fully with the tips. To 
elute the peptides from tips, 10 µL of 50% ACN/1% acetic acid solution was used, then the 
sample was ready for analysis.  
 
For screening both small and large peptides, two matrices were used. Sinapinic acid 
(SA, at 1 mg/mL) allowed detection of peptides > 2500 Da and α-cyano-4-hydroxycinnamic 
acid (CCA, at 2.5 mg/mL) permitting screening of peptides < 2500 Da. Virtual post-
translational modification of MbtB was performed in Peptide Mass Software (Expasy Tools) 
to compare to those generated in-gel digestion. An aliquot (1-0.7 µL) of the purified digest 
was spotted into the matrices and the prepared plates were analysed in the mass analyzer 4800 
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MALDI TOF/TOF (Applied Biosystems) and carried out in the Pharmaceutical Biotechnology 
Department, University of Saarland, Saarbrücken, Germany. Proteins were identified by a 
combination of the Peptide Mass fingerprint and the data for the tandem mass measurement of 
digested peptides. Evidence of post-translational modification of the carrier proteins fragments 
was sought by manually inspection of the generated masses in the spectra and compared with 
the predicted modified peptides.    
 
2.2.5.2 Screening for in vivo post-translational modification of carrier proteins by 
HPLC. 
The post-translational modification of MbtB by PptT involves the transfer of the 
phosphopantetheine which presents a thiol group that serves as the linkage point for the carrier 
proteins during mycobactin assembly. By using a fluorescent dye, Alexa Fluor® 488 C5-
maleimide (Molecular Probes Invitrogen), a reagent that reacts with thiol groups on proteins 
to give thioether-coupled products, post-translational modification can be monitored. Thus, 
the modification of MbtB were detected by HPLC by labeling with a fluorophore. 
 
 Co-overexpression and purification of the MbtB recombinant protein was carried out 
as described in section 2.2.5. In-solution trypsin digestion was performed to generate peptides 
from MbtB. Trypsin Gold Mass Spectrometry Grade (Promega) was resuspended at 1 µg/uL 
in 50 mM acetic acid, 5 mM β-mercaptoethanol, 0.1 % SDS as was indicated by the manufac-
turer. A concentration of trypsin 1:20 (w/w) (protease: protein ratio) was added to the protein 
solution, and the reaction was incubated for 20 minutes at 37ºC. Solution was chilled on ice 
for 30 minutes to stop the reaction. Then, labeling was performed by conjugating with a 10-
fold molar excess of the dye in 50 mM Tris-HCl-pH 7.9-500 mM NaCl for 4 hours at room 
temperature in the dark. Labelled peptides were purified by Reverse Phase-HPLC at A=493 
and analysed by MALDI-MS. 
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2.2.6 In vitro post-translational modification of MbtB. 
In vitro phosphopantetheinylation by PptT was attempted by molecular cloning, expression 
and purification of the PptT as well as MbtB. For cloning pptT the following primers were 
used: up 5'-GATCGATCCATATGACGGTAGGCACGCTGG-3' down 5'-
GATCGATCGCGGCCGCTCATAGCACGATCGCGGTCAGCAC-3’ (NdeI and NotI 
restriction sites are underlined) and the PCR product was inserted into pET28b to create pptT-
pET28b which featured an in-frame fusion with an N-terminal hexa-histidine tag to facilitate 
protein purification using metal chelate affinity chromatography. The ligation mixture was 
used to transform E. coli TOP10 (Invitrogen) for screening under Kanamycin (Kan, purchased 
from Sigma Aldrich) resistance marker. Molecular cloning of the mbtB gene is described in 
section 1.5.1.1. Nucleotide sequence of DNA plasmids from recombinant transformants were 
confirmed by double digest and their integrity verified by sequencing. 
 
 The examine expression of pptT-pET28b, an aliquot of 50 µL E. coli C41 (DE3) 
(OverExpress) chemical competent cells was transformed with 1 µL pptT-pET28b by heat 
shock at 42ºC for two minutes. Conditions were tested as previously detailed in section 
1.5.1.4. Cells were grown at 37ºC followed by the addition of 1 mM of IPTG to induce 
overproduction of the recombinant gene. To scale up protein production, cells from a single 
colony were used to inoculate 50 mL of LB Broth supplemented with Kan (25 µg/mL) and 
cultured overnight at 37ºC with shaking (180 rpm). From this starting culture, 5 mL was 
transferred to 1 L of TB media (solution 1) supplemented with salts (solution 2) and Kan (25 
µg/mL). The large-scale culture was incubated at 37ºC until the OD600 reached 0.5-0.6 and 
recombinant gene expression induced with 1 mM IPTG. The culture was further incubated for 
4 hours followed by harvesting by centrifugation at 8, 000 rpm for 5 minutes at 4ºC. 
 
Cells were resuspended in 200 mM NaCl, 1 mM EDTA, 20 mM Tris-HCl pH 7.4 as 
described by Quadri et al., (1998). Following resuspension cells were disrupted by two 
passages through a French Press cell (3000 psi) and serine protease inhibitors added to the cell 
debris. The extract was clarified by centrifugation at 15,000 for 30 minutes at 4ºC. 
Supernatant was collected and the recombinant protein purified by affinity chromatography 
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using a Ni2+pre-charged and equilibrated His-Trap column (5 mL) following the 
manufacturer’s instructions (Amersham). A step gradient of 50-500 mM imidazole was used 
to elute the protein. The purity of the protein was assessed by 12 % SDS-PAGE and Coomasie 
blue stain staining. Purified protein fractions were pooled and dialysed against 10 mM Tris-
HCl, pH 8.0, 1 mm EDTA, 1 mM DTT and 5% glycerol, and concentrated using a Centricon 
YM-10 filter unit (Millipore) and stored at -80C ºC until use. The protein concentration was 
estimated by the BCA assay (Pierce) and by absorbance at 280 nm with the predicted molar 
extinction coefficient (ε= 24 708.44 M-1 cm-1).  
 
2.2.6.1 Screening for in vitro post-translational modification of MbtB. 
In vitro assays were performed in an attempt to modify MbtB. The typical biochemical assay 
for determining the conversion from apo-protein to holo-protein was carried out in 100 µL 
reaction following previous method reported by Quadri et al., (1998) with minor 
modifications: 75 mM Tris-HCl (pH 7), apo-protein (~100 µM), PptT (25-55 nM), 1 mM 
CoA, and 10 mM MgCl2. The reaction mixtures were incubated at 37ºC and samples were 
taken at different time points (0, 30, 60, 120, and 240 minutes) to analyse them by MALDI-
MS. 
 
Lanes on a 12% SDS-PAGE gel that contained the protein of interest (about 151 kDa) 
were excised and treated in-gel trypsin digestion as was described above. Samples were 
concentrated and desalted by using Zip Tip (section 2.2.5.1). Once the samples were purified, 
peptides were analysed by MALDI-MS (section 2.2.5.1). In addition, both MbtB and PptT 
proteins were separately loaded on gels and treated for mass spectrometry analyses to compare 
the results from the reactions carried out to modify MbtB.   
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2.2.7 Molecular cloning and expression of the ArCP domain of MbtB. 
Other research groups have been successful in achieving ArCP phosphopantetheinylation 
allowing study of the initial transfer reaction, but study of further biochemical reactions by 
MbtB requires the modification of a further peptidyl carrier domain. However, cloning only 
the ArCP domain (the amino terminus of MbtB) would simplify the 
phosphopantetheinylation. For this purpose, expression vectors from IMPACT-CN system 
(New England Biolabs) were tested. This system allows protein purification that utilises the 
inducible self-cleavage activity of a protein splicing element (termed intein) to separate the 
target protein from the affinity tag. A target protein is fused to a self-cleavable intein tag in 
which a chitin binding domain allows affinity purification of the fusion precursor on a chitin 
column. In the presence of thiols such as DTT, β-mercaptoethanol or cysteine, the intein 
undergoes specific self-cleavage which releases the target protein from the chitin-bound intein 
tag resulting in a single-column purification of the target protein (Chong et al., 1998) with 
gentle and efficient post-column processing to achieve a protein product of near native 
sequence. The pTYB expression vectors allow the fusion of the cleavable intein tag to either 
the C-terminus (pTYB1 and pTYB2, C-terminal fusion) or N-terminus (pTYB11 and 
pTYB12, N-terminal fusion) of a target protein (New England Biolabs). pTYB1 and pTYB2 
allow cloning the interest gene in fusion with intein tag (and the cleavage site) without adding 
extra amino acid residues to the recombinant protein, whereas pTYB11 and pTYB12 will add 
a small peptide that is cleaved and co-eluted with recombinant protein during purification. The 
pTYB vectors use a T7/lac promoter to provide stringent control of the fusion protein. 
Another feature of the pTYB vectors is that they carry an ampicillin gene marker. 
 
PCR amplification of the ArCP truncated gene from M. tuberculosis H37Rv was 
performed with VentTM DNA polymerase (New England Biolabs). Primers used to clone the 
ArCP gene into pTYB vectors are listed in Table 9. PCR reactions were attempted as was 
described in section 2.5.1.1 Amplicons were obtained for all pTYB vectors and the PCR 
products were then directly ligated according to their respective vectors. Ligations mixes were 
used to transform E. coli TOP 10 cells (Invitrogen). However, only the following genetic 
constructs were created: ArCP-pTYB1, ArCP-pTYB2 and ArCP-pTYB12. The nucleotide 
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sequences of plasmid DNA from recombinant transformants were confirmed by sequencing as 
described above. The genetic constructs were used to attempt both in vivo and in vitro 
modification of the ArCP protein. 
 
Seeking optimal over-expression conditions of the ArCP protein, using E. coli ER2566 
(New England Biolabs) as described in section 2.2.3, no expression was found. However, 
further analysis of the genetic constructs by Western Blot and Immunodetection were carried 
out to determine overexpression.  
 
Table 9. Primers used to clone ArCP in pTYB vectors. Restrictions sites are underlined and 
showed on the right side of the table. 
Vector Primer 
Restriction site 
(underlined) 
pTYB1 Up 5’-GATCGATCCATATGGTGCATGCTACGGCGTGCTCGGAGATC-3’ Nde I 
 Down 5’-GATCGATCTGCTCTTCCGCACCCTGGTGCGGCAACTGCCGTGGGCGC-3’ Sap I 
pTYB2 Up 5’-GATCGATCCATATGGTGCATGCTACGGCGTGCTCGGAGATC-3’  Nde I 
 Down 5’-GATCGATCCCCGGGCCCTGGTGCGGCAACTGCCGTGGGCGC-3’ Sma I 
pTYB11 
Up 5’-ATCGTTATTGCTCTTCCAACATGGTGCATGCTACGGCGTGCTCGGAGATC-
3’   
Sap I 
 Down 5’-ATC GTT CTG CAG TCA CCC TGG TGC GGC AAC TGC CGT GGG CGC-3’ Pst I 
pTYB12 Up 5’-GATCGATCGAATGCTGTGCATGCTACGGCGTGCTCGGAGATC-3’ Bsm I 
 Down 5’-ATCGTTCTGCAGTCACCCTGGTGCGGCAACTGCCGTGGGCGC-3’ Pst I 
 
 
 
Disrupted cells (crude extract) and clarified lysate (supernatant) derived from 
screening optimal over-expression conditions were loaded into a 15 % SDS-PAGE. Proteins 
were transferred onto a nitrocelluse membrane by Western Blot. Immunodetection was carried 
out with antibodies against the chitin-binding domain of the fusion protein as a first antibody 
(New England Biolabs). Secondary antibody, rabbit-IgG linked to alkaline phosphatase 
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conjugate (Sigma Aldrich) and BCIP/NBT (Sigma Aldrich) was used as a substrate for the 
latter.  
 
2.2.7.1 Protein purification of ArCP in chitin matrix column.  
Once optimal over-expression of the ArCP was determined, protein purification was carried 
out by affinity chromatography using a chitin column. The chitin-binding domain (CBD) in 
the intein tag from the vectors allows affinity purification of the fusion protein. A 25 mL 
chitin matrix column was prepared and equilibrated with 10 times buffer A (20 mM Tris-HCl, 
pH 7.9, 500 mM NaCl, 1 mM EDTA) at 4°C. Optimal over-expression of the ArCP-pTYB1 in 
E. coli ER2566 was found to be at 0.5 mM IPTG and cells growing at 16°C. After induction 
and growth, cells were harvested, resuspended with buffer A and lysed through two passages 
using a French Press cell. The extract was clarified by centrifugation at 15, 000 rpm for 30 
minutes at 4ºC. The supernatant was collected and loaded onto a chitin bead column, and left 
for 30 minutes for specific binding of the fusion protein. Then, the column was washed with 
10 bed volumes of the column buffer making sure that the clarified extract was not present in 
the column. The protein was released from the chitin column by induction on-column 
cleavage by quickly flushing 3 bed volumes of cleavage buffer B (20 mM DTT, 20 mM Tris-
HCl, pH 7.9, 500 mM NaCl, and I mM EDTA) and the column was left for further 16 hours. 
The following day, the protein was eluted with buffer A. Purity of the protein was monited by 
electrophoresis 15% SDS-PAGE and Coomasie blue staining. Fractions containing the 
purified protein were pooled and dialysed against storage buffer (10 mM HEPES, 10 mM 
NaCl, 1 mM EDTA, 1 mM DTT, and 5% glycerol, pH 8.6), and concentrated using Centricon 
YM-3 filter unit (Millipore) and stored at -80C ºC until use. Protein concentration was 
estimated by the BCA assay (Pierce) and by absorbance at 280 nm with the predicted molar 
extinction coefficient (ε=9121 M-1 cm-1).  
 
     113
Chapter 2                                                                  Post-translational modification of MbtB 
2.2.7.2 Screening in vivo and in vitro post-translational modification of the ArCP 
protein. 
A 50 µL stock E. coli ER2566 was transformed with ArCP-pTYB1 and chemical competent 
cells were prepared. Large-scale cultures were prepared for protein production. The 
recombinant protein was purified as in section 2.2.7.1, followed by in-gel trypsin digestion 
and MALDI-TOF analysis as mentioned in section 2.2.5.1. The intact protein was also 
analysed by Fourier transform ion cyclotron resonance mass spectrometry (FT-ICR) and 
Electro Spray-MS (ES-MS).  
 
 For in vitro post-translational modification, the ArCP-pTYB1 and pptT-pET28b 
recombinant proteins were purified and biochemically assayed. The typical biochemical assay 
for determining the conversion from apo-protein to holo-protein was carried out as in section 
2.2.6.1.        
 
2.2.8 In vivo post-translational modification of the carrier proteins of MbtB by a broad 
substrate phosphopantetheinyl transferase. 
The phosphopantetheinyl transferases are classified according to their primary sequence and 
substrate specificity, and one class exhibits broad substrate specificity that can 
phosphopantetheinylate diverse carrier proteins from PCPs to ACPs (Gaitatzis et al., 2001; 
Gross et al., 2005). This type of PPTases is sometimes named “promiscous PPTase”, “relaxed 
PPTase” or “broad substrate PPTase”. In this study, the term “broad substrate PPTAse” will 
be used. Complete post-translational phosphopantetheinylation of apo-MxcF and apo-MxcF, 
nonribosomal peptide synthetases involved in myxochelin biosynthesis, was achieved by co-
overexpression of MtaA, a “broad phosphopantetheinyl transferase”, from Stigmatella 
aurantiaca DW4/3-1. The protein was also able to modify other carrier proteins, such as the 
acyl carrier protein (ACP) domain of the mta gene cluster for myxothiazol biosynthesis from 
S. aurantiaca, a PCP of unknown function from Sorangium cellulosum and the ArCP of the 
enterobactin synthetase (EntF) from E. coli (Gaitatzis et al., 2001). Hence, the MtaA 
represented a potential PPTase to achieve modification of the ArCP and MbtB proteins. 
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The mtaA gene from S. aurantiaca has been cloned into pUS vector giving rise to 
pUSMtaA genetic construct as reported by Gaitatzis et al., (2001). The pUS plasmid has the 
P15A replicon and chloramphenicol (Chl) resistance marker, genetic features that allowed in 
vivo post-translational modification of the ArCP and MbtB proteins by co-overpression of the 
genetic constructs using E. coli as heterologous host. Co-overexpression experiments were 
carried out as described in section 1.5.1.4., in which mbtB-pET23b and ArCP-pTYB1 were 
transformed in E. coli C41 (DE3) and E. coli ER 2566, respectively, to prepare chemical 
competent cells followed by second round of transformation in each set with pSUMtaA. 
Cultures of each set were initially grown at 37°C until OD600=0.5-0.6 containing Amp (100 
µg/mL) and Chl (30 µg/mL) and gene expression was induced with 0.5 mM IPTG. Incubation 
was continued for further 16 hours at 16°C. Large-scale cultures were prepared to yield and 
purify each recombinant protein as described above. Determination of post-translational 
modification was performed by MS analysis as described in section 2.2.5.1.  
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2.3 Results. 
2.3.1 In vivo post-translational modification of MbtB by the intrinsic 
phosphopantetheinyl transferase of M. tuberculosis.  
E. coli has been successfully used for in vivo reconstitution of other carrier proteins from 
siderophores, phosphopantheinyl transferases (pptT, acpS) of aryl-N-capped siderophores such 
as yersiniabactin (Bobrov et al., 2002), enterobactin (Gehring et al., 1997a) and other 
molecules produced by NRPSs (Gruenewald et al., 2004). The choice of E. coli as a 
heterologous host for expression is due to the following reasons: established cultures, ease of 
handling, low cost and availability of vectors (Makrides, 1996). Thus, we adopted this system 
and E. coli C41 (DE3) was chosen as the heterologous host to express both mbtB and pptT 
simultaneously with the expectation that this strain might modify both ArCP and PCP of 
MbtB via the activity of PptT. Along with the favourable host, the plasmids used in this study, 
pCDFDuet and pET23b, are compatible vectors which can co-exist in E. coli and therefore 
express the interested genes, mbtB and pptT.   
 
A requirement for the modification for both carrier proteins, ArCP and PCP, of MbtB 
is the addition of phosphopantetheinyl (P-pant) arm by PPTtase. Initially, modification of 
MbtB was attempted by simultaneous induction of recombinant genes from pCDFDuet-pptT, 
encoding the intrinsic PPTase of M. tuberculosis, and mbtB-pET23b, by heat shock 
transformation at 42°C in E. coli C41 (DE3). To determine if such a modification was 
achieved, MbtB was purified by affinity chromatography and then analysed by MALDI-MS. 
The optimal expression conditions for mbtB were at 16°C with 1mM of IPTG with 16 hours of 
incubation, yielding approximately 3 mg/mL. The production of both proteins was difficult to 
assess by analysis of cell lysates on SDS-PAGE. Although production of a very high 
molecular protein, presumably MbtB, was apparent under expression analysis.  
 
Identification of a band that could be attributed to recombinant PptT was not possible 
during expression analysis (data not shown). Previous experiments had suggested that the 
expression of similar pptT construct identified via a specific stain for its C-terminal hexa-
histidine tag, a property not shared with the current construct in order to limit the possibility of 
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co-purification, was relatively poor (L.G. Dover, unpublished results, personally 
communicated) at 16°C, but might be considered significant for its proposed catalytic role 
here. Regardless, recombinant MbtB was purified from these extracts via its His6-tag by Ni2+-
affinity chromatography. Analysis by SDS-PAGE revealed that a single protein band was 
eluted in several fractions that migrated above the 116 kDa lane marker upon 12% SDS-
PAGE (Figure 16), consistent with the expected behaviour of the tagged MbtB (151 kDa). 
 
 
 
 
 
 
 
 
 
Figure 16. Coomasie blue staine E gel of MbtB purified. M= molecular 
size standards. Lane 1 shows MbtB purified by Ni
d 12% SDS-PAG
 
-gel trypsin digestion of MbtB was carried out and the generated peptides 
subsequ
2+-affinity chromatography. Protein solution 
fractions purified were pooled for in-gel trypsin digestion and then analysed by MALDI-MS. 
 
In
ently analysed by MALDI-MS. Two methods for desalting and concentrating the 
samples were investigated. In the first method, the tips were prepared with 100% ACN, 0.1% 
TFA, and then the sample eluted using 1% formic acid/ 50% methanol, whereas for the second 
method tips were hydrated and equilibrated with 50% ACN and 1% acetic acid, respectively, 
and then the samples eluted using 50% ACN/1% acetic acid. The second method was chosen 
since it allowed most of the MbtB peptide constituents to be analysed by MALDI-MS.        
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Virtual trypsin digestion determined the theoretical modification of the peptides in 
each carrier protein. Since the modification of both carrier proteins of MbtB involves the 
transfer of the P-pant group which has a mass of 339.32 Da, an increase in mass in the 
peptides would determine the modification of each carrier protein. Thus, the ArCP peptide of 
1903.9984 Da was expected to increase to 2243.3218 Da, whereas the PCP peptide 2914.4693 
Da was expectecd to increase to 3253.7927 Da. Peptides generated by in-gel digestion of 
MbtB were analysed in two different matrices, SA and CCA, which allowed the screening of 
either small or large peptides. An increase of mass by addition of the (P-pant) group (339.32 
Da) from CoA by PPTase was expected in each carrier protein, but neither ArCP nor PCP of 
MbtB was observed, as analysed by MALDI-MS. Only the peaks corresponding to ArCP or 
PCP in their apo-form were observed (Figure 17).      
 
To screen further for post-translational modification of MbtB, after co-overexpression 
with pptT, in-solution trypsin digestion of MbtB was carried out to identify peptides. After 
digestion, a sample was taken and analysed by 15% SDS-PAGE. Migration of different size 
bands on the gel indicated that digestion of MbtB was achieved and the generation of peptides 
for subsequent labelling with fluorescent dye. Peptides generated by digestion were 
subsequently labelled with Alexa Fluor-maleimide. Maleimide reacts with thiol groups, and 
since MbtB possess 10 cysteine residues, it was expected that addition of the fluorescent dye 
would yield 9 labelled peptides (one peptide has two cysteine residues). Also, by addition of 
the phosphopantetheine group, which at its end also possesses a thiol group, to modify MbtB 
in its holo-form, two additional peptides were expected to be labelled if the PPTase modified 
both carrier proteins. Labelled peptides were subsequently analysed by HPLC to separate the 
interest peptides and elution of Alexa fluor modified peptides was carried out at 493 nm. The 
HPLC profile showed some peaks that could be labelled, and apparently the maximum 
number of labelled peptides detected was 8 (data not shown). Most of the peaks overlapped 
and only two peaks, 7 and 8, were separated at different retention times. Despite this poor 
resolution, all labelled peptides were purified and analysed by MALDI-MS to determine their 
nominal mass. However, the determination of the nominal mass of those peptides was not 
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achieved either because under acidic conditions a spontaneous cleavage of the peptides 
occurred or during ionisation in MS, desorption of peptides did not occur.     
Figure 17. MALDI-MS analysis of peptides from MbtB. After co-overexpression of mbtb-
pET23b and pptT-pCDFDuet-1 in E. coli C41(DE3), followed by MbtB purification by Ni2+-
affinity chromatography. In-gel trypsin digestion of the MbtB was carried out, and the 
peptides were then analysed by MALDI-MS to screen for modifications. No modification of 
both ArCP and PCP of MbtB were observed and only the carrier proteins in their apo-form 
were detected (indicated by arrows). 
 
 
2.3.2 In vitro post-translational modification of MbtB. 
Since in vivo MbtB post-translational modification by PptT, using E. coli as a heterologous 
host, was not successful, mbtB and pptT were expressed separately into pET vectors and 
transformed E. coli C41 (DE3) and the modification attempted by in vitro assays. The mbtB 
gene had already been cloned into a pET23b-expression vector and expressed in E. coli C41 
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(DE3), followed by Ni2+-affinity chromatography purification. In order to attempt in vitro 
modification, the pptT gene was cloned into a pET28b-expression vector with an N-terminal 
hexa-histidine tag, and subsequently expressed in E. coli C41(DE3), achieving good yields of 
soluble protein. The recombinant PptT was purified by Ni2+-affinity chromatography and it 
was obtained pure. The purified protein migrated as a single band on 12 % SDS-PAGE with 
an apparent molecular mass of 30 kDa, although the molecular mass calculated for PptT is 24 
kDa (Figure 18). This abnormal mobility of PPTases on SDS-PAGE has been observed 
previously (Ku et al., 1997; Sánchez et al., 2001). 
 
 
 
 
 
 
 
 
 
 
 
Figure 18.  Coomasie blue stained 12% SDS-PAGE of PptT purified. The recombinant 
protein was purified in a step gradient concentration of imidazole (50-500 mM). The purified 
protein migrated as single band with an apparent molecular size of 30 KDa (calculated MW 
for His6 –tagged PptT is 25.53 KDa) on 12 % SDS-PAGE.  
 
 
To establish if PPTase could catalyse the transfer of the P-pant group in the conserved 
serine residue into either apo-ArCP or apo-PCP of MbtB to their holo-forms, both proteins 
were incubated at 37ºC in a time course assay. Then, for each time point a sample was taken 
and loaded onto 12% SDS-PAGE, the carrier protein band was excised and in-gel protein 
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digestion performed by trypsin. Samples were treated to desalt and concentrate with the 
second method for MS analyses which allowed detection of most MbtB peptides constituents. 
No modification of either carrier protein was observed when the MbtB peptide constituents 
were analysed. Only the peptides, which corresponded to either ArCP or PCP in their apo-
form were observed (data not shown). Therefore, results indicated that this recombinant form 
of the intrinsic M. tuberculosis PPTase did not transfer the phosphopantetheine group from 
CoA to the serine residues in each carrier protein of MbtB.   
 
2.3.3 Cloning, expression, and post-translational modification of the ArCP. 
Since neither in vivo nor in vitro strategies produced efficient post-translational modification 
of MbtB by the intrinsic PPTase of M. tuberculosis, cloning and expression of the truncated 
ArCP from MbtB represented an alternative approach. The pTYB expression vectors were 
used to attempt cloning and expression of the ArCP in E. coli ER2566. Hence, the truncated 
ArCP gene was cloned into pTYB1, pTYB2 and pTYB12.  
 
E. coli was transformed with the ArCP-pTYB1 construct and the cultures (100 mL in 
LB medium) were grown at 37°C until OD600=0.5-0.6. Cultures were cooled to 16°C and gene 
expression induced by the addition of different IPTG concentrations (0.1 mM, 0.5 mM and 1 
mM). Incubation was continued for a further 16 hours at 16°C with shaking. Cells were 
disrupted by French Press followed by centrifugation and the clarified (supernatant) and crude 
extracts analysed by SDS-PAGE. Since the ArCP (MW 9.12 KDa) was cloned in fusion with 
the Chitin Binding Domain (CDB, 56 KDa) of the pTYB1 expression vector, a fusion (CBD)-
recombinant protein ArCP with a MW 65 KDa was expected. A band migrated about 66 KDa 
in all clarified samples from each IPTG concentration tested, including in the negative control 
upon 12% SDS-PAGE. Nevertheless, Western Blot and Immunodetection analyses were 
performed to further screen expression. Analyses of banding patterns suggested that anti-
CBD-intein had recognised several molecular species with mass ranging between 66-56 kDa 
in the clarified samples. The signal intensity was significantly increased in extracts of cells 
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treated with IPTG consistent with the overproduction of the ArCP-CBD fusion protein (Figure 
19A). 
Figure 19. Over-expression and purification of ArCP. A) Western Blot and 
Immunodetection analysis. Strong signals were observed (indicated between brackets) in 
samples coming from induced cells with IPTG at: Lane: 1 mM; Lane 2: 0.5 mM; Lane 3: 0.1 
mM. In lane 4, the control (no IPTG added) was loaded and no strong signal was observed. 
Numbers on the right are molecular masses (in kDa) based on broad-range prestained 
standards (New England Biolabs). B) Coomasie blue stained 15% SDS-PAGE of the ArCP of 
MbtB. Lanes as following: M: marker; Lane 2: purified protein. The purified protein migrated 
(pointed with an arrow) below the 14 marker band and this indicated that the interest protein 
was expressed in E. coli ER2566. Due to the presence of another band below the protein, it 
was assumed that the ArCP was modified in vivo by the heterologous host. 
 
 
 
Thus, E. coli ER 2566-ArCP-pTYB1 was grown in 4 L of TB media and the 
expression induced with 0.5 mM IPTG at 16ºC overnight. After induction, cells were 
harvested and treated as before. The clarified supernatant was loaded onto a 25 mL bed of 
chitin beads and purification performed. Here the chitin-adsorbed fusion protein was treated 
with 20 mM DTT to release ArCP domain from its intein-linked fusion partner (Figure 19B). 
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The eluted protein was electrophoresed upon 15% SDS-PAGE and showed the presence of 
two distinct bands (Figure 19B, pointed by two arrows), suggesting that the ArCP might have 
been in vivo modified by the intrinsic PPTase of E. coli ER2566; similar electrophoretic 
behaviour was observed with AcpM of M. tuberculosis that participates in mycolic acid 
biosynthesis in similar analyses (Kremer et al., 2001). To confirm this, FT-ICR and ES-MS 
analyses were performed for the intact fusion protein and for the two bands, but in both 
analyses modification of the ArCP was not detected (Figure 20). 
 
Figure 20. ES-MS analysis of the ArCP. The ArCP was overproduced in E. coli ER2566 
and purified by chitin bead affinity chromatography. The ArCP was analysed by ES-MS to 
seek post-translational modification. The molecular weight calculated for ArCP is 9121.57 
Da. Addition of the phosphopantetheine group (339.32) should have increased the mass up to 
9460.89. However, post-translational modification was not achieved, and only a peptide 
exhibiting the nominal mass of the unmodified ArCP (indicated with the arrow) was observed.    
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In another attempt, both the recombinant PptT (decribed earlier) and the ArCP proteins 
were purified separately and in vitro assays were carried out seeking modification of the 
truncated protein. Here also, MALDI-MS analysis of in-gel trypsin treated samples provided 
no evidence for the post-translational modification of the carrier protein.   
 
2.3.4 In vivo post-translational modification of the ArCP and MbtB by a broad 
substrate phosphopantetheinyl transferase. 
The PPTases are classified into three groups or families based on their sequences, structural 
similarities and substrate specificities. The first family designated “Sfp-type”, denominated 
after Sfp (surfactin phosphopantetheinyl transferase from Bacillus subtilis), include PPTases 
having ~230 amino acid residues in length and with broad substrate specificity (Lambalot et 
al., 1996). Members of this family often participate in PKSs/NRPSs hybrid systems, such as 
siderophore biosynthesis, i.e. enterobactin and pyochelin. Since the intrinsic PPTase of M. 
tuberculosis did not carry out the post-translational modification of the carrier proteins, 
another approach was to examine a broad substrate PPTase. Hence, the MtaA, a PPTase from 
myxochelin biosynthesis of Stigmatella aurantiaca was chosen because of the enzyme’s 
demonstrated ability to carry out phosphopantetheinylation of fatty acid and carrier proteins of 
NRPSs (Gaitatzis et al., 2001). Based on amino acid sequence aligments and conserved 
motifs, PptT and MtaA appear to be related to Sfp. Therefore, based on these experimental 
and bioinformatic information, MtaA was viewed as a potential candidate for attempting post-
translational modification of the carrier proteins of MbtB and the ArCP domain.  
 
Firstly, mbtB-pET23b and ArCP-pTYB1 were transformed into E. coli C41 (DE3) and 
E. coli ER2566, respectively, to prepare chemical competent cells. Then, a second round of 
transformation using the pSUMtaA (genetic construct carrying the mtaA gene encoding for the 
MtaA provided as a gift by Prof. Rolf Müller, Department of Pharmaceutical Biotechnology, 
Saarland University, Germany), was performed. As negative controls, the ArCP-pTYB1 and 
mbtB-pET23b constructs were expressed in their respective heterologous host without 
pSUMtaA. After co-overexpression of each of the protein sets (ArCP/MbtB) with mtaA in 
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their respective heterologous host, purification, in-gel trypsin digestion and MALDI-MS 
analysis of the peptides of each protein, both proteins showed mass increases ~340 Da, in the 
carrier proteins, which corresponds to the mass of the attached phosphopantetheinyl group. 
Thus, MtaA activated both the ArCP and the MbtB proteins in E. coli (Figure 21).  
 
 
 
 
Figure 21.  MALDI-MS analysis of the carrier proteins of MbtB. The mbtB-pET23b and 
pSUmtaA genes were co-overexpressed in E. coli C41 (DE3). After co-overexpression, 
purification, in-gel trypsin digestion, and MALDI-MS analysis of the peptide constituents of 
MbtB, post-translational modification was observed in both carrier proteins. A) As negative 
control, the mbtB-pET23b was overexpressed in E. coli C41 (DE3), without the pSUMtaA 
construct, followed by purification, in-gel trypsin digestion, and MALDI-MS analysis. Only 
the apo-forms of the carrier proteins were observed (indicated by arrows). By co-
overexpression of the mbtB-pET23b and pSUMtaA both the ArCP (B) and the peptidyl carrier 
protein (C) were partially phosphopantetheinylated by MtaA.    
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However, it was clear that complete post-translational modification of MbtB had not 
been achieved and the efficiency at which the ArCP and PCP domains within MbtB had been 
modified was not uniform. Approximately 75% of the total ArCP was activated (Figure 21B), 
judged from the peak area in the MALDI-MS spectra, whereas only 30% of the PCP was 
modified (Figure 21C). However, when the modification of the isolated ArCP domain was 
analysed, phosphopantetheinylation appear to be complete (Figure 22).         
 
 
Figure 22. MALDI-MS analysis of the truncated ArCP. The ArCP-pTYB1 was co-
overpressed with pSUMtaA in E. coli ER2566, followed by purification, in-gel trypsin 
digestion, and MALDI-MS analysis. A) For negative control ArCP-pTYB1 was 
overexpressed without pSUMtaA; only the apo-form of the carrier protein was observed. B) 
Complete in vivo post-translational modification of the ArCP by MtaA was observed.  
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2.4 Discussion. 
Numerous antibiotics and other secondary metabolites are produced by complex NRPSs and 
PKSs megaenzymes. NRPSs and PKSs are organized in modules, and each module contains 
multiple and different catalytic domains. A simple NRPS module may consist of an 
adenylation domain (A) for substrate recognition and activation, a carrier protein domain (CP) 
that accepts the activated substrate and holds its residue as a thioester, and a condensation 
domain (C) for peptide bond formation. A final domain might be present in this multienzyme 
complex, the thioesterase domain (TE) that cleaves the growing molecule from the terminal 
NRPS. Additional enzyme activity can be found by the presence of extra domains such as the 
epimerisation domain (E) that catalyses racemisation and the cyclisation domain (Cy), 
catalysing both condensation and intramolecular heterocyclisation of serine, threonine or 
cysteine (Challis & Naismith, 2004).  
 
A typical PKS module consists minimally of an acyltranferase (AT) to extend unit 
selection, an acyl carrier protein (ACP) for extender unit loading, and ketoacyl synthase 
domain (KS) for decarboxylative condensation between the aligned acyl thiosters to elongate 
the growing polyketide chain (Du et al., 2001). NRPSs enzyme activities may be coupled with 
PKSs to form NRPS/PKS hybrid systems to produce complex molecules, i.e. siderophores, 
from simple building substrates. NRPSs and PKSs have common organization domains: i) 
both systems use carrier proteins (PCP in NRPSs and ACP in PKSs) to tether the growing 
product; ii) both PCP and ACP are post-translationally modified by phosphopantetheinyl 
transferases; iii) the growing chain is released by a TE domain (Du et al., 2001; Schwarzer et 
al., 2003).   
 
 There is increasing interest in elucidating the complete structure and function of 
NRPSs and PKSs enzymes to develop novel biological molecules of pharmacological 
importance. Furthermore, establishing the biochemical sequence reactions, as well as substrate 
recognition, during siderophore biosynthesis, would aid in designing new drugs against 
pathogenic bacteria (Schwarzer et al., 2003). However, investigation of these enzymes has 
been hampered due to their enormous size representing not only a problem for molecular 
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cloning, but also hindering heterologous expression and purification of the gene products 
(Keating et al., 2000c). In addition, appropriate functions of each module might be coupled 
with other synthetases as a single complex interaction. All these challenges are represented in 
cloning and expression the mbtB gene of M. tuberculosis, a NRPS required for the core 
structure of mycobactin-carboxymycobactin biosynthesis (De Voss et al., 2000; Quadri et al., 
1998). Furthermore, the high GC content of mycobacteria genomes represents an additional 
challenge for molecular cloning. Despite these challenges, in this study the full length of mbtB 
was cloned and successfully expressed and purified as a soluble protein in E. coli C41 (DE3). 
The MbtB modular enzyme (~151 KDa) consists of the following five domains: an 
adenylation domain to activate serine/threonine, two carrier proteins, one for salicylic acid 
(ArCP) and one for serine/threonine (PCP) covalent tethering, a cyclisation domain (Cy) to 
condense and cyclise the activated substrates to form the oxazoline ring, and a thioesterase 
domain (TE) for releasing the growing product.  
 
 In order to carry out subsequent biochemical studies, the carrier proteins of MbtB, 
ArCP and PCP, must be post-translational modified by a dedicated phosphopantetheinyl 
transferase (PPTase). The PPTase catalyses the transfer of the phosphopantetheinyl moiety 
from CoA to the hydroxyl group in the side-chain in a conserved serine residue of the carrier 
protein domains. M. tuberculosis possesses only two PPTases: i) Rv2523C, also called acpS 
because the encoded protein displays similarity in activity, amino acid sequence, and substrate 
specificity, to AcpS, a E. coli PPTase (Chalut et al., 2006); ii) Rv2794c, which encodes for 
227-aa PPTase, named PptT, which is involved in pre-mycobactin biosynthesis (Quadri et al., 
1998), as well as in numerous PKSs and NRPSs biosynthesis (Chalut et al., 2006).     
 
 In this study, the first attempt to achieve in vivo post-translational modification of the 
carrier proteins of MbtB was the co-overexpression of the intrinsic pptT gene of M. 
tuberculosis in E. coli C41 (DE3). Several reasons supported the use of E. coli to carry out 
this study: i) E. coli has been successfully used for in vivo reconstitution of carrier proteins 
and PPTases involved in aryl-N-capped siderophore production, such as yersiniabactin 
(Bobrov et al., 2002) and enterobactin (Gehring et al., 1997a), as well as other molecules 
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produced by NRPSs (Gruenewald et al., 2004); ii) the availability of established cultures, ease 
of handling, low cost and a range of expression vectors; and iii) co-overexpression of 
mycobacterial genes in E. coli represented a strategy to measure interaction between 
associated gene products (Mir et al., 2006). Hence, the genetically compatible constructs were 
created: mbtB-pET23b and pptT-pCDFDuet-1, in which the expression vectors displayed the 
required genetic features, different replicons and resistance markers, for in vivo post-
translational modification of MbtB by PptT in E. coli C41 (DE3). After co-overexpression, 
protein purification, in-gel trypisn digestion and MALDI-MS analysis of the peptide 
constituents of MbtB, phosphopantetheinylation by PptT was not detected. The modification 
both ArCP and PCP of MbtB was not achieved probably because the intrinsic 
phoshophopantetheinyl transferase of M. tuberculosis was not produced in the concentrations 
required to carry out its activity under these conditions. Despite the likely copy number of 20-
40, production of the protein in E. coli C41 (DE3) was probably not achieved at high enough 
levels. The use of E. coli C41 (DE3) as host was due to this strain being modified to avoid 
high production of proteases and allows good co-expression host for globular and membrane 
protein over-production (Miroux & Walker, 1996). On the other hand, poor plasmid stability 
has been observed in this strain, although the target proteins were overexpressed. Expression 
of some heterologous genes from plasmids may be toxic to E. coli C41 (DE3). These plasmids 
are unstable and may be lost from up to 50% of the population (Dumon-Seignovert et al., 
2004). Maybe, the pptT-pCDFDuet-1 is relatively unstable in E. coli C41 (DE3) and therefore 
the production of PptT was compromised since no modification of MbtB was observed.  
 
Research in PKSs and NRPSs biosynthesis has been difficult due to inability to 
produce their fully active holo-forms in other hosts, because the host PPTases fail to either 
recognise or act inefficiently on these carrier proteins substrates. Many organisms utilise more 
than one PPTase-dependent pathway for either primary or secondary metabolism. E. coli 
produces three PPTases, the AcpS required for fatty acid biosynthesis, EntD a PPTase 
involved in enterobactin production (Lambalot et al., 1996; Lambalot & Walsh, 1995), and 
YhhU (also called o195) rendering function similarity to AcpS under certain cell environment 
conditions (Flugel et al., 2000). It is interesting to note that regardless of similar function of 
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the AcpS and EntD PPTases, the proteins are able to recognise their respective specific 
substrates: AcpS recognizing only ACP and EntD only accepting ArCP and PCP of NRPSs 
(Lambalot et al., 1996). It has been shown that EntD does not cross-interact with primary 
metabolism, since EntD may be only expressed under iron-deficient environments (Lambalot 
et al., 1996). However, partial or fully post-translational modification of the carrier proteins is 
observed in E. coli due to its endogenous PPTases. Obviously, over-expressing ACPs in E. 
coli affords activation of this type of proteins, but levels vary from complete to almost 
undetectable modification of the proteins (Crosby et al., 1995; Jackowski & Rock, 1983; 
Keating et al., 1995; Keating et al., 1996; Kremer et al., 2001).  
 
The ArCP and PCP domains from vibriobactin biosynthesis of Vibrio anguillarum 
reached 46-56% and 28-70% holo-conversion by the E. coli EntD. The relative modification 
of these carrier proteins was attributed to the high similarity with their counterparts in 
enterobactin biosynthesis (Liu et al., 2005). In contrast, attempting to carry out post-
translational modification of tyrocidine synthetase 1 (TY1), a NRPS produced by Bacillus 
brevis ATCC 8185, failed when the protein was expressed in E. coli. The aminoacylation 
activity was low as the majority of the enzyme molecules were unmodified (Pfeifer et al., 
1995). The truncated recombinant PCP from the tyrocidine synthetase A of B. subtilis was 
partially modified in E. coli, activity attributed to the EntD enzyme (Stachelhaus et al., 1996). 
Clearly, E. coli does not support in vivo post-translational modification of NRPSs and PKSs 
due to its endogenous PPTases. To overcome this problem, co-overexpression of exogenous 
PPTases in E. coli has achieved phosphopantetheinylation of the carrier proteins from diverse 
systems. The co-overexpression of the Streptomyces ACPs from the actinorhodin and 
griseusin PKSs with E. coli AcpS led to high levels (>90%) of holo-ACP production (Cox et 
al., 1997).  
 
The PPTase required for the gramicidin biosynthesis from Bacillis subtilis, named Gsp 
(gramicidin sythetase phosphopantetheinyl transferase), was co-overexpressed with the 
truncated phenylalanine-activating module GrsA protein of gramicidin S synthetase in E. coli 
X90 leading to the isolation of fully modified active holo-enzyme (Ku et al., 1997). The sfp 
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gene that encodes a broad substrate PPTase from B. subtilis was inserted in the chromosome 
of E. coli and subsequently co-overexpressed with the genes encoding two modules, TycA and 
TycB1, for the biosynthesis of the antibiotic tyrocidine from B. brevis. The resulting E. coli 
sfp+ strain converted the apo-form of the module to their holo-form (Gruenewald et al., 2004). 
Also, the angD gene that encodes a PPTase for the biosynthesis of anguibactin, a siderophore 
in Vibrio anguillarum, modified ArCP and PCP domains successfully when the gene was 
expressed in E. coli entD mutant AN90 since this strain lacked the PPTase responsible for the 
NRPS activation for the siderophore enterobactin (Liu et al., 2005).   
 
Since in vivo post-translational modification of MbtB by PptT did not work, in vitro 
assays were carried out by cloning and expressing the pptT and mbtB, separately. Thus, the M. 
tuberculosis pptT gene was cloned into another E. coli expression vector (pET28b), allowing 
PptT to be produced as a His-tagged protein and homogenously purified by Ni2+-affinity 
chromatography. The mbtB-pET23b was overproduced in E. coli C41(CE3) and purified 
similar to PptT. To establish if PptT could catalyse the phosphopantetheinylation of MbtB, 
both proteins were incubated at 37°C in a time course in vitro assay. However, after in gel-
trypsin digestion and MALDI-MS analysis of MbtB, modification of the carrier domains was 
not detected. The results obtained in this study differ from that found when both ArCP of 
MbtB and PCP from MbtE were converted to their holo-forms by PptT in vitro assays (Quadri 
et al., 1998). The ArCP, PCP and PptT genes were cloned and overproduced as maltose-
binding protein fusions (MBP) allowing good production of the recombinant proteins. The 
PptT activity was assessed by the incorporation of the [H3]-pantetheine group into the carrier 
domains. In addition, the quantitative conversion of apo-proteins into their holo-form was 
proved by HPLC and MALDI-TOF (Quadri et al., 1998). Here, the expression and production 
of MbtB and PptT was sufficient and the proteins were obtained as soluble enzymes, however 
holo-conversion of the carrier proteins was not achieved probably due to PptT exhibited no 
catalytic activity. 
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The initial in vivo and in vitro approaches were not successful strategies to achieve 
MbtB modification by PptT, another way to overcome this challenge was to clone the ArCP 
from MbtB. Hence, the ArCP domain was cloned into pTYB1 as a fusion frame with an intein 
CBD tag allowing single step purification. Initial expression experiments of ArCP-pTYB1 in 
E. coli ER2566 did not show overproduction of the protein. Western Blot and 
Immunodetection analysis provided hints of ArCP overexpression, but large amounts of 
culture (at least 4 L of TB medium) were needed to achieve enough protein yields. Based on 
15% SDS-PAGE analysis, the protein showed the presence of two distinct bands, suggesting 
thus that the ArCP might has been in vivo activated by the endogenous E. coli ER2566 
PPTases. This assumption was supported by an earlier report in which the M. tuberculosis 
AcpM was in vivo phosphopantetheinylated by E. coli. ES-MS analysis confirmed not only 
the holo-form of AcpM, but also determined the palmitoylated-AcpM form (Kremer et al., 
2001). Hence, each band derived from ArCP was analysed by ES-MS and FT-ICR MS, but 
these experiments did not show modification of the truncated protein. Therefore, the presence 
of these distinct bands of ArCP may be attributed to a limited degradation of the protein 
during purification process. To seek further modification of the ArCP, in vitro assays were 
attempted to achieve post-translational modification of ArCP. Both proteins (pptT-pET28b 
and ArCP-pTYB1) were overproduced in their respective host and purified separately to carry 
out in vitro assays. However, this approach did not achieve activation of the ArCP either. 
 
 MbtB represents a potential enzyme for not only understanding mycobactin 
biosynthesis, but also the protein could be the basis to exploit its structure for rational design 
of new drugs to combat TB. Thus, a further attempt embarked on the use of broad substrate 
phosphopantetheinyl transferases that could allow modification of the MbtB, as well as the 
truncated ArCP. The phosphopantetheinyl transferases form a superfamily of enzymes, which 
are classified into three groups based on their sequences, structural similarities, and susbtrate 
specifities (Lambalot et al., 1996). The first group is exemplified by AcpS of E. coli, which 
consist of PPTases about 120 amino acids in length, function as homotrimers, and modify 
only ACP of FAS and PKSs (Lambalot et al., 1996).  Members of the second group, typified 
by the Sfp of B. subtilis, are usually at least 240 residues long, function as monomers, and 
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have very broad substrate specifities. These PPTases are mainly found in NRPSs and PKSs as 
well as in siderophore biosynthesis (Reuter et al., 1999). The PPTases of the third group act as 
integrated domains on their cognate ACP of type I FAS in Saccharomyces cerevisae 
(Fichtlscherer et al., 2000). The remarkable broad substrate of the second PPTase group 
provide another alterative to accomplish post-translational modification of the carrier proteins 
in MbtB. Hence, the MtaA was chosen due to: i) the similarity of MtaA in activity and 
substrate recognition compared to that of Sfp-prototype and PptT (Silakowski et al., 1999); ii) 
the ability of the protein to modify in vivo diverse carrier proteins using E. coli as 
heterologous hosts; iii) the features of the pSUMtaA genetic construct, different replicon and 
resistance marker (Gaitatzis et al., 2001). These features pointed to MtaA as a valuable tool to 
carry out co-overexpression along with mbtB-pET23b and ArCP-pTYB1 in E. coli. Therefore, 
co-overexpression was performed for each set of carrier proteins with and without MtaA. 
After analysis, both carrier proteins were phosphopantetheinylated to some extent. Co-
overexpression of mbtB-pET23b and pSUMtaA in E. coli C41(DE3) led to activation of the 
ArCP domain to 75%, whereas only 30% of the PCP domain was modified. There was no 
modification, when only the carrier proteins were overproduced in E. coli, indicating that 
phosphopantetheinylation observed was entirely dependent upon MtaA and was not mediated 
by the endogenous E. coli PPTases.  
 
The proportional modification of the carrier proteins may be attributed either to a 
stress response (metabolic burden) of E. coli or substrate preference by MtaA towards ArCP. 
Metabolic burden is defined as the amount of resources (raw material and energy) that are 
withdrawn from the host metabolism for maintenance and expression of foreign DNA. As 
result of this metabolic burden due to high synthesis of protein, amino acid starvation occurs 
as well as other resources (Bentley et al., 1990). It has been suggested that the intracellular 
concentrations of the CoA and Mg2+, the required substrate and co-factor for PPTase activity, 
tend to be reduced during cellular growth and thus become a limiting factor for complete 
activation of the carrier proteins. Expansion of the intracellular CoA pools in cells 
overproducing ACP (through pantothenate supplementation together with a mutation giving a 
feedback-insensitive pantothenate kinase) markedly increased the conversion of apo-ACP to 
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its holo-form (Keating et al., 1995). Furthermore, the CoA pool limitations decrease 
translational efficiency of certain amino acids, mainly glutamate and other derived amino 
acids from tricarboxylic acid, which in turn affects synthesis of proteins (Keating et al., 1996). 
Taking into account the length of the overproduced recombinant proteins (MbtB:1414 and 
MtaA:277), the incomplete activation of the overproduced recombinant protein by MtaA may 
be due to low concentrations of CoA, Mg2+ and amino acids in the media during growth of the 
heterologous host. Interestingly, co-overexpression of ArCP-pTYB1 and pSUMtaA in E. coli 
ER2566 achieved full phosphopantetheinylation of the truncated aryl carrier protein (89 amino 
acids in length), supporting the above hypothesis that such metabolic burdens may be of 
significance in this process; this assumption must be further tested by other means. It is 
interesting to note that other studies have found partial modification of carrier proteins when 
co-overpression was attempted. Co-overexpression of PspT, a PPTase from Pseudomonas 
syringae, and Cfa1 (ACP), in E. coli DH10B resulted in only 25% conversion of Cfa1 to its 
holo-form (Seidle et al., 2006). There was only 90% conversion of Streptomyces apo-ACP to 
holo-form when co-overexpressed along with the acpS gene in E. coli K38 (Cox et al., 1997).  
 
 Although, the broad substrate PPTases are well known to modify diverse carrier 
proteins, the means by which they recognise their substrates are not fully understood. Most 
organisms employ more than one phosphopantetheine-dependent pathway also contain more 
than one PPTases, but Cyanobacteria and Pseudomonas seem to have only one PPTase 
suggesting their essentiality to carry out the modification of both carrier proteins of primary 
and secondary metabolism (Copp & Neilan, 2006; Finking et al., 2002; Seidle et al., 2006). In 
bacteria that lack a PPTase of primary metabolism, the Sfp-type seems to have been 
evolutionarily selected for high efficiency with CPs of primary metabolism, although the 
enzymes maintain broad substrate tolerance (Finking et al., 2002; Keszenman-Pereyra et al., 
2003). Moreover, genes encoding for NRPSs and PKSs are often clustered in one region of the 
bacterial chromosome. Then, if every NRSP and PKS has its own dedicated PPTase, one 
should expect to find a PPTase gene within each cluster. Indeed, some genes encoding for 
PPTases are found clustered, for instance enterobactin in E. coli (Lambalot et al., 1996), 
surfactin in B. subtilis (Nakano et al.,1992) and gramicidin in B. brevis (Borchert et al., 1994). 
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However, there are exceptions in which the PPTases genes are not clustered within the NRPSs 
and PKSs, such as the mycobactin-carboxymycobactin biosynthesis in some mycobacteria 
species (Quadri et al., 1998). In addition, the structure, physical and biochemical properties of 
ACPs and PCPs are different, features that may account into PPTase recognition (Mofid et al., 
2002). All these observations raise the question how the PPTases interact with their 
corresponding carrier proteins.  
 
The answer may lie in the structures of both PPTases and the carrier proteins. 
Independent of substrate specificity, all biochemically characterised PPTases have three 
conserved motifs (Table 10). Additionally, the resolved crystal structures of AcpS and Sfp 
revealed a striking similar folding (Chirgadze et al., 2000; Parris et al., 2000). However, these 
structures revealed first that all AcpS-type PPTases are enzymatically active homotrimers 
(Chirgadze et al., 2000; Parris et al., 2000) whereas Sfp-type is a pseudohomodimer 
composed of two halves that resemble the AcpS monomer (Reuter et al., 1999), suggesting 
that Sfp arose from a gene duplication and further accumulation mutations of acpS. The Sfp-
type CP recognition site is a flexible loop, whereas AcpS uses a rigid helix for the interaction 
with ACP, which may contribute to substrate recognition among CP domains (Parris et al., 
2000).  
 
 
Table 10. Conserved motifs in PPTases. Independent of their recognition substrate, three 
conserved motifs are present in all PPTases. *h refers to a hydrophobic residue in motif 3. 
 
 Motif Conserved residues 
P1 PXWPXGX2GS(M/L)THCXGY 
P2 (V/I)G(V/I)D 
P3 (F/W(S/C/T)XKE(A/S)hhK* 
 
 
 
 
 
     135
Chapter 2                                                                  Post-translational modification of MbtB 
On the other hand, based on the crystal structures of E. coli ACP and B. brevis TycC3-
PCP, the construction of a hybrid PCP/ACP, and mutational analysis of ACPS and PCPs 
revealed that the carrier proteins may also play an important role in PPTase recognition. The 
PCP and ArCP domains in NRPSs and the ACPs in FASs and PKSs share a conserved 
sequence motif (GX(D/H)S(L/I)(D/K) containing an invariable serine residue. The 
tridimensional structure of ACP and PCP show no significant differences in the overall 
folding pattern, having both CPs a characteristic four-helix bundle folding (Weber et al., 
2000). Further analysis revealed some differences between ACPs and PCPs, being the 
difference in the electrostatic surface potential, especially around the invariant serine residue 
and adjacent helix 2 (Mofid et al., 2002). Mutational analysis in PCPs and ACPSs, determined 
that a single point mutation in PCP (residue 47, numbering based on the crystal structure of 
TyC3-PCP) domains allowed to be recognised in vivo and in vitro by AcpS (Finking et al., 
2004). However, since the NRPSs and PKSs are organised in modules which might act either 
in cis or in trans,  it cannot be ruled out that conformational change of the proteins contributes 
to the recognition of substrates as well (Marshall et al., 2002).    
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2.5 Further work. 
Despite the partial modification of MbtB carrier proteins, optimal conditions during growth 
must be examined to achieve higher phosphopantetheinylation. Biochemical characterisation 
of the MbtB domains should then be attempted, particularly the communication between the A 
domain, Cy domain and PCP domain for substrate recognition (serine/threonine) and 
formation of the oxazoline ring following experimental methods reported elsewhere (Keating 
et al., 2000b). Mutation of the active sites of ArCP and TE domains would be needed to 
address some of these experiments. Hence, all the above experiments will allow further testing 
of different drugs obtained either in house or in silico to block early mycobactin-
carboxymycobactin biosynthesis, although the first step can be already assessed (Chapter 3). 
The need for rational design of drugs to combat TB, prioritises the structural characterisation 
of MbtB and the modification of the protein achieved here offers the possibility that mutants 
can be constructed that accumulate thioster-bound precursors and reveal useful data.      
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3.1 The old anti-TB drugs and their drawbacks. 
The World Health Organisation has recently reported that TB is still a menace for the human 
kind. Despite current chemotherapy, vaccination and the implementation of the DOTS 
program, the incidence of TB has not decreased. Contributing factors are the emergence of M. 
tuberculosis strains resistant to both first and second line drugs, co-infection with HIV, and 
related social and economical problems in high incidence countries (WHO, 2008).  
 
 The current TB drugs were developed between the 1940 and 1960s by screening a 
multitude of synthetic compounds, as well as natural products derived from other bacteria. 
However, following this period, no effective antibiotics have been developed to treat TB, 
except for the quinolones that were developed in the 1980s (Zhang, 2005). Because no 
biochemical tools were available and there was a general lack of understanding of M. 
tuberculosis biology, the target of these drugs was not identified. In fact, soon after STR was 
introduced for TB treatment, it became apparent that the bacillus could acquire resistance. The 
subsequent discovery of PAS and its combination with STR for TB treatment either delayed 
or reduced STR resistant. That observation suggested that TB could not be effectively treated 
with a single drug from those available.  
 
The discovery of INH changed TB chemotherapy completely; the combination of this 
highly active and inexpensive drug with PAS and STR led to improved efficacy. Through, 
various experimental and clinical studies, modern TB chemotherapy was developed ultimately 
to the DOTS program (Saltini, 2006). The chemotherapeutic aspect of this broad public health 
initiative comprises a six to eight month regimen with four different drugs for treating patients 
infected by drug-susceptible organisms. For new TB cases, the regimen consists of an initial 
two-month bactericidal phase of treatment including four drugs (INH, RIF, PZA, and EMB), 
followed by a continuation phase of treatment with INH and RIF for four months (WHO, 
2003). The regimens can be more complicated and extended with patients suffering co-
infection with HIV-AIDS or infected by MDR-TB and therefore DOTS-Plus is implemented 
(WHO, 2003).    
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 Although TB can be cured with the current treatment, complications may arise from 
the necessary duration, complexity and associated secondary effects of TB treatment which 
lead to poor patient compliance. Compared with treatment of other bacterial infections, such 
as Helicobacter pylori and pneumococcal infections, taking usually two or three weeks, TB 
chemotherapy requires at least six months. This requirement for such an extended treatment 
time is related to the disease pathology, biology of the bacillus, and immunology of the host. 
As aerosol particles, TB infection begins with the inhlation of M. tuberculosis. Afterwards, the 
bacilli are engulfed by alveolar macrophages and at this stage the bacterium either survives to 
continue infection or is contained by the activation of more macrophages and cellular 
immunity at the site of infection leading to the formation of a tubercle or granuloma (Russell, 
2007). M. tuberculosis survives and multiplies in different environmental niches. 
Subpopulations of the bacillus are mainly located in necrotic lesions, but a significant portion 
of bacteria are associated with macrophages located in the periphery of the lesion (Russell, 
2007). Moreover, in some cases the granuloma becomes quite large and the caseous material 
liquifies into the airway in which a large number of bacilli is present, representing a major 
problem for chemotherapy (Woolwine & Bishaie, 2006). Individuals with a strong immune 
system develop granulomas in which viable bacilli may be present and represents latent TB 
infection (LTBI). In this physiological state, M. tuberculosis becomes “dormant or latent” and 
no clinical symptoms and signs characteristic of TB infection are shown (Cosma et al., 2003). 
During development of TB infection, all of these subsets maybe present within M. 
tuberculosis populations and their metabolic heterogeneity hinders TB drug therapy. 
According to their metabolic activity, these sub-populations can be divided into four subsets. 
(i) Actively metabolising and rapidly growing, (ii) semidormant in an acidic intracellular 
environment, (iii) semidormant in a non-acidic intracellular environment and (iv) dormant 
(Mitchison, 1985). Certain drugs are more effective against some of these subpopulations 
INH, RIF, STR and EMB exhibit rapid bactericidal action against actively metabolising 
organisms, whereas pyrazinamide (PZA) appears to be more effective against semidormant 
bacilli in an acidic/hypoxic intracellular environments and RIF is effective against 
semidormant bacilli in non-acidic environments. Thus, current TB drugs are only active 
against growing bacilli, but there is no drug to kill “dormant bacteria”(Zhang, 2005). On the 
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other hand, the host immune system may not effectively eliminate residual tubercle bacilli not 
killed by TB chemotherapy.  
 
Intrinsic and acquired drug resistance are observed in M. tuberculosis. Intrinsic 
resistance is attributed to: (i) the formidable permeability barrier afforded by the lipid-rich cell 
wall; (ii) mechanisms that activate genes for self-defending secondary metabolites or the 
production of enzymes that degrade or modify the drugs rendering them useless; and (iii) 
spontaneous chromosomal mutations of the drug targets (David, 1970; Leonard, 2006; Morris 
et al., 2005; Nguyen & Thompson, 2006). The latter mechanism is considered the most 
significant driving force for adaptation and survival of microorganisms in new environments, 
rendering benefical mutations and fitness factors that explain antibiotic resistance and 
virulence in bacteria (Perfeito et al., 2007; Woodford & Ellington, 2007). In fact, mutations in 
the genome of M. tuberculosis, that can confer resistance to anti-TB drugs, occur 
spontaneously with an estimated frecuency (per bacterium per generation) of 3.5 x 10-6 for 
INH, 3.1 x 10-8 for RIF, 3.8 x 10-8 for STR and 0.5 x 10-4 for EMB (David, 1970). In clinical 
terms, acquired resistant mutants are selected as a result of ineffective treatment due to 
noncompliance. This selection favours the evolution of M. tuberculosis by acquiring 
sequential mutations in the drug target, which provides resistance and has promoted the 
emergence of MDR- and XDR-TB (CDC, 2006; Crofton et al., 1997). During infection, 
antibiotics kill most of the growing bacilli, but some may become phenotypically resistant to 
the drugs, i.e. “persisters”  (Zhang, 2005). This subpopulation may become actively growing 
when antibiotics are removed or present in low concentrations (Zhang, 2007). This 
phenomenon of reverted-sub-populations has effects in the selection of competitive fitness of 
M. tuberculosis resistant to drugs with a high probability to spread and become prevalent in 
human populations (Gagneux et al., 2006). Nowadays, M. tuberculosis strains resistant to 
almost all the front line TB drugs have emerged, demonstrating the high adaptability of the 
bacterium (Table 11).    
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Table 11. Mechanism of current anti-TB drugs action, genes associated with resistance 
and adverse effects (Hopewell, 2006; Sacchettini et al., 2008; Zhang, 2007). 
 Antibiotic Mechanism and Target Gene mutations 
associated with 
resistance 
Toxicity 
Isoniazid Inhibits mycolic acid synthe-
sis; primary targets InhA and 
secondary targets as KasA and 
DfrA 
katG, inhA, and others Hepatoxicity and 
peripheral neuropathy 
Rifampicin Inhibits transcription; RNA 
polymerase β-subunit 
ropB Display a range of adverse 
effects: rashes, hepatitis, 
gastrointestinal upset 
Ethambutol Inhibits arabinogalactan 
synthesis, EmbB 
embB Inflammation of the optic 
nerve 
Pyrazinamide No specific target has been 
found; probably inhibits FAS-I 
or alters membrane proteins 
pncA (required for 
drug activation) 
Hepatitis, hyperuricaemia 
(high levels of uric acid in 
blood) 
Streptomycin Inhibits protein synthesis; 30S 
ribosomal subunit. 
rpsL, rrS Ototoxicity (damage of the 
ear) 
p-Aminosalicylic 
acid 
Folate or mycobactin 
biosynthesis. 
thyA (folate 
biosynthesis) 
Gastrointestinal upset 
Kanamycin Inhibitis proteins biosynthesis rrS Hearing loss, Renal 
malfunction  
Fluroquinolones Inhibits DNA gyrase gyrA 
 
Nausea, vomiting,  
dizziness 
Ethionamide Inhibits mycolic acid 
biosynthesis: InhA 
inhA, ethA, ethR Gastrointestinal upset  
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The phenomenon of latent TB infection adds another complication for TB control. The 
WHO has estimated that one-third of the world’s population is latently infected with TB. In 
2000, there were an estimated 8-9 million TB new cases and this scenario has not changed and 
around 9.2 million new TB cases were reported in 2008 (WHO, 2008). This may be a 
reflection of latent TB and co-infection with HIV might trigger the emergence of new TB 
cases, specifically in those countries in which TB-HIV synergy has high incidence rates 
(WHO, 2008).  
 
Another problem of TB chemotherapy is the adverse effects of the drugs (Table 11). The 
long last-duration of TB chemotherapy with INH may cause hepatoxicity and peripherial 
neuropathy (damage to nerves of the peripherial nervous system). Rashes, hepatitis, 
gastrointestinal upset, are adverse effects due to daily use of RIF (Hopewell, 2006). The 
emergence of MDR-TB requires the use of second-line drugs which are more expensive and 
have more side effects (WHO, 2008). Furthermore, there is evidence of drug-drug interactions 
between some of the antiretroviral agents for HIV treatment and key antitubercular drugs, in 
particular RIF (Ginsberg & Spigelman, 2007). RIF is a potent inducer of the hepatic 
cytochrome P450 isoenzyme CYP3A4. Protease inhibitors and non-nucleoside reverse 
transcriptase inhibitors are metabolised by this enzyme and it has been documented that co-
administration results in reduced levels of the antiretroviral drugs (Pozniak et al., 1999).   
 
3.2 The new generation of anti-TB drugs. 
All the above observations have prompted a search for new drug targets and novel compounds 
to alleviate M. tuberculosis infection. Thus, the new goals for improving TB chemotherapy 
are: (i) shortening and simplifying the treatment of active-TB; (ii) treating MDR and XDR-
TB; (iii) simultaneously treating TB and HIV-AIDS; and (iv) shorting the treatment for LTBI 
(Ginsberg & Spigelman, 2007; Sacchettini et al., 2008). A new era of TB drug discovery has 
emerged and there is an increasing interest from both private and public sectors to develop 
new drugs. The Global Alliance for TB Drug Development is coordinating all efforts at all 
stages of the TB drug development pipeline (Dover et al., 2008; TB-Alliance, 2007).  
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However, new drugs must meet certain characteristics to improve TB treatment. (i) The 
new drug target should be essential for bacterial growth, metabolism, viability and persistence 
(genes expressed and essential during the time that treatment occurs); (ii) the targets must be 
unique to mycobacteria, which are unrepresented in the human genome and absent in other 
bacteria (gut flora); (iii) the new compounds should be “druggable”, that is they should have a 
range of biochemical and physical properties (drug-like properties); and (iv) the new 
compounds must modulate their action towards their targets. In order to facilitate these goals, 
development of appropriate in vivo and in vitro models to study “persisters” and “dormant” 
populations of M. tuberculosis are required (Balganesh et al., 2004; Ginsberg & Spigelman, 
2007; Williams & Duncan, 2007). 
 
 Many promising new drug targets and active compounds have been identified in recent 
years. After several decades in which little TB research and development was carried out, a 
list of new compounds are being tested for their potential effectiveness in the treatment of TB. 
Some of these compounds are an improvement of the existing TB drugs, such as rifapentine 
(RPT) a long-lasting compound derived from rifamycin, the fluoroquinolone family, 
macrolides, oxazolidinones and nitroimidazoles. Representative of novel compounds are the 
pyrroles, pleuromutilins, and diarylquinolines (Spigelman, 2007; Zhang, 2007). Despite these 
advances, only a few drugs are under clinical trials (Table 12) and, therefore, new drug targets 
and novel compounds are urgently needed.    
 
 
3.3 Tools and basis for the identification of new drug targets. 
Although, there are promising new candidates in the drug pipeline and new targets, the main 
aim is to improve TB chemotherapy by shortening the regimen and preventing selection of 
resistant M. tuberculosis strains (Ginsberg & Spigelman, 2007). Ideally, new anti-TB drugs 
should have certain characteristics and it is essential to know the precise targets (Balganesh et 
al., 2004; Williams & Duncan, 2007). 
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Table 12. Potential anti-TB drug candidates under clinical tests (Ginsberg & Spigelman, 
2007; Sacchettini et al., 2008; Spigelman, 2007; TB-Alliance, 2007; Zhang, 2007). 
Drug Target Features, drawbacks, and clinical trial stage 
Moxifloxacin DNA gyrase It could replace INH or EMB. Compatibility with HIV 
therapy. Phase IIIB.   
Gatifloxacin DNA gyrase It could replace INH or EMB. Compatibility with HIV 
therapy. A particular concern is the reported increased risk of 
dysglycemia (abnormal blood sugar metabolism). Phase 
IIIB. 
Nitroimidazopyran 
(PA-824) 
Prodrug  activated by 
F420-dependent  
glucose-6-phosphate 
dehydrogenase. 
Probably inhibits cell 
wall biosynthesis 
No specific mode of action identified yet. However, exhibits 
activity against both replicating and non-growing M. 
tuberculosis. Phase I 
Nitrodihydroimidazo-
oxazole  
(OPC-67683) 
Inhibits mycolic acid 
biosynthesis 
No specific mode of action identified yet. Extremely potent, 
in vitro and in vivo activity. It could be used in combination 
with HIV therapy. Phase I. 
Diarylquinoline 
(R207910, TMC207, 
or J compound) 
Fo subunit of ATP 
synthase (atpE) 
Initial tests indicate that there are no toxicity effects. Phase 
II. 
Diamine analog  
(SQ-109) 
Inhibition of cell wall 
biosynthesis. 
No specific target identified yet. Shares structural similarity 
to EMB, but superior in vitro and in vivo activity. Phase I. 
Pyrrole (LL-3858) No information 
available  
Bactericidal activity similar to INH. No public information 
available about mode of action. Phase I. 
Metronidazole Damage to DNA by 
reactive radicals 
Active against dormant M. tuberculosis. Phase II. 
Rifapentine Inhibition of RNA 
synthesis 
Superior activity compared to RIF. Long life in serum. Phase 
IIIB 
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The availability of the genome sequences of several strains of M. tuberculosis as well as 
other mycobacteria and members of the Corynebacterineae has afforded an opportunity to 
further investigate the biology of the organism, informing the selection of a range of potential 
drug targets to be screened (Cole et al., 1998). Furthermore, the advancement of drug research 
technology, as well as increasing genetic and biochemical tools in mycobacterial research 
have enhanced and expedited the identification of new drug targets in TB (Balganesh et al., 
2004). Modern drug discovery strategies exploit two main approaches, (i) whole-cell target 
and (ii) target-based screening. The whole-cell strategy involves screening for potent 
inhibition of bacterial growth or killing activity of potential drugs. The fact that the 
compounds have activity implies that these drugs can penetrate the rigid M. tuberculosis cell 
wall. However, as this is not target based, there is a considerable risk of finding compounds 
that have generalised toxicity and the lack of information on the target will hinder the 
optimisation process (Balganesh et al., 2004; Sacchettini et al., 2008; Williams & Duncan, 
2007). In contrast, target-based screening or enzyme-inhibition permits high-throughput 
automated screening of a large number of compounds against a purified protein. Nevertheless, 
the “hit” may have high in vitro activity but poor whole-cell potency (penetration) due to the 
M. tuberculosis cell wall (Balganesh et al., 2004; Williams & Duncan, 2007), efflux pump 
mechanisms and antibiotic degradation/modifiying enzymes (Nguyen & Thompson, 2006). 
The availability of X-ray crystal structures of interesting proteins provides the opportunity to 
carry out virtual screening (in silico). In silico screening, using computational methods, can be 
complementary to a biochemical high-throughput screen due to the potential for screening a 
larger chemical space quickly (drug libraries) and inexpensively. Virtual screening can be 
used in two ways, (i) to identify compounds that are consistent with a pharmacophore (the 
chemical functional group or groups possessed by a molecule that enables its biological 
activity) model irrespective of the identity of the structure of the pertinent protein target or 
targets and (ii) to develop inhibitors of a protein (or related protein) based on its known three-
dimensional structure (Arcus et al., 2006; Balganesh et al., 2004; Williams & Duncan, 2007). 
Undoubtely, combining these drug-discovery methods increases the possibility to find 
potential novel compounds that could be used for further investigation. 
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3.4 Mycobactin biosynthesis: a potential new drug target.   
Recently, products of several M. tuberculosis genes have been identified as potential drug 
targets. These mainly participate in cellular metabolism, cell wall biosynthesis, signal 
transduction, transcription, translation, persistence and virulence (Hasan et al., 2006; Vohra et 
al., 2006). Snow (1970) proposed that enzymes participating in mycobactin biosynthesis are 
potential drug targets since mammalian cells do not produce siderophores and thus adverse 
effects might be avoided. Hence, salicylic acid biosynthesis itself from chorismate, the 
salicylate adenylation activity of MbtA, the formation of oxazoline/thiazoline rings, the 
formation of N-hydroxylysine, the introduction of acetyl groups into the central lysine, and the 
phosphopantetheinylation mediated by the mycobacterial PPTases, PptT and AcpS, are 
considered potential drug targets (Chalut et al., 2006; Krithika et al., 2006; Ratledge, 2004). 
Moreover, the idea of using mycobactins as a “Trojan horse” is also attractive. Since M. 
tuberculosis possesess a complex cell wall that prevents drug permeability, the use of 
mycobactins and its analogues by coupling a known bacterial growth inhibitor may overcome 
permeability issues (Vergne et al., 2000). However, this Trojan horse concept has the inherent 
danger of allowing the bacteria to become resistant to the agent more easily (Ratledge, 2004). 
 
What evidence exists to consider mycobactin biosynthesis as a potential drug target? 
Iron is an important element for diverse cell process in eukaryota and prokaryota, and its role 
in virulence of pathogenic bacteria has been clearly demonstrated (Andrews et al., 2003; 
Miethke & Marahiel, 2007). M. tuberculosis is an intracellular pathogen that resides within 
the macrophage phagosome and prevents-lysosome fusion. The phagosome is considered to 
have an acidic pH and M. tuberculosis perceives it as a low-iron environment, thus iron-
acquisition becomes important for the survival of the bacilli (Cosma et al., 2003). It has been 
demonstrated that intraphagosomal M. tuberculosis can acquire iron from lactoferrin, ferritin 
and citrate (Olakanmi et al., 2004). The cell-bound mycobactin has not been isolated in vivo 
and this detracts its attractiveness as a potential drug target. However, this lack of detection in 
vivo should not be taken as absolute absence but may indicate that a physiologically relevant 
concentration of mycobactins is beyond the limits of detection of the analytical methods 
applied. The impressive yields of mycobactins seen in iron-limited batch culture in vitro are 
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almost certainly an exaggerated response to an environment with an absolute limitation on 
iron rather than the in vivo situation characterised by an abundance of sequestered iron. This 
absence may be due to many factors. The pH of the phagocytic vacuole lies somewhere 
between 4.5 and 6.0, allowing the dissociation of iron from host iron carrier proteins 
generating a state of iron sufficiency, which may ultimately eliminate the need for 
mycobactins. The relationship between the stage of an infection and iron 
sufficiency/deficiency is unknown and the lack of any detectable mycobactins does not 
necessarily mean they were never involved in iron transport. The mycobactin may be 
produced at an early stage of infection and then degraded when a state of iron sufficiency is 
reached (Lambrecht & Collins, 1993). This scenario may be different during LTBI, in which 
siderophore biosynthesis could be re-activated for iron-uptake. However, recent studies 
provide genetic and biochemical data supporting the importance of mycobactin biosynthesis, 
as well as iron homeostasis during M. tuberculosis infection (Rodriguez, 2006). M. 
tuberculosis is able to acquire iron from transferrin and lactoferrin by secreting 
carboxymycobactins when the bacilli are grown in medium (Farhana et al., 2008; Gobin & 
Horwitz, 1996) and the production of the siderophores is tightly regulated by IdeR  
(Rodriguez, 2006) and required for growth in macrophages (De Voss et al., 2000). 
Furthermore, transcription analysis during M. tuberculosis infection has demonstrated the up-
regulation of mycobactin biosynthesis as a survival response in macrophages (Schnappinger et 
al., 2003). Iron limitation induces transcription of at least 35 M. tuberculosis genes, including 
mbtA-J, but represses bfrA, which encodes an iron-storing bacterioferritin (Schnappinger et 
al., 2003). In addition, during immune control of M. tuberculosis replication, mbtB mRNA 
levels increase and bfrB mRNA levels decrease several weeks after infection in mice (Dubnau 
et al., 2005; Timm et al., 2003). The fact that the expression of mbtA-J genes are induced 
under iron-deficient environments during growth in culture medium and in macrophages 
strongly suggests that siderophores are important for survival and therefore represent potential 
new drug targets. 
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The microbial activity of PAS was first reported in 1946 (Lehmann, 1946). PAS is 
highly effective against M. tuberculosis, but its use was discontinued due to adverse effects. 
However, the emergence of MDR-TB has indicated PAS as an alternative theraupetic option, 
but it is rarely used in the regimens for the treatment of TB. The mode of action of PAS is still 
unclear, but it has been suggested to inhibit mycobactin biosynthesis by interfering with the 
salicylate adenylation (Brown & Ratledge, 1975; Ratledge & Dover, 2000). On the other 
hand, PAS may also target thymidylate synthase (thyA), an enzyme involved in folate 
biosynthesis (Rengarajan et al., 2004). Recently, the inhibition of aryl-N-capped siderophore 
biosynthesis in pathogenic bacteria such as Y. pestis, M. tuberculosis and P. aeruginosa has 
been demonstrated (Ferreras et al., 2005; Miethke et al., 2006a; Somu et al., 2006a). The first 
step during aryl-N-capped siderophore biosynthesis is the activation of either salicylic acid or 
DHB depending on the enzymatic activity of the microorganism by the adenylation domain. 
In this reaction the α-phosphate of ATP is charged by the substrate to generate a tightly bound 
acyl-adenylate, salicyl-AMP for instance, with subsequent release of pyrophosphate. This 
biosynthetic step resembles a similar reaction mechanism in all members of the adenylate 
enzyme superfamily and the functionally related aminoacyl tRNA synthetases (Schimmel et 
al., 1998). In the next reaction, the adenylation domain binds the phosphopantetheine arm of 
the thiolation domain, ArCP domain, and transfers the aryl-adenylate onto the nucleophilic 
sulphur atom of this cofactor moiety to provide salicyl-bound-ArCP (Figure 23)(Quadri et al., 
1998).    
 
 In this study, analogues of salicylic acid derived from in house synthesis and in silico 
screening have been tested to inhibit early steps in mycobactin biosynthesis.  
Activity of the drugs is being assessed by a combination of target-based enzyme and whole-
cell methods.  
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Figure 23. Enzymatic activity catalysed by MbtA. The adenylation domain activates 
salicylic acid by ATP reaction dependent to form acyl-adenylate (salicyl-AMP), and then the 
enzyme transfers the substrate to the phosphopantethein arm of the ArCP domain. Analogues 
of salicylic acid should block the salicyl-AMP formation as first step as well as the salicyl-
ArCP domain intermediate, which eventually stops mycobactin biosynthesis.  
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3.5 Material and methods. 
3.5.1 In silico approach to seek potential inhibitors of MbtA. 
There is no crystal structure solved for MbtA, however the availability of the co-crystal 
structure of DhbE with its substrate from B. subtilis has provided the correct core motifs for 
the deduction of substrate specifity between amino and aryl acid-activating domains and for 
discriminating between DHB (2,3-dihydroxybenzozate) and SAL (salicylic acid) activating 
enzymes (May et al., 2002). Therefore, an MbtA homology model was constructed using the 
structure of the DhbE-adenylate ligand (PDB code 1md9) in the CPHmodels 2.0 server (Lund 
et al., 2002). Then, the program Insight II (Accelrys Inc) was used to dock potential inhibitors 
in this structure by searching a 3-D compound database (Maybridge Library) to identify “hits” 
that satisfy chemical and geometrical requirements of the model.   
  
 
3.5.2 In house chemical synthesis of analogues of salicylic acid. 
Based on the PAS structure, 13 analogues were chemically synthesized (a collaboration with 
Prof. Colin Ratledge, University of Hull, UK). Due to intellectual property rights, structures 
and methods for preparation of these compounds are not described here. To validate their 
target and specifity inhibition towards MbtA, the hits and analogues of SAL compounds will 
be assessed by in vitro assay as described in 3.5.4. In addition, in vivo activity of the 
compounds was investigated against M. bovis BCG as described in 3.5.5.  
 
 
3.5.3 Molecular cloning and expression of M. tuberculosis mbtA in E. coli and M. 
smegmatis mc2155. 
The adenylation enzyme (mbtA) was amplified from M. tuberculosis H37Rv genomic DNA. 
The cloning of mbtA was attempted in five different vectors: pTYB1 (New England Biolabs), 
pMAL-C2X (New England Biolabs), pMV261, pSD26 and pVV16. Amplification was 
performed with different polymerases KOD DNA (Novagen), Pfu Platinum (Promega), 
Accusure (Bioline), Deep VentTM and Phusion High-Fidelity (New England Biolabs). Primers 
used for each vector are listed in Table 13. However, PCR products were obtained only with 
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Pfu Platinum DNA and Phusion High-Fidelity polymerases. Vectors and amplicons were 
digested with their appropriate restriction endonucleases (New England Biolabs), followed by 
ligation with T4 DNA ligase (New England Biolabs) at 16°C for 16 hours. Each ligation mix 
was used to transform E. coli TOP 10 (Novagen). Selection of mbtA-pMAL-C2X and mbtA-
pTYB1 were performed on LB agar plates containing ampicillin (100 µg/mL), whereas for 
mbtA-pMV261, kanamycin (50 µg/mL) was added to the media. For mbtA-pSD26 and mbtA-
pVV16, hygromycin (200 µg/mL) was added to LB agar. Screening was performed by double 
digestion followed by electrophoresis analysis on agarose gel and staining using EtBr. 
Integrity of genetic constructs was verified by nucleotide sequencing.   
 
 
Table 13.  Primers used to clone mbtA. Restrictions sites are underlined and shown. aThe 
plasmid was digested with HindIII/MscI to ligate the amplicon.  
Vector Primers Restriction sites 
underlined 
pTYB1 Up5’-GATCGATCCATATGCCACCGAAGGCGGCAGATGGC-3’ NdeI  
 Down5’-GATCGATCTGCTCTTCCGCATCAATGGCAGCGCTGGGTCGT-3’ SapI  
pMAL-C2X Up5’-GATCGATCGGAAGGATTTCAATGCCACCGAAGGCGGCAGA-3’ XmnI  
 Down5’-GATCGATCAAGCTTTTAATGGCAGCGCTGGGTCGTC-3’ HindIII 
pMV261a Up5’-CCCCACCGAAGGCGGCAGATGGCCGCCG-3’ HindIII 
 Down 5’-GATCGATCAAGCTTTCAATGGCAGCGCTGGGTCG-3’ HindIII  
pSD26 Up5’-GATCGATCGGATCCATGCCACCGAAGGCGGCAGAT-3’ BamHI  
 Down5’-GATCGATCGATATCATGGCAGCGCTGGGTC GT-3’ EcoRV  
pVV16 Up5’-GATCGATCCATATGCCACCGAAGGCGGCAGAT-3’ NdeI  
 Down5’-GATCGATCAAGCTTATGGCAGCGCTGGGTCGT-3’ HindIII  
 
  
 The mbtA-pMAL-C2X and mbtA-pTYB1 constructs were transformed by heat shock at 
42°C into E. coli K12 and E. coli ER2566, respectively. Gene expression analysis was 
determined by testing different temperatures, incubation times and IPTG concentrations as 
described in Chapter 2, section 2.5.1.2. To seek expression of mbtA-pMV261, mbtA-pSD26 
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and mbtA-pVV16, stocks of 50 µL electrocompetent M. smegmatis mc2155 cells were 
transformed by electroporation. Briefly, aliquots were transferred into an ice-cold cuvette (1 
mm, Cell projects) and 1 µL of each construct added, followed by incubation on ice for 20 
minutes. The cuvettes were then transferred into an electroporator (Eppendorf Electroporator 
2510, settings: 1800 mV, 1000 Ohms, 25 µF), with subsequent incubation on ice for 20 
minutes. Afterwards, 1 mL of LB broth was added to the cuvettes and incubated at 37°C for 4 
hours without shaking. The electrotransformed cells were selected on LB agar with the 
appropriate antibiotic [for mbtA-pMV261 (Kan 25 µg/mL), mbtA-pSD26/pVV16 (Hyg 50 
µg/mL)] further incubated at 37°C until single colonies appeared on plates. 
 
 Cells from a single colony on a LB agar plate were used to inoculate 5 mL of LB broth 
supplemented with a suitable antibiotic and incubated at 37°C with shaking (180 rpm) until 
culture was turbid. This starting culture was used to inoculate 1 L of fresh LB broth 
supplemented with the antibiotic and 0.05% Tween 80, and the culture incubated at 37°C with 
shaking (180 rpm) until an OD600=0.5-0.6 was obtained. To induce expression for mbtA-
pSD26, 0.2 % acetamide was added to cultures and the cells allowed growing for an additional 
4 hours. Cells were harvested by centrifugation at 5, 000 rpm for 10 minutes at 4°C. The cell 
pellet was resuspended in buffer (50 mM Tris-HCl, pH 7.9 and 500 mM NaCl) containing 
DNAase and serine protease inhibitors (PMSF and benzamidine at 1 mM final concentration) 
and disrupted by sonication (Soniprep 150, settings: Amplitude microns 1,100, 7 cylces, 30-s 
burst/45-s of cooling). The extract was clarified by centrifugation at 15, 000 rpm for 30 
minutes at 4°C. The supernatant was collected and loaded into Ni2+-charged and equilibrated 
His-Trap column (5 mL) following the manufacturers’ instructions (Amersham). The clarified 
extract was applied to the column and non-binding material collected for analysis. The column 
was then washed with 50 mL of binding buffer A (50 mM Tris-HCl, pH 7.9, 500 mM NaCl) 
and the protein eluted with a step-wise gradient of 10-500 mM of increasing imidazole 
concentration in buffer A. The purity of the protein was monitored by 12% SDS-PAGE and 
Coomasie blue staining. Purified protein fractions were pooled and dialysed against buffer B 
(10 mM Tris-HCl, pH 7.9, 1 mM EDTA and 5% glycerol), concentrated using a Centricon 
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YM-10 filter unit (Millipore) and stored at -80°C until use. The protein concentration was 
estimated using the BCA protein assay (Pierce) and by absorbance at 280 nm with the 
predicted molar extinction coefficient for each recombinant protein.               
 
 
3.5.4 Salicylation and arylation assays. 
The assay was carried out as that reported by Quadri et al. (1998) with slight modifications. 
Incorporation of [14C]-salicylic acid (50 mCi/mmol, purchased from American Radiolabeled 
Chemicals Inc.) by MbtA into holo-carrier proteins of MbtB was be quantified in 100 µL 
reactions containing 10 mM ATP, 25 mM DTT, 25 mM MgCl2, 75 mM Tris-HCl, pH 7.5. 
Enzyme concentrations and [14C]-salicylic acid were varied to obtain the kinetic data. 
Reactions were incubated at 37°C for up to 15 hours. After incubation, reactions were 
quenched with 900 µL of 10% ice-cold trichloroacetic acid (TCA) and 50 µL of bovine serum 
albumin (BSA, 2 mg/mL) as a carrier. Precipitation was completed by incubation on ice for 10 
minutes, followed by centrifugation at 10,000 rpm for 10 minutes at 4°C. The protein pellet 
was washed with 900 µL of 10% TCA before dissolving in 20 µL of 2% SDS containing 20 
mM aqueous NaOH. The amount of radioactivity (cpm) incorporated was quantified by re-
dissolving the proteins with 5 mL of scintillation cocktail (EcoScintA).  
 
 
3.5.5 Determination of the in vivo effect of inhibitors against M. bovis BCG. 
Compounds were evaluated for whole-cell activity against M. bovis BCG in iron-sufficient 
medium. Cells were initially grown in Middlebrook 7H9 media supplemented with OADC 
and 0.05 % Tween 80 (v/v) until OD600 ~0.2. Low-cell density allows the potency of the 
inhibitors and avoids their inactivation by inoculum size. Hence, the starting culture was used 
to determine the minimum inhibitory concentrations (MIC99) that inhibited >99% cell growth 
in 96-well microplates using Proskauer and Beck medium (PB) (Allen, 1998). Prior PB 
medium preparation, glassware was first deferrated as follows. Glassware were filled with 
alcoholic KOH (2%) and left overnight. Then, glassware was washed with deionised water 
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and filled with 8 M HNO3 overnight. Glassware was again washed with deionised water and 
autoclaved at 127ºC for 15 minutes prior to use. Afterwards, PB medium was prepared in the 
deferrated glassware.  
 
 
3.5.5.1 Preparation of 96-well microplates.  
The method reported by Franzblau et al. (1998) was followed to prepare the 96-well 
microplates (Corning Incorporated Costar 96-well microplates). Two hundred microliters of 
deionised water were added to all outer well perimeters to minimise evaporation of the 
medium during the experiment. The wells from B to G received 100 µL of PB media along 
with 0.05% Tween 80 as shown in Figure 24. Column 10 was used as a positive control, with 
the bacteria in the media, whereas column 11 was used as a negative control, with media only. 
Additionally, 100 µL of media was added to columns B2, D2 and F2 for diluting the stock 
drug solutions.   
 
 
3.5.5.2 Preparation of drug stock solutions. 
One mg of each compound was resuspended in 100 µL of DMSO giving a 10 mg/mL stock 
solution. Serial 1:2 dilutions were continued from the initial high concentration. From the 
initial M. bovis BCG growth culture, suspensions of 1:25 dilution were prepared in PB media 
and 0.05 % Tween 80.  From this dilution, 100 µL were added to the wells in rows B to G in 
column 2 to 10, yielding a final volume of 200 µL per well. Plates were sealed with parafilm 
and incubated at 37°C in a static incubator for 6-8 days. Isoniazid, chloramphenicol, 
rifampicin, and ethambutol were included as positive controls for comparison. 
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Figure 24. Schematic diagram depicting the order of solutions, medium and drug 
solutions, added into 96-well microplates. 
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3.6 Results.  
The results shown here are preliminary and, therefore, they are not intended to provide 
conclusions derived from initial experiments.  
 
3.6.1 In silico screening for potential inhibitors of MbtA. 
The availability of the DhbE crystal structure from B. subtilis provided the correct core motifs 
for the deduction of substrate specifity between amino and aryl acid-activating domains and 
for discriminating between DHB and SAL activating enzymes (May et al., 2002).  Hence, a 
homology model of MbtA was constructed based on DhbE-DHB (PDB 1md9) to determine 
the putative binding pocket valid. Analysis of the primary sequence between the DhbE and 
MbtA aryl acid-activating domains showed 42.1 % identity (Figure 25). Although, below the 
threshold (70 %) for predicting good homolog models, the MbtA structure taking DhbE as a 
template could be predicted. This model structure was very similar to the structure 1md9 with 
a RMSD= 0.69 Å. The co-crystallisation of DhbE with ATP and DHB determined the core 
motif for recognising the substrate specifity in aryl acid-activating adenylation domains. In 
agreement with this, amino acid residues Asn235, Ser240, and Val377 of DhbE and the 
corresponding residue Cys263 of MbtA seem to be involved in key interactions with the DHB 
and SAL aryl substrates. The conserved Asn235 and Ser240 residues of DhbE bind to the 2 
and 3 hydroxyl groups of DHB, respectively. However, the Ser40 residue is replaced by Cys 
residue in SAL-activating domains as in MbtA and YbtE (Figure 26) (May et al., 2002).  
 
 The individual molecules of the Maybridge screening collection were as virtual ligands 
using the autodock facility of Insight II (Accelrys Inc.) for the modeled MbtA structure. Six 
compounds from this library from over 56,000 molecules were predicted to be potential 
inhibitors of MbtA on the basis of their predicted dissociation constant (Ki), which in all cases 
were <7.40 x 10-17 M (HTS07619) at 25°C (Figure 27). Other hits from the library were 
predicted with Ki values at least six order of magnitude greater and were not considered for 
testing. In the simulations, these molecules all bound to a region near the entrance to the 
active site with most (except HTS10034 and SPB01127) penetrating into the site (Figure 28).  
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                 1                                               50 
     DhbE    (1) ---------------MLKGFTPWPDELAETYRKNGCWAGETFGDLLRDRA 
     MbtA    (1) MPPKAADGRRPSPDGGLGGFVPFPADRAASYRAAGYWSGRTLDTVLSDAA 
                 51                                             100 
     DhbE   (36) AKYGDRIAITCG-----NTHWSYRELDTRADRLAAGFQKLGIQQMDRVVV 
     MbtA   (51) RRWPDRLAVADAGDRPGHGGLSYAELDQRADRAAAALHGLGITPGDRVLL 
                 101                                            150 
     DhbE   (81) QLPNIKEFFEVIFALFRLGALPVFALPSHRSSEITYFCEFAEAAAYIIPD 
     MbtA  (101) QLPNGCQFAVALFALLRAGAIPVMCLPGHRAAELGHFAAVSAATGLVVAD 
                 151                                            200 
     DhbE  (131) AYSGFDYRSLARQVQSKLPTLKNIIVAGEAEEFLPLEDLHAEP---VKLP 
     MbtA  (151) VASGFDYRPMARELVADHPTLRHVIVDGDPGPFVSWAQLCAQAGTGSPAP 
                 201                                            250 
     DhbE  (178) EVKSSDVAFLQLSGGSTGLSKLIPRTHDDYIYSLKRSVEVCWLDHSTVYL 
     MbtA  (201) PADPGSPALLLVSGGTTGMPKLIPRTHDDYVFNATASAALCRLSADDVYL 
                 251                                            300 
     DhbE  (228) AALPMAHNYPLSSPGVLGVLYAGGRVVLSPSPSPDDAFPLIEREKVTITA 
     MbtA  (251) VVLAAGHNFPLACPGLLGAMTVGATAVFAPDPSPEAAFAAIERHGVTVTA 
                 301                                            350 
     DhbE  (278) LVPPLAMVWMDAASSRRDDLSSLQVLQVGGAKFSAEAARRVKAVFGCTLQ 
     MbtA  (301) LVPALAKLWAQSCEWEPVTPKSLRLLQVGGSKLEPEDARRVRTALTPGLQ 
                 351                                            400 
     DhbE  (328) QVFGMAEGLVNYTRLDDPEEIIVNTQGKPMSPYDEMRVWDDHDRDVKPGE 
     MbtA  (351) QVFGMAEGLLNFTRIGDPPEVVEHTQGRPLCPADELRIVNADGEPVGPGE 
                 401                                            450 
     DhbE  (378) TGHLLTRGPYTIRGYYKAEEHNAASFTEDGFYRTGDIVRLTRDGYIVVEG 
     MbtA  (401) EGELLVRGPYTLNGYFAAERDNERCFDPDGFYRSGDLVRRRDDGNLVVTG 
                 451                                            500 
     DhbE  (428) RAKDQINRGGEKVAAEEVENHLLAHPAVHDAAMVSMPDQFLGERSCVFII 
     MbtA  (451) RVKDVICRAGETIAASDLEEQLLSHPAIFSAAAVGLPDQYLGEKICAAVV 
                 501                                            550 
     DhbE  (478) PRDEAPKAAELKAFLRERGLAAYKIPDRVEFVESFPQTGVGKVSKKALRE 
     MbtA  (501) FAGAPITLAELNGYLDRRGVAAHTRPDQLVAMPALPTTPIGKIDKRAIVR 
                 551                                            565 
     DhbE  (528) AISEKLLAGFKK--- 
     MbtA  (551) QLGIATGPVTTQRCH 
 
Figure 25. Alignment of the primary structures of Bacillus subtilis DhbE and M. 
tuberculosis MbtA.  Sequences were aligned using the ClustalW algorithm within the AlignX 
component of the Vector NTi suite of programs (Invitrogen). The algorithm predicted amino 
acid identity at 42.1% and consensus at 57.5%. 
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Figure 26. Homology model of MbtA. The MbtA model (red) was made using CPH models 
2.0 Server (http://www.cbs.dtu.dk/services/CPHmodels/) and DhbE (1md8 pdb, in green) 
from Bacillus subtilis as template. Superimposition of model on template is shown in lower 
right hand corner (RMSD = 0.69Å). The main figure shows the positions of DhbE-bound 2,3-
dihydroxybenzoate (DHB) and important residues for substrate specificity; in this class of 
enzyme Ser (DhbE) selects for DHB while Cys (MbtA) selects for 2-hydroxybenzoate 
(salicylate). 
 
 
 
The predicted binding of these compounds at this site in combination with such low 
dissociation constants indicated that in vitro analyses of MbtA inhibition was appropriate. The 
compounds in the Maybridge library generally obey the Lipinski’s “rule of five” that provide 
an estimation of drug solubility and permeability, important parameters for initial drug 
discovery and drug development (Lipinski et al., 2001). These hits along with 13 compounds 
synthesised elsewhere resembling the PAS structure, were initially evaluated for whole-cell 
activity against M. bovis BCG as described below. 
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Compound Exp num Predicted Ki Structure 
2-(cyclopropylmethyl)-1H-1,2-
benzisothiazole-1,1,3(2H)-trione 
(HTS10034) 
1 9.66x10-25M 
N
S
O
O
O
 
N1,N1-diethyl-2-[(7-
methoxybenzo[e][1,2,4]triazolo[3,4-
c][1,2,4]triazin-1-yl)thio]acetamide 
(BTB11368) 
4 6.61x10-21M 
N
N
N
N
N
S
O
N
O
 
ethyl 2-methyl-4-(4-nitrophenyl)-5-
oxo-4,5-dihydro-1H-indeno[1,2-
b]pyridine-3-carboxylate 
(JFD00435) 
2 2.5x10-18M 
HN O
O
N+
O
O-
O
 
N-(4-phenyl-1,3-thiazol-2-yl)-2-
furamide 
(NH00363) 
3 4.08x10-18M 
N S
O
NO
 
3-(tert-butyl)-1H-pyrazole-5-
carbohydrazide 
(SPB01227) 
 
 
5 6.03x10-17M 
N
N
O
N
N
 
ethyl 2-amino-4-(4-nitrophenyl)-5-
oxo-4H,5H-pyrano[3,2-c]chromene-
3-carboxylate 
(HTS07619) 
 
 
 
6 1X10-17M 
O O N+
O
O-
O O
ON
 
Exp num= number of compound assigned for whole-cell assay experiments (section 3.6.2, Table 14). 
 
Figure 27. Potential inhibitors of MbtA. Based on the co-crystal structure of DhbE and DHB, an 
MbtA homology model was constructed. The model was used to dock potential inhibitors by searching 
a 3-D compound database (Maybridge Library) to identify “hits” that satisfy chemical and geometrical 
requirements. Six compounds were predicted to be potential inhibitors and their name, dissociation 
constant (Ki) and structure are shown below. Code within parenthesis indicates catalog number. 
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Figure 28.  Predicted binding sites for virtual screening hits.  The molecules identified from 
the Maybridge library as potential inhibitors of MbtA, by virtue of the predicted Ki in autodock, are 
shown in relation to the homology model produced as part of this study. For orientation purposes, the 
side chain atoms of active site residue Cys263 which interact with the 3-position of the salicylate ring 
are shown. Panel A, BTB11368; Panel B, HTS07619; Panel C, JFD00435; Panel D, HTS10034; Panel 
E, NH00363; Panel F, SPB01127. 
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3.6.2 In vivo activity of inhibitors on M. bovis BCG. 
Initial attempts to determine accurate MIC by different methods were hindered due to the drug 
behaviour in the media. Firstly, the Alamar Blue Assay (MABA) was tested, since this assay 
determines metabolically active cells by measuring their capacity to convert rezarusin to a 
fluorescent resorufin. However, the reagents did not react uniformly, even in the controls, a 
result that may indicate an incompatibility with the PB medium used here. Optical density was 
not used as an indicator of growth inhibition because the drug solutions showed some 
turbidity that could bias readings. Therefore, the classical microdilution minimum inhibitory 
concentrations (MICs) method provided the best mode to determine in vivo activity of the 
compounds. Hence, all potential inhibitors were evaluated against M. bovis BCG under iron-
sufficient conditions in 96-well microplates.  
 
The MIC at which growth of M. bovis BCG was completely inhibited were recorded 
when bacteria reached good macroscopic growth in control wells, generally after 6 days of 
incubation (Table 14). None of these compounds exhibited in vivo activity that was 
comparable to that of current anti-TB drugs. The lowest MIC observed shared by seven of the 
compounds was 32 µg/mL, whereas six other antibiotics did not show growth inhibition at all. 
Although, all compounds were selected to target mycobactin biosynthesis, particularly 
salicylate adenylation, unexpectedly, compounds 2,3, and 4 derived from the virtual screening 
and those chemically prepared 8,9,10 and 11 had similar in vivo activity despite their 
unrelated chemical structure. These preliminary data shows the activity of compounds under 
iron-sufficient conditions, and to validate their target it will be more interesting to evaluate the 
inhibitors in enzyme assays and both iron-deficient environments and over-expressing the 
mbtA in M. bovis BCG. At this point, there are only seven compounds providing interesting 
activity in whole-cell assays.  
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Table 14. In vivo activity of compounds against M. bovis BCG. MICs were determined 
after six days of incubation at 37°C. Isoniazid (ISO), Rifampicin (RIF), Chloramphenicol 
(CHL) and Ethambutol (EMB) were included in the experiments as positive controls. NI= no 
growth inhibition. aCompounds derived from in silico screening. bCompounds analogues to 
PAS. Experiments were performed in triplicate.  
 
Compound MIC99 (µg/mL) Compound MIC99 (µg/mL) 
1a 128 13b NI 
2a 32 14b  64 
3a 32 15b 128 
4a 32 16b NI 
5a NI 17b 64 
6a  NI 18b NI 
7b  64 19b NI 
8b 32 ISO 4 
9b  32 RIF 0.5 
10b  32 CHL 8 
11b  32 ETH 4 
12b  128   
 
 
 
3.6.3 Cloning and expression analysis of MbtA in E. coli and M. smegmatis mc2155. 
The mbtA gene was cloned in five expression vectors, however, only three constructs provided 
gene expression; in one case, the MbtA was insoluble but two provided soluble recombinant 
protein. Firstly, expression of mbtA-pTYB1 in E. coli ER2566 was attempted. Since, MbtA 
(MW 59.28 KDa) was cloned in fusion with the Chitin Binding Domain (CDB, 56 KDa) of 
the pTYB1 expression vector, a fusion (CBD)-recombinant protein (MbtA) with a MW ~115 
KDa was expected to be detected upon analysis by 12% SDS-PAGE. However, no band was 
observed with the expected mobility in any of the clarified samples in each condition tested 
(IPTG concentration, time and temperature incubation). In further attempts to seek expression 
of mbtA-pTYB1, Western Blot and Immunodetection analyses were performed. Consistent 
with the previous analyses no evidence for mbtA expression in E. coli ER2566 was found. 
Then, over-expression of mbtA-pMAL-C2X was analysed using E. coli K12. The mbtA gene 
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was cloned as a fusion with the Maltose Binding Protein (MBP, MW ~42.48 KDa) in the 
pMAL-C2X vector. Hence, a recombinant fusion protein MBP-MbtA with MW ~102 KDa 
was expected to be detected on 12% SDS-PAGE. The fusion recombinant protein was 
expressed in all investigated conditions (IPTG concentration, time and temperature 
incubation), although higher expression was observed when E. coli K12-mbtA-pMAL-C2X 
was incubated at 16°C for 16 hours (Figure 29). However, analysis of the supernatant after 
centrifugation at 15, 000 rpm showed that the recombinant protein was not present suggesting 
that the fusion was in an insoluble form. Solubilization experiments were not attempted since 
this does not always lead to preparation of an active protein. Instead, the cloning of mbtA was 
further attempted into E. coli-mycobacteria shuttle vectors, pMV261, pSD26 and pVV16.    
 
 M. smegmatis mc2155 was electrotransformed using mbtA-pMV261 and expression 
analysis was carried out. However, in the conditions investigated, expression of mbtA was not 
observed (data not shown). Then, each of the mbtA-pSD26 and mbtA-pVV16 constructs were 
also used to electrotransform M. smegmatis mc2155 to seek protein expression. Both 
constructs feature a C-terminal hexa-histidine tag. The mbtA-pSD26 was induced using 0.2% 
acetamide, whereas mbtA-pVV16 expression was assured by the relatively hsp60 strong 
promoter. Transformed M. smegmatis mc2155 was grown at 37°C. Recombinant MbtA was 
purified by Ni2+-affinity chromatography. The purified protein migrated as a single band on 
12% SDS-PAGE above the expected molecular mass calculated ~60.90 KDa (MbtA: 59.28 
kDa plus amino acids of the acetamidase promoter and six histidine residues) (Figure 30). 
Identity of the protein was verified by MALDI-MS analysis. The protein yield from each 
plasmid was approximately similar (0.17 mg/L). Hence, the adenylation domain, MbtA, was 
cloned and expressed in M. smegmatis mc2155 allowing the activity of potential the inhibitors 
to be tested in vitro.  
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Figure 29. Expression analysis of mbtA-pMAL-C2X in E. coli K12. The mbtA was cloned 
as fusion with the maltose binding protein (MBP) in pMAL-C2X. Analysis of the crude lysate 
and supernatant extract, a band in lanes 6, 8 and 10 (crude lysates) with the expected MW 
~102 KDa of the fusion recombinant protein migrated on 12% SDS-PAGE, indicating that the 
fusion recombinant protein was expressed. However, the protein was in insoluble form. M= 
standard molecular protein marker; Lanes 1 and 2: extracts from E. coli-pMAL-C2X (1: 
supernatant, 2: crude lysate); Lanes 3 and 4: extracts from E. coli-mbtA-pMAL-C2X without 
IPTG (3: supernatant; 4: crude lysate); Lanes 5 and 6:  E. coli-mbtA-pMAL-C2X plus 0.1 mM 
IPTG (5: supernatant; 6: crude lysate); Lanes 7 and 8: E. coli-mbtA-pMAL-C2X plus 0.5 mM 
IPTG (7: supernatant; 8: crude lysate); Lanes 9 and 10: E. coli-mbtA-pMAL-C2X plus 1 mM 
IPTG (9: supernatant; 10: crude lysate).  Here, it is only shown expression analysis carried out 
at 16°C for 16 hours; the fusion recombinant protein was also expressed at 37°C in all 
investigated conditions, but lower expression was observed as compared with the above 
conditions.   
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Figure 30. Coomassie blue stained 12% SDS-PAGE of MbtA purified. The recombinant 
protein was purified using Ni2+-affinity chromatography in a step gradient concentration of 
imidazole (10-500 mM). The purified protein migrated as a single band consistent with the 
expected molecular mass calculated ~60.90 kDa. M= standard molecular protein marker. Lane 
1: MbtA purified. Here the product of mbtA-pVV16 is illustrated; a similar result was obtained 
from mbtA-pSD26. 
 
 
3.6.4 Salicylate adenylation assays.  
This part of the project was significantly delayed by the difficulties encountered in producing 
phosphopantetheinylated acceptors. However, preliminary results have shown that the 
recombinant MbtA has enzymatic activity. During initial screening for MbtA activity, a set of 
different reactions were performed in which the presence and absence of MbtA and SAL were 
investigated. In presence of MbtA and SAL, higher counts per minute (CPM) were observed 
compared to reactions in which MbtA and substrate were absent, indicating that MbtA 
exhibited enzymatic activity (Figure 31A). Then, the concentration of SAL was held, whereas 
MbtA was varied to determine the initial rate (Figure 31B). Although, these preliminary data 
provide hints of MbtA activity, its catalytic function will be further investigated to establish 
the true kinetics of the enzyme.  
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Figure 31.  Enzymatic activity of MbtA. A) The assay was carried out (1) in presence of the 
enzyme [~8 µM] and substrate [~60 µM], (2) in absence of enzyme, (3) in absence of enzyme 
and substrate (3). B) Concentration of MbtA was varied to determine initial rate reactions. 
Experiments represent the mean of two repeats.   
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3.7 Discussion. 
The fact that TB is responsible for 2 millions deaths each year and that a third of the world 
population may be latently infected with M. tuberculosis, twinned with the emergence of 
MDR and XDR-TB, has urgently prompted the search for novel drugs against TB (WHO, 
2008). Hence, discovery and characterisation of new enzymes involved in M. tuberculosis 
biosynthetic pathways is important for the designation of novel targets and therefore 
development of new drugs to combat TB.  
 
The new targets should fulfil certain characteristics to be considered in TB treatment. 
The targets must be essential for bacterial growth, metabolism, viability, persistence and must 
be unique to mycobacteria. Thus, mycobactin biosynthesis represents a good target, since the 
enzymes involved in the biosynthesis of these siderophores have no homology in mammals. 
The disruption of mbtB also impaired growth of M. tuberculosis H37Rv in macrophages (De 
Voss et al., 2000). The understanding of the mechanisms involved in the enzyme catalysed 
reactions toward mycobactin biosynthesis has provided opportunities to design new inhibitors 
that can block siderophore biosynthesis and, hence, bacterial growth and virulence during 
infection. In the early stages of mycobactin biosynthesis, the salicylate adenylating enzyme 
(MbtA) catalyses the activation of SAL and transfers it to the ArCP domain of MbtB to form a 
salicyl-ArCP domain thioester intermediate through a two step-reaction. The first step, in 
which ATP and SAL are bound, is followed by the nucleophilic attack of the substrate 
carboxylate on the α-phosphate of ATP to generate a tightly bound aryl adenylate (salicyl-
AMP) intermediate and the release of pyrophosphate. In the second, MbtA binds the 
phosphopantetheine cofactor of the ArCP domain and transfers the aryl adenylate to the 
nucleophilic sulphur atom of this co-factor to provide salicyl-bound-MbtB (Quadri et al., 
1998). It has been reported that the adenylate-forming enzymes bind their cognate acyl-AMP 
intermediates 2-3 orders of magnitude more tightly than their carboxylic acid and ATP 
substrates (Schimmel et al., 1998). Thus, analogues based on the aryl-adenylate could serve as 
mechanism-based inhibitors of adenylate-forming enzymes, such as MbtA.  
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Since there is no crystal structure for MbtA, a homology model, based on the co-crystal 
structure of DhbE and its substrate, was constructed to screen for potential inhibitors in a drug 
library. Six compounds were selected that were predicted to bind to the active site of MbtA, 
and based on their low dissociation contants those compounds promised to be potential 
inhibitors of the adenylation enzyme. Additionally, 13 other compounds were designed as 
analogues of PAS were tested to investigate their potential as anti-TB drugs. Whole-cell 
assays against M. bovis BCG under iron-sufficient conditions were performed to determine 
MICS. Only seven compounds exhibited significant growth inhibiton, and unexpectedly, these 
compounds had similar MIC values despite their unrelated chemical structure. The 
compounds derived from virtual screening are structurally diverse and were selected based on 
the binding site of MbtA, whereas other compounds are analogues of PAS. It is important to 
highlight that the condition in which the antibiotics were tested does not reflect their activity 
to a specific target, in this case MbtA. These preliminary data serve to highlight several lead 
compounds that might target iron uptake via their inhibition of the early stages of mycobactin 
biosynthesis. The reproducible phosphopantetheinylation of MbtB and ArCP now allow the 
detailed study of the mode of action of these lead compounds in vitro. On the other hand, 
analogues of aryl adenylate have been investigated to block mycobactin biosynthesis of M. 
tuberculosis. Although, these compounds inhibited mycobactin production in iron-deficient 
medium, the compounds were also able to inhibit growth of bacteria under iron-supplemented 
media, suggesting that the analogues may act on other targets by other mechanisms (Ferreras 
et al., 2005; Qiao et al., 2007; Somu et al., 2006a; Somu et al., 2006b). Based on the salicyl 
adenylate scaffold, four structural domains (aryl, linker, glycosyl and  base) (Figure 32) have 
been exploited to design inhibitors towards activity of MbtA (Somu et al., 2006a) as well as 
other adenylating enzymes from other bacteria. The first inhibitor, salicyl-AMS (SAL-AMS), 
in which the phosphate group of the linker was replaced by an uncharged sulfamate, was 
found to be a potent inhibitor of MbtA and was also shown to inhibit siderophore biosynthesis 
of M. tuberculosis and Yersinia pestis under iron-limiting conditions (Ferreras et al., 2005). 
Furthermore, SAL-AMS was tested in iron-suficient conditions, in which siderophore 
biosynthesis is not required, and was found to inhibit M. tuberculosis growth but not Y. pestis, 
although it was required to increase the inhibitor concentration up to 18-fold. This result 
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suggests that SAL-AMS may also inhibit another target other than mycobactin biosynthesis 
(Ferreras et al., 2005).   
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Figure 32. Salicyl adenylate scaffold. Four structural domains have been exploited to design 
novel inhibitors towards activity of adenylation enzymes [Adapted from Somu et al., (2006a)].  
 
 
In another study, the substitution of the sulfamate oxygen in the linker domain with 
nitrogen afforded a new inhibitor, salicyl-sulfamide. This inhibitor was directly tested against 
whole-cell M. tuberculosis H37Rv under iron-limiting conditions and displayed significant 
growth inhibition which rivals isoniazid (Somu et al., 2006a). Also, the role of the glycosyl 
unit of SAL-AMS has been investigated. The ribofuranose ring oxygen was replaced by a CH2 
and this new compound displayed potent both in vitro and in vivo inhibition activities towards 
MbtA and whole-cell M. tuberulosis assay, respectively. Removal of the both 2’- and 3’- 
alcohols in the glycosyl domain resulted in complete loss of activity (Somu et al., 2006b). 
Recently, the investigation of the aryl scaffold structural domain has also been explored (Qiao 
et al., 2007). This study demonstrates that substitutions in the ortho-hydroxy group and 
modifications at the C4 of the aryl group are poorly tolerated, a result consistent with the 
substrates specificities of NRPSs adenylation enzymes. However, modifications only at the C4 
with either F (4-fluorosalicyl-AMS) or NH2 (p-aminosalicyl-AMS) led to the synthesis of 
analogues exhibiting potent both in vitro and in vivo inhibition activities.    
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Hence, the compounds investigated in this study must be tested under other conditions 
to validate their target; low-iron environments in which MbtA is being activated for the early 
siderophore biosynthesis, over-expressing the mbtA in M. bovis BCG and in vitro enzyme 
assays will provide more accurate information about activity and specificity. Analyses of their 
activity against iron-starved bacteria may, however, be difficult to interpret. Bacteria grown 
this way present an extremely exaggerated response to iron-limitation of a magnitude that has 
never been observed in vivo.  
 
To determine in vitro activity and specificity of compounds, mbtA gene was cloned in 
different vectors. Initial attempts to clone the gene into E. coli expression vectors resulted in 
either undetectable yields of gene product (mbtA-pTYB1) or insolubility of the recombinant 
fusion protein (mbtA-pMAL-C2X). The early work by Quadri et al. (1998) reported that the 
expression of mbtA, containing hexahistidine-tags at its carboxy termini did not show 
expression. Then, the gene was cloned as a fusion with the maltose binding protein, as well as 
the His-tags, and this strategy allowed expression and purification of MbtA in E. coli BL21 
(DE3)pLysS, although no high protein yield was obtained (0.1 mg/L). In the present study, 
mbtA was cloned into E. coli-mycobacteria shuttle vectors, pSD26 and pVV16, resulting in 
expression and purification of the adenylation domain in M. smegmatis mc2155. The pSD26 
vector harbours an acetamidase promoter, whereas the pVV16 has the hsp60 promoter, but 
both vectors possess hexa-histidine-tags for ease purification. Since these constructs are over-
expressed in mycobacteria, activity of the enzyme is expected. Preliminary in vitro assays of 
mbtA-pVV16 showed enzymatic activity, but this must be tested further. Although, the KM for 
ATP and SAL have been reported elsewhere (Quadri et al., 1998; Somu et al., 2006b), the 
kinetics of the MbtA for both substrates must be again tested since differences in protein-
tagging, protein purification strategy, buffer assay, and host source of expression may account 
for difference in KM obtained in different set of experiments. Thus, either constructs will be 
valuable to determine and validate the activity and specificity of the investigated compounds. 
Furthermore, in the previous section the activation of the carrier proteins of MbtB has been 
described, which will allow a greater understanding of the enzymology during the early 
mycobactin biosynthesis.   
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3.8 Further Work. 
The over-expression of mbtA, as soluble protein, will allow determination of its kinetics for 
ATP and SAL substrates. Knowing the KM for each substrate, in vitro inhibition by potential 
drugs can be precisely assessed. Next, inhibiton of the second stage, formation of salicyl-
arylation intermediate, will be also tested since the activated carrier proteins are already 
available Chapter 2. In parallel, in vivo growth inhibition by the inhibitors will be investigated 
under iron-deficient medium and over-expressing the mbtA in M. bovis BCG to determine 
MIC.      
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4.1  The flavin-dependent monooxygenases.  
The first committed step in the biosynthesis of various bacterial and fungal siderophores of the 
hydroxamate type, such as aerobactin (E. coli plasmid ColV-K30), alcaligin (Aerobacter sp.), 
ferrichrome (Ustilago sp.), involves the N-hydroxylation of a primary amino group (Stehr et 
al., 1998). Most of these enzymes are referred to as dehydrogenases, but some are called 
oxidases, peroxidases, oxygenases or reductases (Horton et al., 2002). 
 
The nomenclature for enzymes that catalyse these reactions is often confusing. 
Oxidase is the general name for enzymes that catalyse oxidations in which molecular oxygen 
is the electron acceptor. Oxygenases catalyse oxidative reactions in which oxygen atoms are 
directly incorporated into the subtrate molecule, yielding a new hydroxyl or carbonyl group 
(Nelson & Cox, 2004). Oxygenases play an important role in both prokaryota and eukaryota. 
In bacteria, the oxygenases degrade aromatic compounds both by hydroxylating the aromatic 
ring in preparation for ring-cleavage and by catalysing the ring-fission reaction. In mammals, 
oxygenases are involved in the synthesis of steroids, neurotransmitters and in detoxication 
(Harayama et al., 1992).     
 
The oxygenases are diverse and they differ in structure, mechanism, and coenzyme 
requirements. They can be simplified into two groups based on the number of oxygen atoms 
being incorporated into the substrate. Hence, the oxygenases are divided into dioxygenases 
(two oxygen atoms) and monooxygenases (one oxygen atom) (Gunsalus et al., 1975; 
Harayama et al., 1992; Mason & Cammack, 1992). The monooxygenases are a very abundant 
enzyme class and this is reflected in their diversity. The best-known monooxygenases are the 
P450 heme-containing oxygenases (EC 1.14.14 and EC 1.14.15), which are abundant in 
mammals and present in prokaryota, which can catalyse hydroxylation in unactivated carbon 
atoms. Other monooxygenases include the non-heme (EC 1.14.16) and a variety of copper-
dependent (EC 1.14.17 and EC 1.14.18) variants. Monoxygenases use different co-substrates, 
such as reduced flavin nucleotides (FADH2 or FMNH2) or reduced nucleotides (NADH  or 
NADPH) (van Berkel et al., 2006). Monoxygenases that use FADH2 or FMNH2 act as 
prosthetic groups are often called flavin-dependent monooxygenases, flavoenzymes or 
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flavoproteins (EC 1.14.12 and EC 1.14.13) (Horton et al., 2002). However, some 
monooxygenases do not require cofactors, such as the polyketide monooxygenase ActV-OrF6, 
involved in actinorhobdin biosynthesis in Streptomyces coelicolor (Sciara et al., 2003), and 
YigN, a quinol monooxygenase from E. coli that oxidizes multiringed aromatic substrates 
(Adams & Jia, 2005). Despite this diversity, the monooxygenases catalyse the hydroxylation 
in the following general mechanism: 
 
AH + BH2 + O-O A-OH + B + H2O 
 
where AH is the main substrate and BH2 the co-substrate. Since, most monoxygenases 
catalyse reactions in which the main substrate becomes hydroxylated, they are also called 
hydroxylases, mixed-function oxidases or mixed-function oxygenases. The latter indicates that 
they oxidise two different substrates simultaneously (Nelson & Cox, 2004). For instance, the 
p-hydroxybenzoate hydroxylase (PHBH), a flavin monooxygenase of Pseudomonas 
aeruginosa PAO1, catalyses the hydroxylation of aromatic substrates, incorporating an atom 
of oxygen using O2, NADPH and FAD giving 3,4-dihydroxybenzoate, water, and NADP 
(Figure 33) (Palfey et al., 1999). 
 
 
OHHOOC
p -Hydroxybenzoate
+ NADPH + H+ + O2 OHHOOC + NADP
+ + H2O
OH
p-hydroxybenzoate
hydroxylase (PHBH)
3,4-Dihydroxybenzoic acid
NADPH NADP+
FAD FADH2
  
Figure 33. Reaction catalysed by p-hydroxybenzoate hydroxylase. p-Hydroxybenzoate 
hydroxylase with its co-factor FAD catalyses the incorporation of an atom of oxygen into p-
Hydroxybenzoic acid to produce 3,4-dihydroxybenzoic acid (Palfey et al., 1999). 
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Intramolecular reactions between O2 and other molecules induce a number of 
interesting phenomena. The electronic ground state (lowest-energy state) of dioxygen is a 
triplet 3O2, in which two unpaired electrons are present. Pairing these electrons to give one 
with “up” spin and one “down” gives a single state 1O2 (singlet oxygen). In the ground state, 
the two highest energy electrons reside in identical molecular orbitals with the same spin and 
therefore they cannot occupy the same region of space (the Pauli exclusion principle). 
Electrons with opposite spin, as in O2, can occupy the same region in space, that renders 
greater repulsion between them to react with other molecules, but this requires energy and the 
reactions are kinetically slow (Pryor et al., 2006). When oxygen oxidises organic molecules, it 
is itself reduced. By adding electrons to the molecular orbitals of the ground state of dioxygen, 
a stepwise reduction of oxygen products results. By addition of one electron, superoxide (O2-) 
is formed, whereas addition of two electrons produces peroxides (HO2, H2O2) are produced. 
These small molecules are highly reactive oxygen intermediates (ROIs) that can inactivate 
many enzymes, membrane lipids and nucleic acid, with subsequent damage of cells (Valko et 
al., 2007). Hence, the activation of dioxygen not only requires energy, but also a safe 
chemical reduction process to avoid ROS (van Berkel et al., 2006). In heme-enzymes, e.g. 
P450 monooxygenases, transition metals are required to activate molecular oxygen (Nelson & 
Cox, 2004). On the other hand, the flavin-dependent monooxygenases employ the reduced 
flavin cofactor for oxygenation reactions (van Berkel et al., 2006). To avoid confusion in the 
subsequent paragraphs, hereafter the flavin-dependent monooxygenases will be denominated 
FDMOs. The FDMOs carry out the oxygenation in three common chemical processes: (i) 
reduction of flavin by NAD(P)H; (ii) reaction of reduced flavin with O2 to provide a C4a-
flavin (hydro)peroxide, which is the oxygenating reagent (it is peroxide for electrophilic 
substrates and the hydroperoxide for nucleophilic substrates); and (iii) binding, orienting, and 
activating the substrate for its oxygenation by the C4a-flavin (hydro)peroxide (Figure 34) 
(Ballou et al., 2005). However, the common mechanisms differ according to the number of 
polypeptides involved in oxygenation. The single-component FDMOs carry out all catalytic 
reactions in which three conformational changes in which both protein and FAD are important 
for catalysis (Ballou et al., 2005; Malito et al., 2004). The two-component FDMOs divide the 
catalytic tasks by employing two different polypeptides. Firstly, a reductase which generates 
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reduced flavin and secondly a hydroxylase using reduced flavin to catalyse substrate 
monooxygenation (Ballou et al., 2005; van Berkel et al., 2006).     
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Figure 34. General mechanism for FAD–dependent oxygenation.  FDMOs oxygenate 
substrates by initially forming a flavin hydroperoxide at the enzyme active site (1), which then 
transfers the terminal oxygen atom of the hydroperoxide (OH) to the substrate (2). The 
remaining "hydroxyflavin" then reoxidizes with the release of water (3). For ‘external’ 
FDMOs (illustrated here), NADPH is then used to regenerate the FAD (4 & 5) for the next 
round of catalysis; the flavins of internal FDMOs are reduced by the substrate itself. 
 
 
Although, most enzymes are specific for one electron acceptor, some display dual 
specificity. Sequence aligment of a set of Baeyer-Villiger monooxygenases (BVMOs) with a 
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preference for NADPH using 4-hydroxy-acetophenone monooxygenase (HAPMO) as a 
prototype and mutagenesis analysis of the latter, revealed three amino acid residues that were 
important for co-enzyme specificity in HAPMO (Arg339, Lys439 and Arg440) (Kamerbeek et 
al., 2004). The mutants Arg339Ala and Lys439Ala showed decrease affinity for NADPH. 
Furthermore, replacing the lysine (Lys329) in another Type I BVMO, the cyclohexanone 
monooxygenase, which is analogous to Lys439 in HAPMO, changed the co-enzyme 
specificity towards NADH (Kamerbeek et al., 2004). The electron acceptor may be an integral 
part of the enzyme as shown in the case of the monooxygenase of Methylophaga sp. strain 
SK1 (Alfieri et al., 2008), or replaced during oxygenation of the substrate as in the 
monooxygenase of Schizosaccaromces pombe (Eswaramoorthy et al., 2006). 
 
Although, the flavin nucleotide in most FMDOs is not covalently bound to the protein, 
some enzymes have covalently bound FMN or FAD as prosthetic groups (Mewies et al., 
1998). The FDMOs are involved in a wide variety of cellular processes including drug 
detoxification, biodegradation of aromatic compounds in the environment, biosynthesis of 
antibiotics and siderophores. Oxygenation reactions they catalyse include hydroxylations, 
epoxidations, Baeyer-Villiger oxidations and sulfoxidations (Figure 35).  
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Figure 35. Reactions catalised by flavoprotein monooxygenases. 
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The specific type of oxygenation and selectivity depends on the shape and chemical 
nature of the active site of each specific monooxygenase. However, based on amino acid 
sequence and structural homology, the topology of the enzymes play an important role in the 
type of oxygenation catalysed by these enzymes (van Berkel et al., 2006). The FDMOs can be 
subdivided as external and internal oxygenases. In the external FDMOs, the flavin cofactor 
reacts with the molecular oxygen atom when it is in the reduced form and NADH or NADPH 
are consumed. On the other hand, in the internal FDMOs the flavin is reduced by the substrate 
itself (van Berkel et al., 2006). Furthermore, based on amino acid sequence, structure and 
mechanism, the external monooxygenases are classified in six subclasses (Table 15). 
 
 
Table 15. Classification of external flavoprotein monooxygenases. aThe most commonly 
found in vivo activities are given (van Berkel et al., 2006). 
Sub-class Prototype Reactionsa Cofactor  Coenzyme 
A 4-OH-benzoate hydroxylase Hydroxylation epoxidation FAD NAD(P)H 
B Cyclohexanone monooxygenase Baeyer-Villiger; N-oxidation FAD NADPH 
C Luciferase Light emission; S-oxidation  FMN NAD(P)H 
D 4-OH-phenylacetate hydroxylase Hydroxylation  FAD NAD(P)H 
E Styrene monooxygenase Epoxidation  FAD NAD(P)H 
F Tryptophan 7-halogenase Halogenation  FAD NAD(P)H 
 
 
 
The B flavoprotein monooxygenases are multifunctional enzymes that oxidise carbon 
atoms and other (hetero)atoms (Fraaije et al., 2002). Moreover, this subclass consist of three 
sequence-related monooxygenase subfamilies: flavin-containing monooxygenases (FMOs), 
microbial N-hydroxylating monooxygenases (NMOs) and Type I BVMOs. These enzymes are 
single-component FAD-containing enzymes and are specific for NADPH (Fraaije et al., 
2002). Sequence aligment of the well studied HAPMO, a BVMO from P. fluorescens and 
related FDMOs revealed three conserved motifs in this subclass; two Rossman-fold motifs 
[GXGXX(G/A)] for the two binding domains of FAD and NADPH, and the specific 
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fingerprint [FXGXXXHXXXW(P/D)] located before the second Rossman motif. The latter 
motif is strictly conserved in FMOs and NMOs (Fraaije et al., 2002). Mutation analysis of the 
His and Trp residues leads to insolubility and loss of the FAD co-factor of the enzyme, 
respectively, indicating that these residues are essential for enzyme activity (Fraaije et al., 
2002).  
 
Amino acid sequence comparison of NMOs from E. coli (aerobactin, AerA, IucD), P. 
aeruginosa (pyoverdine, PvdA, PsbA), Bordetella bronchiseptica (alcaligin, AlcA) and 
Ustilago maydis (ferrichrome, Sid1), and 30 sequences of FMOs revealed amino acid 
differences in the two Rossman motifs, as well as another motif (Ambrosi et al., 2000; Stehr et 
al., 1998). In the first Rossman motif (located in the N-terminal of the protein), replacement of 
the last glycine for proline was detected and it was assumed to cause weak binding of FAD to 
lysine N6-hydroxylase (Macheroux et al., 1993). In AlcA and PvdA an alanine residue and in 
Sid1 a serine residue replace the last glycine in the second Rossman motif (Ambrosi et al., 
2000; Stehr et al., 1998). Another motif, [(L/F)ATGYXXXXP)] located at the C-terminal of 
the protein, was predicted to be for substrate binding, since this region is highly hydrophobic 
(Ambrosi et al., 2000; Stehr et al., 1998). However, the crystal structure of a FMO from S. 
pombe shows that the FAD is tightly bound to the enzyme, whereas the NADPH may be 
replaced by the substrate (Eswaramoorthy et al., 2006). In the enzyme-FAD-substrate crystal, 
the substrate is bound to FAD in the isoalloxazine ring and occupies the NADPH binding site, 
indicating that there are no more interactions with the protein (Eswaramoorthy et al., 2006).  
 
 
4.2 The N-hydroxylation in siderophores.  
Many microorganisms utilise hydroxamates and carboxylate siderophores for sequestering 
iron, and their biosynthesis mainly rely in NRPS-independent systems. The biosynthesis of 
these siderophores depends on enzymes, such as NMOs, decarboxylases, aminotransferases 
and aldolases (Challis, 2005). It has been proposed that the formation of hydroxamates, in 
which functional groups are derived from diamino acids, such as L-ornithine and L-lysine, is 
the first step in the biosynthesis of the corresponding siderophore (Miethke & Marahiel, 
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2007). Biochemical data support the above hypothesis, in which L-ornithine N5-hydroxylases, 
such as the CchB involved in Streptomyces coelicolor coelichelin siderophore biosynthesis 
(Pohlmann & Marahiel, 2008), PvdA P. aeruginosa in pyoverdin biosynthesis (Ge & Seah, 
2006) and E. coli K-12 Lysine N6-hydroxylase (IucD) is required in aerobactin (de Lorenzo et 
al., 1986; Plattner et al., 1989), catalysed the hydroxylation of their respective substrates as 
the first biosynthetic step in siderophore synthesis (Figure 36). Other NMOs genes have been 
identified in diverse microorganisms. Aspergillus nidulans, a filamentous ascomycete, 
produces ferricrocin that requires sidA that encodes L-ornithine N5-monooxygenase as the first 
step in the siderophore biosynthesis (Eisendle et al., 2003). In Ustilago maydis, sid1 encodes 
for L-ornithine N5-oxygenase which also catalyses the hydroxylation of L-ornithine as first 
step of the biosynthesis of ferrichrome and ferrichrome A (Mei et al., 1993).  
 
In the gene cluster for mycobactin biosynthesis, a lysine N-oxygenase (mbtG, 
Rv2378c) was found to share homology with ornithine and lysine N-oxygenases activities that 
would be required for N-hydroxylation of the two lysines at some stage during mycobactin 
synthesis (Quadri et al., 1998). In the mature mycobactin molecule, two hydroxylysine 
residues are present. One is found in a central position and one is cyclised and terminally 
situated (Figure 34). Mycobactins contain both hydroxamates and catechols as iron chelating 
groups (Quadri et al., 1998; Ratledge, 2004). The catechol group is introduced during the 
early steps of mycobactin biosynthesis (Quadri et al., 1998; Ratledge & Dover, 2000). The 
same biological process occurs during the biosynthesis of yersiniabactin (Gehring et al., 
1998a) and pyochelin (Quadri et al., 1999), siderophores of Yersinia sp. and P. aeruginosa, 
respectively. The hydroxamates of mycobactins are derivatives of lysine and hydroxylation of 
these amino acids is required to produce the chelating groups for Fe (III) (De Voss et al., 
1999; Ratledge, 2004; Ratledge & Dover, 2000). However, the hydroxylation of lysines in the 
core structure of mycobactin may not occur during the early stage of biosynthesis (Moody et 
al., 2004). 
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Figure 36. Structures of (A) pyoverdine, (B) aerobactin, (C) mycobactin, and (D) 
coelichelin  siderophores. Hydroxamate groups (highlighted in red) are introduced by NMOs. 
For pyoverdine, aerobactin, and coelichelin the hydroxylation occurs as first step, whereas in 
mycobactin the hydroxylation is hypothesised to take place in the late stage of its biosynthesis. 
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the PCP domains. In most NRPSs modules, once the amino acid is activated and transferred to 
PCP domain it can, without losing the covalent linkage, be modified by optional domains such 
as an epimerazation domain. However, the discovery of a compound structurally related to 
mycobactin T, which lacked the oxygen atoms in both lysines, has suggested another 
hypothesis (Moody et al., 2004). Screening for antigens presented by CD1a-restricted T cells 
from M. tuberculosis, a compound initially named 838 based on its nominal mass elucidated 
by mass spectrometry analysis was elucidated. Further structural analyses yielded product ions 
at m/z 642 and m/z 197, which were each 16 u (the mass of oxygen) smaller than the 
previously described mycobactic acid and cobactin fragments from mycobactin T (Snow, 
1965a). The compound was named didehydroxymycobactin (DDM)-838 (Figure 37). 
Identification of MS/MS products at m/z 727 and 84 determined unmodified lysines in the 
proposed structure of DDM (Moody et al., 2004). According to Krithika et al. (2006), MbtG 
was able to catalyse the hydroxylation on both acetylated lysine and L-lysine, although the 
preference was for the former by 5-fold. This result also suggests that the hydroxylation of 
lysines may be the last step for mycobactin biosynthesis, and the discovery of the didehydroxy 
analog of mycobactin isolated from mycobacteria supports this hypothesis (Moody et al., 
2004). Therefore, these studies allow the speculation that unmodified lysines are incorporated 
in the growing chain by the adenylation domains of MbtE and MbtF. The central lysine is then 
N-acylated and the terminal lysine is cyclised, and MbtG subsequently carries out 
hydroxylation to produce a functional mycobactin.  
 
On the other hand, the hydroxylation reaction in some NRPS occurs during the 
biosynthesis before yielding the final product. A number of nonribosomal peptide antibiotics 
contain β-hydroxy amino acids, including vancomicyn and bleomycin (Walsh et al., 2001). 
One antibiotic of this group is novobiocin, produced by Streptomyces spheroides, in which the 
core structure, essential for activity, is formed by 3-amino-4-hydroxy-coumarin. Two open 
reading frames, NovH and NovI, have been predicted to participate in the synthesis of the core 
structure. NovH is a two-domain A-PCP protein, whereas NovI is a heme protein of the 
cytochrome P450 monooxygenase class. The NovH catalyses L-tyrosyl-AMP formation by its 
adenylation domain, which can be transferred on the pantetheinylated PCP domain, producing 
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the covalent L-tyrosyl-S-NovH intermediate on the holo PCP domain. Then NovI installs one 
atom from O2 at the C3 of the Tyr-S-NovH to yield (3R)-3-OH-tyr-S-PCP-NovH (Chen & 
Walsh, 2001; Steffensky et al., 2000). Thus, NovI recognises the L-tyrosyl moiety, presented 
on the pantetheinyl arm of the PCP domain of NovH, NovI acts catalytically on its tyrosyl-S-
NovH partner but the L-OH-Tyr product stays covalently attached on the NovH PCP domain. 
Homologues of the NovH/NovI enzymes are found in other microorganisms that produce 
antibiotics containing L-hydroxyl amino acid moieties, such as vancomycin and nikkomycin. 
This suggests that hydroxylation of a tethered aminoacyl-S-PCP, before yielding the final 
product, may be a general strategy for diversion of a fraction of the amino acid pool to 
modifications that provide building blocks for antibiotic biosynthesis (Chen & Walsh, 2001). 
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Figure 37. Structure of the CD1a-presented antigen, didehydroxymycobactin (DDM)-
838. The DDM structure was deduced from the MS/MS spectrum of [M+H]+ m/z 838. DDM 
might function as an intermediate in mycobactin synthesis and this suggest that the lysines are 
incorporated into the peptide and subsequently hydroxylated by MbtG to produce functional 
mycobactin [Adapted from Moody et al., (2004)]. 
O
C17H35
 
 
 
Despite this partial characterisation of MbtG, there are some biochemical questions in 
mycobactin biosynthesis that remain unanswered. Firstly, is the hydroxylation of lysines the 
last step for mycobactin biosynthesis? If this is the case, the adenylation domains, both MbtE 
and MbtF, will prefer lysines to acylated or hydroxylated lysines. It has been assumed that the 
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major fidelity or editing functions for amino acid selection and incorporation into elongation 
peptide chain reside in the A domain of NRPS (Pavela-Vrancic et al., 2004). Despite this 
specificity, some NRPS systems exhibit relaxed amino acid substrate specificity, allowing the 
production of a variety of isoforms of the respective product. The VibF module, a protein for 
vibriobactin biosynthesis, which contains two heterocyclisation domains, one adenylation 
domain, two condensation domains and peptidyl carrier protein, was able to utilise various L-
threonine analogues, as well as serine and cysteine as alternate substrates in aminoacyl-AMP 
formation (Walsh et al., 2001). For several NRPS systems, like tyrocidine, surfactin, 
cyclosporine and enniatin, nutrient availability conditions can affect the constitution of the 
final product, either in vivo by adding certain amino acids to the medium or in vitro in cell-
free systems with arbitrarily chosen substrate concentrations (Mootz and Marahiel, 1997). The 
relaxed specificities of these domains are likely to respond to biological requirements as they 
can switch from one substrate to another to yield a different product.  
 
On the other hand, the discovery of the DDM compound might be considered as an 
initial step for mycobactin degradation or as defense mechanism against innate immunity of 
the host. In general, once Fe3+ is mobilised and captured by siderophores, it is already 
accessible for cellular uptake (Ratledge & Dover, 2000). The ferric-siderophore complex must 
be dissociated and iron reduced to its soluble  form (Fe2+) to be available for subsequent 
cellular processes (Ratledge & Dover, 2000). The E. coli ferric enterobactin esterase (Fes) was 
the first ferric-siderophore esterase to show hydrolytic activity on the Fe-enterobactin complex 
followed by ferric iron reduction (Brickman & McIntosh, 1992; O'Brien et al., 1971). 
Recently, two other esterases of Salmonella enterica have been biochemically characterised, 
IroD and IroE, with similar catalytic function as Fes (Lin et al., 2005); their genes are part of a 
functional operon mediated by Fur (Baümler et al., 1998). IroD could hydrolyse both apo and 
ferric-siderophore, whereas IroE prefers apo-siderophores as substrates, although another 
study showed different results about substrate specificity of these esterases (Zhu et al., 2005). 
This study showed different substrates specificities for these esterases: IroD preferred free 
iron enterobactin and salmochelin substrates over the ferri-siderophores, while IroE 
hydrolysed both free iron-siderophores and iron-charged diglucosylated enterobactin (Zhu et 
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al., 2005). Although, indirect reduction of ferric-siderophore by soluble flavin reductases has 
been observed in prokaryotes, their ferric-siderophore reductase activity is not considered 
specific as the enzymes are neither substrate specific or iron regulated (Halle & Meyer, 1992). 
Hence, the experimental data suggests that degradation of siderophores may be a required step 
to remove iron from the complex, facilitating reductive release of the metal, a similar 
degradative scenario might be envisaged for the ferric-mycobactin complex, and thus the 
DDM might be a degradation compound.  
 
  Hence, different hypothetical scenarios might occur during in vivo mycobactin 
biosynthesis. Here, the aim of this chapter was to investigate at which stage hydroxylation 
might occur in the lysine residues. To assess the hypothesis that DDM is an intermediate 
product prior mature mycobactin, the mbtG and adenylations gene domains of MbtE and 
MbtF were cloned and expressed for their further biochemical characterisation.  
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4.3 Material and methods. 
4.3.1 Molecular cloning of mbtG and adenylation domains of MbtE and MbtF. 
Amplification of the mbtG gene was performed with Vent DNA polymerase (New England 
Biolabs) using M. tuberculosis H37Rv chromosomal DNA and the following primers: 
pET23bmbtGu 5‘-GATCGATCCATATGAATCCGACGCTCGCGGT-3’ and pET23bmbtGl 
5’- GATCGATCGCGGCCGCTCGAAAGGATTGGTGCTCAC-3’ (NdeI and NotI 
recognition sites underlined). The PCR product was then directly ligated at 16°C for 16 hours 
with T4 DNA ligase (New England Biolabs) into pET23b (Novagen), which had been cut by 
NdeI and NotI (New England Biolabs), thus giving rise to mbtG-pET23b. The ligation mixture 
was used to transform E. coli TOP10 and the nucleotide sequence of plasmid DNA from 
recombinant transformants confirmed by sequencing. The mbtG-pET23b plasmid was then 
subsequently used to transform E. coli C41 (DE3) enabling the production of the recombinant 
MbtG protein.  
  
To clone the adenylation domains of mbtE and mbtF, denominated hereafter as ambtE 
and ambtF, respectively, amino acid sequence aligment of the adenylation domain of 
bacillibactin, DhbE, whose crystal structure has been determined (May et al., 2002), was 
performed to define important structural regions for appropiate folding of the truncated 
proteins. Hence, primers were designed to clone the adenylation domains in a range of 
expression vectors (Table 16). Amplification of the adenylation domains was performed with 
Phusion High Fidelity Polymerase (New England Biolabs) using M. tuberculosis H37Rv 
chromosomal DNA. Amplicons and vectors were digested with their appropriate restriction 
endonucleases (New England Biolabs), followed by ligation with T4 DNAligase (New 
England Biolabs) at 16°C for 16 hours. The ligation mixture ambtE-pET28b was used to 
transform E. coli TOP 10. The ligation mixture of ambtF in each of the vectors was used to 
transform E. coli NEB 5-alpha F´Iq (New England Biolabs).     
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Table 16.  Primers designed to clone the adenylation domains both mbtE and mbtF genes 
into pET and pVV16 vectors. 
Gene Vector Primers 
Restriction site 
(underlined) 
pET28b Up-5’-GATCGATCCATATGGGGATAGGCAGCGAAGACCGG-3’  NdeI 
ambtE 
pET28b Down-5’-GATCGATCGCGGCCGCTTACCGCACACCGACATCGACGCCGAACGC-‘3 NotI 
pET23a Up-5’-GATCGATCCATATGGACGTGAGTCGCGAGACCCCG-3’ (a) NdeI 
pET23a Down-5’-GATCGATCGCGGCCGCCGCAATCCCACGACGGCGCGCGGCCTG -‘3 NotI 
 
 
ambtF pET28b Down-5’-GATCGATCGCGGCCGCTTACGCAATCCCACGACGGCGCGCGGCCTG -‘3 NotI 
 pVV16 Up-5’- GATCGATCCATATGCGCAATCCCACGACGGCGCGCGGCCTG-3’ NdeI 
  Down-5’- GATCGATCAAGCTTCGCAATCCCACGACGGCGCGCGGCCTG-3’ HindIII 
(a) In both genes, the up primers are the same for both vectors. 
 
 
Selection of mbtG-pET23b, ambtF-pET23b, ambtE-pET23b, ambtF-pTYB2 was 
performed on LB agar plates containing Ampicillin (100 µg/mL), whereas for ambtF-pET28b, 
Kanamycin (25 µg/mL) was added to the solid media. For ambtF-pVV16 Hygromycin (200 
µg/mL) was added to LB agar. Screening was performed by double digestion followed by 
electrophoresis on agarose gels and stained with EtBr. Integrity of genetic constructs was 
verified by nucleotide sequencing.   
 
 
4.3.2 Gene expression and protein purification of MbtG and adenylation domains.  
To seek gene expression, E. coli C41(DE3) was transformed with each of the following 
constructs: mbtG-pET23b, ambtF-pET23a, ambtE-pET28b, and ambtF-pET28b, whereas E. 
coli ER2566 was used for ambtF-pTYB2. Gene expression analysis was determined by testing 
different temperatures, incubation time and IPTG concentrations as described in (Chapter 2, 
section 2.2.3). For ambtF-pVV16 M. smegmatis mc2155 was also used as heterologous host 
and gene expression analysis was determined as described in Chapter 3, section 3.5.3. Gene 
products cloned into pET and pVV16 vectors were purified by affinity chromatography using 
a His-Trap column as described in Chapter 2, section 2.2.5, whereas the adenylation domain 
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of MbtF cloned into pTYB1 was purified by affinity chromatography using a chitin column as 
described in Chapter 2, section 2.2.7.1. The purity of proteins was assessed by 12% SDS-
PAGE and Coomasie blue staining. Purified protein fractions were pooled and dialysed 
against against appropriate buffer, and concentrated using Centricon YM-30 filter unit 
(Millipore), and stored at -80 ºC until use. Protein concentration were estimated by the BCA 
protein assay (Pierce).  
 
 
4.3.3 N-Hydroxylation of MbtG on DDM.  
Krithika et al. (2006) reported that MbtG could hydroxylate acylated lysines as the preferred 
substrate. Thus, MbtG will be biochemically characterised using protocols reported elsewhere 
(Plattner et al., 1989) to seek activity of the protein. Hydroxylation will be attempted using 
DDM compound provided by our collaborators Cressida Madigan and Branch Moody 
(Brigham and Women's Hospital, Division of Medical Sciences, Harvard University).  
 
 
4.3.4 Biochemical activity of the adenylation domains.  
To investigate substrate preference by the adenylation domains, ATP-PPi exchange assay will 
be performed as reported by Linne and Marahiel (2004).  
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4.4 Results. 
4.4.1 Expression and purification of MbtG. 
Gene expression analysis of mbtG-pET23b was carried out to determine the optimal 
conditions for mbtG over-expression, which involved incubation with 1mM IPTG at 16°C for 
16 hours. The purification of protein was carried out by nickel affinity chromatography. A 
protein was purified to > 95% purity on the Ni2+-charged resin consistent with the predicted 
molecular mass calculated for MbtG of 46 kDa (Figure 38). During elution of MbtG, there 
were two problems, firstly the protein either precipitated quickly, or secondly, lost its cofactor 
FAD.  
 
 
 
 
 
 
 
 
 
 
Figure 38. Coomasie Blue stained 12% SDS-PAGE of MbtG purified. M= protein 
molecular marker. Lane (1) MbtG purified.  
 
 
4.4.2 Cloning and expression of adenylation domains of MbtE and MbtF. 
As was outlined the initial aim of the project was to elucidate the biochemical function of 
MbtG. Recent studies have shown the predicted function of this protein (Krithika et al., 2006), 
and the discovery of DDM suggests that hydroxylation is the last step in mycobactin synthesis 
(Moody et al., 2004). This information suggests that unmodified lysines are activiated by the 
adenylation domains of MbtE and MbtF, and then subsequently incorporated into the growing 
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core structure of mycobactin. To investigate this hypothesis, the adenylation domains of MbtE 
and MbtF were cloned and their over-expression examined.  
 
Initial attempts were to clone the domains into pET vectors as fused hexahistidine tag 
to facilitate protein purification. The region coding the adenylation domain of MbtE, ambtE 
was cloned into pET28b, whereas the equivalent ambtF was cloned into pET23a. The AMbtE 
protein was over-expressed as an insoluble protein at 37°C in all IPTG concentrations 
examined. When gene expression was induced at this temperature, a heavily staining band 
having migration compatibility with the expected molecular mass of 55.5 kDa, suggested the 
recombinant protein was present in the cell lysate, but no detectable protein remained in the 
supernatant after centrifugation for 30 minutes at 15,000 rpm as determined by 12% SDS-
PAGE (Figure 39). Expression of the protein was not observed in other growth, time and 
temperature conditions as well as different concentrations of IPTG (data no shown). Further 
attempts to clone ambtE were made using different expression vectors but without success.  
 
In addition, similar problems were also found for ambtF expression. Different 
conditions were attempted to allow expression of protein, but again without success. 
Mycobacterial genes can sometimes be difficult to clone and express due to the high G+C 
content, and different strategies have been used to overcome this problem. The codon 
alteration strategy, in which the first codons of the gene are modified in order to prevent the 
formation of secondary structures that might inhibit translation, was successfully used to 
obtain considerable mycobacteria DapF protein expression (Usha et al., 2006). It is likely that 
the high G+C content in the native sequence results in the formation of secondary structures in 
the encoding mRNA. The formation of such a complex can block the binding site of the 
ribosome and eventually lead to the failure of protein expression, i.e. blocking translation. 
Alteration of the DNA nucleotide sequence, and consequently the mRNA, might avoid the 
formation of this complex. 
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Figure 39. Expression analysis of AMbtE. E. coli C41(DE3)-ambtE-pET28b was grown at 
37°C, when O.D600=0.5-0.6, different concentration of IPTG were added to seek expression of 
the adenylation domain. M=protein molecular marker. Lane 1 and 2, crude lysate and 
supernatant, respectively, of negative control [no inducer added to E. coli C41(DE3) 
transformed with only pET28b]; Lanes 3 to 8 samples loaded with E.coli C41(DE3)-ambtE-
pET28b. Lane 3 and 4, crude lysate and supernatant, respectively, induced with 1 mM IPTG. 
Lane 5 and 6, crude lysate and supernatant, respectively, induced with 0.5 mM IPTG. Lane 7 
and 8, crude lyaste and supernatant, respectively, induced with 0.1 mM IPTG. In lanes 3, 5, 7 
a band migrated with the expected size of the protein (55.5 kDa) indicating thus over-
expression of the adenylation domain, although in its insoluble form.    
 
 
There are 64 codons that only encode only 20 amino acids, so alteration of these 
codons, without altering the amino acids sequence, would help the expression of the protein. 
Thus, by adjusting only the primer up of ambtF (altering the native nucleotide sequence) for 
cloning into both pET23a and pTYB2 vectors, one might expect to increase yields of 
recombinant protein at lower temperatures and/or IPTG concentrations which could ultimately 
lead to a soluble protein preparation. Primers were re-designed to clone ambtF into different 
vectors. Thus, E. coli expression vectors were tested using the same codon alteration strategy 
(Table 17).  
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Table 17. Primers were re-designed allowing the cloning of ambtF into two different 
vectors. (a) The sequence of the mutation region of the ambtF forward (For) oligonucleotide 
primer used to amplify ambtF is displayed below the sequence of the corresponding native 
sequence. The first 10 codons of the ambtF mRNA were modified to prevent secondary 
structures that might affect translation, whereas the reverse (Rev) oligonucleotide was 
designed to be homologous to the M. tuberculosis H37Rv to promote efficient priming. (b) 
Restriction sites are underlined. 
Native amino acid 
sequence Asp Val Ser Arg Glu Thr Pro Val Ala Val 
Native nucleotide 
sequence GAC GTG AGT CGC GAG ACC CCG GTG GCC GTC 
(a)  Mutated sequence GAT  GTT TCT AGA GAA ACT CCT GTT GCT GTT 
   
Vectors  Pimers (b) 
For 5’-GATCGATCCATATGGATGTTTCTAGAGAAACTCCTGTTGCTGTCGCGCTGTCCCGTGGT-‘3 NdeI pTYB2 
Rev 5’-GATCGATCCCCGGGCGCAATCCCACGGCGCGCGGCCTG-‘3 SmaI 
For-5’-GATCGATCCATATGGATGTTTCTAGAGAAACTCCTGTTGCTGTTGCGCTGTCCCGTGGTCCG-
‘3 
NdeI pET23a 
Rev-5’-GATCGATCGCGGCCGCCGCAATCCCACGACGGCGCGCGGCCTG -‘3 NotI 
 
 
Hence, ambtF was successfully cloned into pTYB2 vector but not in pET23a using E. 
coli TOP 10 as cloning host. However, when the integrity of the construct was verified by 
nucleotide sequencing, point mutations were observed in different samples. As a result, 
another cloning host was used, E. coli NEB 5-alpha F´Iq, which allowed successful cloning of 
the gene without point mutations. The protein expression analysis was carried out by 
transforming E. coli C41(DE3) with ambtF-pTYB2. Cultures were grown initially at 37˚C, 
then the temperature was shifted to 16˚C and 0.5 mM IPTG added to induce expression. After 
purification using a chitin column, a band migrated at the expected size of the truncated 
protein on 12% SDS-PAGE gels (Figure 40A); the adenylation domain of MbtF is expected to 
have a mass of 56 kDa. To confirm the identity of the truncated protein MALDI-MS was 
carried out. Instead of the mycobacterial protein, an E. coli protein (GroEL, 60 KDa) was 
found to be the expressed and purified. This result is in accordance with the vector 
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manufacturer’s suggestion that either this chaperon or the intein tag (55 KDa) may appear in 
the elution following the on-column cleavage reaction. ambtF was also cloned into pVV16 
followed by transformation into M. smegmatis mc2155. Transformed cells were grown at 37°C 
until an OD600=0.5-0.6 and further incubated for 4 hours. Cells were disrupted by sonication 
followed by centrifugation and the supernanant subjected to affinity chromatography using a 
His-Tag column. After purification, a band migrated on 12% SDS-PAGE with the expected 
size of AMbtF (Figure 40B), however, MALDI-MS analysis of the constituted peptides of the 
purified protein showed the identity of a chaperonin (GroEL1). GroEL1 has an approximate 
similar MW (~60 kDa) to that of AMbtF (55 kDa), and possess a histidine-rich C-terminal 
region, which would also bind to the nickel column during purification.    
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 40. Expression analysis of AMbtF. A) The ambtF was cloned into pTYB2 and the 
plasmid transformed in E. coli C41(DE3). Protein purification was performed using a chitin 
column. B) The ambtF was also cloned into pVV16 and the plasmid transformed into M. 
smegmatis mc2155, followed by purification using a His-tag column. In both cases, a band 
migrated (pointed with arrows) on 12% SDS-PAGE with the expected size of AMbtF, 
however MALDI-MS analysis shown the identity of different proteins. M= molecular protein 
marker. 
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4.5 Disscusion. 
Siderophores depend on three chemical functional groups for iron chelation: catechols, 
hydroxamates, or α-hydroxy-carboxylates (Miethke & Marahiel, 2007). Biosynthesis of 
hydroxamates from diamino acids involves the hydroxylation of the terminal amino group by 
an N-hydroxylating monooxygenases (NMOs) to form a hydroxylamine (van Berkel et al., 
2006). Few NMOs have been biochemically studied due to difficulties in cloning and 
expression of these enzymes (Putignani et al., 2004; Thariath et al., 1993) as well as the low 
affinity for FAD, hindering mechanistic studies (Stehr et al., 1999). Early studies with L-
lysine-Nε-oxygenase (IucD) suggested that this class of monooxygenase is normally attached 
to the cytoplasmic membrane due to the presence of a hydrophobic amino acid sequence 
(Herrero et al., 1988), hampering its isolation or expression (Plattner et al., 1989). Although, 
discrepancies do exist and the gene could be cloned and its product obtained as a cytoplasmic 
protein (Thariath et al., 1993). In addition, similar problems have also been reported for PvdA, 
an L-ornithine Nδ-oxygenase from Pseudomonas species (Ge & Seah, 2006; Meneely & 
Lamb, 2007; Putignani et al., 2004) and the L-ornithine N5-hydroxylase from S. coelicolor 
(CchB) (Pohlmann & Marahiel, 2008). In this study, the mbtG gene was also cloned and 
expressed as a soluble protein using E. coli C41(DE3) with good protein yield.  
 
During MbtG purification the characteristic yellow colour due to the FAD coenzyme 
was observed, which suggests that the protein retains its coenzyme. It has been reported that 
the coenzyme in NMOs weakly bind to the enzyme because of the exchange of the last 
glycine to proline in the FAD-binding motif, a residue which might fulfil an important 
structural role (Stehr et al., 1998; 1999). The lysine N6-hydroxylase IcuD of E. coli is always 
isolated in its apo-form indicating that the enzyme binds to its coenzyme rather weakly 
(Macheroux et al., 1993). This enzyme was incubated with 20-fold excess of FAD followed 
by purification using a Sephadex column. The absorption spectrum of the treated protein was 
similar to that of free FAD enzyme, suggesting that the coenzyme is lost during purification. 
This addition of FAD after purification, led to enhancement of protein activity (Macheroux et 
al., 1993). Similar results are also obtained during purification of PvdA, which has a low 
dissociation constant for flavin (Ge & Seah, 2006). Multiple alignment of the sequences 
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among NMOs of M. tuberculosis (MbtG-H37Rv), M. smegmatis (MbtG-MS), Pseudomonas 
(PvdA), S. coelicolor (CchB) and E. coli (IucD), revealed that the FAD-binding motif, the 
NADP-binding motif, and the FATGY motif are present in all these types of monooxygenases 
(Figure 41). However, the BVMO motif proposed by Fraaije et al. (2002) is not highly 
conserved amongst the NMOs. In the FAD-binding motif, the first two glycines are 
conserved, whereas the last glycine varies in the sequences aligned. In M. tuberculosis 
H37Rv, the FAD-binding motif has an alanine instead of glycine (GAGAKA), but this amino 
acid exchange might not affect the binding of the coenzyme. Interestingly, the MbtG of M. 
smegmatis mc2155 conserves the third glycine in this motif, indicating that the co-enzyme 
should be tightly bound to MbtG.   
 
The hydroxylation of lysines or ornithine residues in hydroxamates siderophores are a 
key step since they are essential for the generation of the chelating groups for Fe (III). L-
ornithine N5- oxygenase from Burkholderia cepacia is an important enzyme for hydroxylation 
of ornibactin. A mutation in pvdA, which encodes for the enzyme, did not carry out the 
hydroxylation of L-ornithine in ornibactin synthesis. However, ornibactin synthesis in the 
mutant was partially restored when the precursor L-N5-OH-ornithine was added to the culture 
medium (Sokol et al., 1999). Three mutants in pvd, were designed to understand the function 
of the enzyme. The first mutant, pvd-1, was unable to hydroxylate L-ornithine in a cell-free 
system. The two other mutants appear to block further steps in the biosynthetic pathway 
leading to pyoverdin (Visca et al., 1992). The product of the iucD gene, a 53 kDa protein, is 
required for the hydroxylation of Nε-hydroxylysine in the biosynthesis of the E. coli K-12 
aerobactin (de Lorenzo et al., 1986). 
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Figure 41. Multiple sequence alignment of NMOs. The sequences were aligned using 
ClustalW2 (default settings) and Esprit.  The FAD-binding motif is indicated by (▲), whereas 
the NADP(H)-binding motif is indicated by (▼). Red closed-circles indicate the predicted 
specific motif of BVMOs as described by Fraaije et al. (2002). Pink closed-circles shows the 
predicted hydrophobic motif described by Stehr et al. (1998). PvdA (L-ornithine N5-
oxygenase) from P. aeruginosa; CchB (L-ornithine N5-hydroxylase) from S. coelicolor; 
MbtG-H37Rv, MAPA, and MS, from M. tuberculosis H37Rv, M. avium subsp. 
paratuberculosis and M. smegmatis, respectively; IucD (lysine N6-hydroxylase) from E. coli.    
 
 
Different hypotheses have been postulated to understand how the lysines are 
incorporated into the core structure of mycobactins. It was thought that hydroxylation occurs 
prior to the amino acids being incorporated into the growing mycobactin by MbtE and MbtF. 
Another scenario was hypothesised, in which the amino acids are first activated by the 
adenylation domains followed by hydroxylation, then further modifications on the lysines, 
acylation and cyclisation in the central and terminal residues, respectively, were likely to 
occur. However, the discovery of DDM-838 (Moody et al., 2004) with lysines unmodified in 
the core structure of mycobactin T has suggested that hydroxylation of these amino acids 
occurs as the last step in mycobactin biosynthesis. Biochemical data supports this hypothesis, 
in which the the MbtG could hydroxylate an acetylated lysine preferentially over lysine 
(Krithika et al., 2006) suggesting thus that DDM is an intermediate compound. On the other 
hand, the Lysine Nω-hydroxylase (IucD) of E. coli, prefers lysine as a substrate (Marrone et 
al., 1996). Lysine analogues, in which the ω-amino position are changed to methyl or acylated 
groups, were not hydroxylated by the enzyme, whereas modification at the α-position results 
in hydroxylation (Marrone et al., 1996). In addition, PvdA is also specific for its substrate, L-
ornithine, although, the enzyme could carry out NADPH oxidation on lysines without 
formation of the hydroxylated product (Ge & Seah, 2006; Meneely & Lamb, 2007). Perhaps 
the topology of the enzyme might be the key of the mechanistic reaction observed in MbtG, 
which is able to hydroxylate both lysines and acetylated lysines.   
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If DDM is a true intermediate, it is logical to assume that the adenylation domains of 
MbtE and MbtF should activate first unmodified lysines, and then the residues are modified 
(acylation and cyclisation) in their corresponding NRPS, followed finally by hydroxylation by 
MbtG to produce a functional mycobactin. To investigate this hypothesis, cloning and 
expression of the adenylation domains were attempted in this study. Thus, ambtE was 
successfully cloned and expressed in pET28b using E. coli C41(DE3) as heterologous host, 
although, the protein was insoluble. As outlined before, cloning domains of NRPSs and PKSs 
is always difficult since the exact borders of conserved and less conserved amino acids in 
interdomains regions are not easy to define. Misfolding and solubility problems might arise 
from incorrectly designed domains when trying to express recombinant peptide synthetases in 
heterologous hosts. In both cases, the result might be the interruption in the intramodular 
communication, incorrect folding and therefore affecting enzymatic activity (Weber et al., 
2000). Furthermore, over-expression of foreign proteins from cloned genes in heterologous 
hosts, such as E. coli, often leads to the formation of insoluble intracellular aggregates of the 
expressed protein, the so-called inclusion bodies. Evidence suggests that inclusion bodies arise 
by the inappropriate aggregation of partially folded or misfolded polypeptides, rather than 
insolubility or instability of the native protein (Baneyx & Mujacic, 2004).  
 
The ambtF was also cloned into pET23a, however, the gene was not expressed despite 
different conditions attempted. As an alternative method, the codon alteration strategy was 
employed to overcome this problem (Usha et al., 2006). The gene was successfully cloned 
into pTYB2 but not in pET23a. Expression analysis of ambtF-pTYB1 using E. coli ER2566 as 
heterologous host, no evidence for ambtF expression was found. M. tuberculosis possesses a 
high G+C content around 65 mol% (Cole et al., 1998). This G+C richness is reflected in a 
strong bias towards C- and G-ending codons for every amino acid with an overall G+C 
content at the third position of codons of 83%. However, there is a significant variation in 
codon usage patterns among genes, which appears to be associated with gene expression level 
(Andersson & Sharp, 1996). Although several codons can encode the same amino acid, E. coli 
contains tRNA for certain high-usage codons than other low-usage codons (Ikemura, 1985). 
As codons usage is thought to have coevolved with tRNA population, the use of heterologous 
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hosts phylogenetically closer to M. tuberculosis, such as Streptomyces, Corynebacteria, and 
the rapidly growing and non-pathogenic M. smegmatis, may solve gene expression. Since M. 
tuberculosis tRNA populations are closer in M. smegmatis, ambtF was further cloned using its 
native forward primer into pVV16 and expression analysis was carried out in M. smegmatis 
mc2155, however, gene expression was not observed. Different growth conditions might give 
positive result, but this has not been evaluated yet.   
 
There is another way to test the above hypothesis by deleting the mbtG gene (gene 
knockout) from the chromosome of any mycobacteria species that produces mycobactin, such 
as M. tuberculosis or M. bovis. Thus, deleting the gene and growing the mutant in iron-
deficient conditions, the mycobacteria phenotype should produce the intermediate mycobactin 
(DDM), in which the lysines are not hydroxylated. This approach has been attempted; 
however, re-generation of the mutant has been hindered (Dr. Apoorva Bhatt, personal 
communication). The mbtG gene was deleted from M. bovis BCG chromosome by 
especialised transduction (Bardarov et al., 2002). To further study this phenotype, several 
attempts to culture the mutant in different types of medium was not afforded.    
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4.6 Further work. 
Since MbtG is not stable for a long period, conditions (pH, buffer, temperaure) will be 
investigated to obtain a stable enzyme. In order to analyse the hydroxylation of DDM by 
MbtG, first enzymatic activity of MbtG will be investigated by oxidation and hydroxylation 
assays with lysine and modified lysines as reported for PvdA and IucD (Macheroux et al., 
1993; Meneely & Lamb, 2007). Then, hydroxylation of the unmodified lysines present in 
DDM compound will be attempted. Furthermore, expression trials will be investigated to 
obtain soluble and active AMbtE. Since adenylation domains are responsible for amino acid 
recognition, ATP binding and amino acyl adenylate formation, AMbtE substrate preference 
(unmodified or modified lysines) can be assessed using the ATP:PPi exchange assay (Linne & 
Marahiel, 2004). 
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5.1 Molecular Biology Techniques. 
5.1.1 Polymerase chain reaction (PCR). 
Amplification of genes by PCR was carried out using M. tuberculosis H37Rv chromosomal 
DNA. Primers were designed in house and purchased from Eurofins MGW Operon. A typical 
PCR reaction contained 100 µL of final volume, in which the ingredients were mixed well and 
DNA polymerase was added last to initiate the reaction. Different DNA polymerases were 
used for cloning the genes, which are mentioned in each chapter. The basic PCR reaction 
described below was used for cloning some genes and modifications in some conditions were 
done according to the needs. Multigradient step PCR reactions was used for cloning difficult 
genes, such as ArCP, mbtA, and ambtF.  
 
 
A) Recipe  
2 µL 
2 µL 
1 µL 
2 µL 
10 µL 
8 µL 
2 µL 
1 µL 
72 µL 
5’ Cloning primer (100 pmole) 
3’ Cloning primer (100 pmole) 
Genomic DNA (H37Rv) (1 µg/µL) 
dNTP’s  
Thermostable buffer (10X) 
DMSO (optional) 
MgSO4 (optional) (100 mM) 
DNA polymerase1 
ddH20 (for molecular biology) 
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B) PCR conditions 
 
95ºC 
95ºC 
3 minutes 
1 second 
 
60-70ºC 
68ºC 
30 seconds 
0.5 minutes 
35 cycles 
68ºC 
4ºC 
10 minutes 
¥ 
 
 
 
 
5.1.2 Isolation of plasmid DNA. 
Plasmid DNA was isolated using the Quiaprep spin miniprep kit (Qiagen) according to the 
manufacturer’s instructions.  
 
5.1.3 Restriction enzyme digestion of DNA. 
The restriction endonuclease digestions were perfomed according to manufacturer’s 
recommendations. Buffer and temperature of digestion were chosen based on optimal function 
of the used enzyme. The final volume for a typical digestion was 20 µL. 
 
Restriction enzyme digest Total reaction volume (20 µL) 
DNA 5 µL 
Buffer 10X 2 µL 
Restriction enzyme 1 1 µL 
Restriction enzyme 2 1 µL 
adH2O 11 µL 
aMolecular grade dH2O was used for reactions.  
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5.1.4 Electrophoresis of DNA. 
PCR products and restriction digests were analysed by horizontal slab agarose gel 
eletrophoresis (Hoefer). Percentage of agarose was prepared according to the size to the 
analysed DNA. Agarose gels were prepared by dissolving electrophoretic grade agarose 
(Bioline) in 1 X TAE (Tris-acetate-EDTA buffer). 1 X TAE was made up to 40 mM Tris-
acetate and 1 mM EDTA. DNA samples for electrophoresis were prepared by mixing with 
1/5th volume of the 5X DNA loading dye [0.25 % bromophenol blue, 0.25% xylene cyanol 
FF, and 40% (w/v) sucrose in dH2O]. The samples were run at 110 volts until the dye 
migrated the required distance. The gel was stained with 0.5 µg /mL solution of ethidium 
bromide for 20 minutes, and visualised in a UV transiluminator. The gel was photographed 
using the Bio-rad gel software.   
 
5.1.5 Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE). 
Expression analysis and purification of proteins were analysed by subjecting on 10-15 % 
SDS-PAGE gel by the discontinous gel method (Laemmli, 1970). A Hoefer “mighty small” 
SE 200 vertical slab gel system was used. Resolving and stacking gels and the 
acrylamide/bis/water mix were prepared as follows: 
 
Resolving gel: 
Composition For two gels 
a4 X resolving gel buffer 3.75 mL 
bAcrylamide/bis/water mix 11.25 mL 
cTEMED 30 mL 
10% ammonium persulfate 75 mL 
  
aThe 4 X resolving buffer consists of 1.5 M Tris-HCl, pH 8.8 and 0.4% SDS. 
bPercentage of acrylamide/bis.water was varied according to needs.  
cTEMED (Tetramethylethylenediamine).  
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Stacking gel:  
Composition For two gels 
d4 X stacking gel buffer 1.25 mL 
Acrylamide 0.65 mL 
TEMED 15 mL 
10% ammonium persulfate 75 mL 
H2O 3.05 mL 
dThe stacking gel buffer consists of 0.5M Tris-HCl, pH 6.8 and 0.4% SDS.  
 
Protein samples were prepared by mixing with 1/5th the volume of SDS loading buffer (360 
mM Tris-HCl, pH 8.8, 9% (w/v) SDS, 0.9% (w/v) bromophenol blue, 15% (w/v) b-
mercaptoethanol and 30% glycerol) and boiled at 95°C for 5 minutes. The samples were 
loaded onto the gel and run at 25 mA for approximately an hour. The running buffer was 
made up of 25 mM Tris-HCl, 190 mM glycine and 4 mM SDS. Protein gels were stained with 
Coomasie brilliant blue R-250 stain (5% glacial acetic acid, 0.025% Coomasie brilliant blue 
(w/v) and 50% methanol) and left for 30 minutes. The excess stain was removed with a 
destaining solution (10% glacial acetic acid and 30% methanol). The gels were photographed 
using the Bio-rad software. Gels were dried between two sheets of cellophane.  
 
5.1.6 Estimation of protein concentration. 
The concentration of total protein concentration present in cell wall material and membranes 
were measured using the Bicinchoninic protein assay (BCA) kit (Pierce). The assay was 
performed according to the manufacturer’s protocol. The assay was calibrated over the range 
3.5-5.0 ug/mL by using a range of standards derived from a 2 mg/mL solution of bovine 
serum albumin (BSA) (Pierce). Samples, standards and blanks were assayed in duplicate. 
Samples were also diluted 1 in 5 to ensure a reading was obtained within the limits of the 
standard curve. The assay was incubated at 37°C for 30 minutes and the colorimetric change 
was measured at 562 nm. 
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5.2 Culture Media. 
5.2.1 Luria-Bertani (LB) medium. 
 
Composition Per liter 
Bacto-tryptone 10 g 
Bacto-yeast extract 5 g 
NaCl 10 g 
 
LB broth and LB agar were obtained from Sigma-Aldrich Company. Medium solutions were 
prepared following the manufacturer’s instructions. Media were sterelised by autoclaving at 
121°C for 15 minutes. 
 
5.2.2 Terrific Broth (TB) medium. 
Solution A 
Composition Per 900 mL 
Bacto-tryptone 12 g 
Bacto-yeast extract 24 g 
Glycerol 4 mL 
 
Solution B 
Composition Per 100 mL 
KH2PO4 2.3 g 
K2HPO4 12.5 g 
 
Solutions were prepared separately followed by autoclaving at 121°C for 15 minutes. To 
prepare the final medium, 100 mL of solution B was added to solution A.  
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5.2.3 Proskauer and Beck (PB) medium.  
Glassware for preparing media was deferrated: glassware were filled with alcoholic KOH 
(2%) and left overnight. Then, glassware was washed with deionised water, followed by 
filling with 8 M HNO3 and leaving overnight. Glassware was autoclaved at 127ºC for 15 
minutes prior to using. Afterwards, PB medium was prepared in the deferrated glassware. 
Since M. bovis BCG cannot use glucose as carbon source, sodium pyruvate (1%) was used 
instead. The glpK gene, which encodes a glycerol kinase, required for phosphorylation of 
glycerol, is a pseudogene in this strain. 
 
Composition Pero liter 
Monopotassium phosphate 5 g 
Asparagine 5 g 
Magnesium sulphate 7H2O 0.6 g 
Magnesium citrate 2.5 g 
Sodium pyruvate 10 g 
 
Ingredients were dissolved in that order, being certain that each compound was solubilised 
before adding the next one. The pH was adjusted to 7.8 by the addition of 40% NaOH 
followed by autoclaving at 121°C for 15 minutes after the pH should be 7.4. Next, the 
medium was filtered throught Whatman Filter to remove precipitation; aliquots were prepared 
according to the desired volume and autoclaved again at 121°C for 15 minutes. 
 
5.3 Strains and vectors. 
5.3.1 Strains.  
E. coli TOP 10 (Invitrogen), E. coli XL1 Blue (Strategene) and E. coli NEB 5-alpha F´Iq 
(New England Biolabs) were used for plasmid maintenance, whereas E. coli C41(DE3) 
(OverExpress), E. coli K12 and E. coli ER566 (New England Biolabs) were used for protein 
expression. E. coli strains were grown at 37°C in an orbital shaker at a speed of 180 rpm. M. 
bovis BCG Pasteur was used for whole-cell assay, whereas M. smegmatis mc2155 was 
employed for heterologous expression. 
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5.3.2 Vectors. 
The vectors used in this study are the following: 
Vector Concentration of antibiotic used for selection (µg/mL) 
pET23a Ampicillin (100) 
pET23b Ampicillin (100) 
pET28b Kanamycin (25) 
pCDFDuet1 Streptomycin (100) and Spectinomycin (100) 
pSU Chloramphenicol (30) 
pTYB series Ampicillin (100) 
pMAL-C2X  Ampicillin (100) 
pMV261 Kanamycin (50) 
pVV16 aHygromycin (200) and Kanamycin (50) 
pSD26 aHygromycin (200)  
aFor E. coli strains Hygromycin (200 µg/mL) was used, whereas for M. smegmatis mc2155 (50 
µg/mL) was utilised.  
 
  
 
5.3.3 Preparation of competent cells. 
5.3.4.1 Chemical competent cells.  
The rubidium chloride protocol was used for preparing chemical competent cells. Original E. 
coli glycerol stocks were inoculated in 5 mL of fresh LB medium. Cells were grown overnight 
at 37ºC in an orbital shaker at 180 rpm. The following day, the entire overnight culture was 
transferred to 50 mL of LB medium containing 20 mM MgSO4. Cells were grown at 37ºC in 
an orbital shaker at 180 rpm until OD600=0.5-0.6. The cells were harvested by centrifugation 
at 5,000 rpm for 10 minutes at 4ºC. The pelleted cells were gently resuspended in 0.4 volume 
(based on the original culture volume) of ice-cold TFB1 buffer. The resuspended cells were 
incubated on ice for 30 minutes at 4ºC. The cells were pelleted again by centrifugation at 5, 
000 rpm for 10 minutes at 4ºC. Cells were gently resuspended in 0.04 of the original volume 
of ice-cold TFB2 buffer, and incubated on ice for 30 minutes at 4ºC. Next, cells were 
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aliquoted and flash-frozen as 50 µL stocks, using liquid nitrogen, and stored at -80ºC until 
required. 
 
TFB1 buffer. 
Composition Concentration 
Potassium acetate 30 mM 
CaCl2 10 mM 
MnCl2 50 mM 
RbCl 100 mM 
Glycerol 15% 
The pH is adjusted to 5.8 with 1 M acetic acid. Filter-sterilise (0.2 µm) and store at 4°C. 
 
TFB2 buffer 
Composition Concentration 
MOPS or PIPES, pH 6.5 10 mM 
CaCl2 75 mM 
RbCl 10 mM 
Glycerol 15% 
The pH is adjusted to 6.5 with 1 M KOH. Filter-sterilise (0.2 µm) and store at 4°C. 
 
 
5.3.4.2 Heat shock transformation.  
A 50 µL stock was thawed on ice for at least 10 minutes, then transferred to a cold-Falcon 
Tube (14 mL). To the chemical competent cells, 1 µL of plasmid DNA was added and mixed 
gently, and the mix was incubated on ice for 10 minutes. Next, the tube was heated at 42ºC for 
2 minutes, and incubated on ice for 10 minutes. Fresh LB medium (150 µL) was added to the 
tube, followed by incubation at 37ºC for one hour in an orbital shaker at 180 rpm. The 
transformed cells were plated in LB agar containing the appropriate antibiotic.      
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5.3.4.3 Preparation of electro-competent M. smegmatis mc2 155 cells. 
A starter culture of M. smegmatis mc2155 was grown overnight in LB (100 mL) broth 
supplied with 0.05% Tween 80 at 37ºC in an orbital shaker at 180 rpm. The following day, a 
0.6% inoculum of the overnight culture was transferred to 50 mL of fresh LB medium 
containing 0.05% Tween 80. The culture was incubated in an orbital shaker at 37ºC until 
OD600=0.5-0.6. Cells were harvested by centrifugation at 5, 000 rpm at 4ºC, which were then 
resuspended in 30 mL of ice-cold 10% glycerol. The resuspended cells were incubated on ice 
at 4ºC for 20 minutes and centrifuged again as above. The process was repeated four times by 
re-suspending each time with reducing volumes of 10% glycerol (20, 10, 5 and 2.5 mL 
respectively). The pelleted cells were finally re-suspended in 2 mL of 10% glycerol, aliquoted 
as 50 µL stocks, flash-frozen using liquid nitrogen and stored at -80ºC.      
 
5.3.4.4 Transformation of electro-competent M. smegmatis mc2155 with plasmid DNA. 
A 50 µL aliquot of electro-competent M. smegmatis mc2155 cells was thawed on ice at 4ºC. 
Next, plasmid DNA (1 µL) was added to the electro-competent cells and mixed gently; the 
mix was incubated on ice at 4ºC for 30 minutes. The mix was transferred to an ice-cold 
electro-cuvette (1 mm cuvette gap) and electroporated using an Eppendorf Electroporator 
2510 (settings: 1800 mV, 1000 Ohms, 25 µF). After electroporation, 250 µL of fresh LB 
medium was added, mixed gently, and incubated at 37ºC for 4 hours without shaking. Next, 
transformed cells were plated in LB agar containing the appropriate antibiotic and incubated at 
37 ºC until single colonies were grown (~ 2-4 days).   
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